,Study_Allocation,Arm_Group_Information,Baseline_Analyzed_List,Baseline_Group_List,Baseline_Measure_List,Brief_Summary,Short_Title,Agreements,Collaborators,Completion_Date,Primary_Disease_or_Condition,Conditions,Eligibility_Criteria,Detailed_Description,Download_Date,Eligibility_Criteria,Eligibility_Gender,Eligibility_Healthy_Volunteers,Eligibility_Maximum_Age,Eligibility_Minimum_Age,Enrollment,First_Received_Date,First_Received_Resuls_Date,First_Received_Results_Disposition_Date,Eligibility_Gender,Eligibility_Gender_Based,Gender_Eligibility_Description,Has_Expanded_access,Eligibility_Accepts_Healthy_Volunteers,Interventions,Intervention_Browse,Intervention_Model,Intervention_Model_Description,Investigator_Information,Primary_Disease_or_Condition_Keywords,Last_Changed_Date,Lead_Sponsor,Limitations_and_Caveats,Link_Text,Location,Location_Countries,Masking,Masking_Description,Eligibility_Maximum_Age,Eligibility_Minimum_Age,Clinical_Study_ID,Number_of_Arms,Number_of_Groups,Observational_Model,Official_Title,Organization_Study_Id,Outcomes,Overall_Official,Overall_Recruitment_Status,Oversight_Info,Participant_Flow,Participant_Flow_Group_List,Participant_Flow_Period_List,Patient_Data,Phase,Point_of_Contact,Pre_Assignment_Details,Primary_Completion_Date,Primary_Outcome_Measure_Information,Primary_Purpose,Recruitment_Details,Removed_Couontries,Serious_Reported_Events,Reported_Events_Group_List,Other_Reported_Events,Responsible_Party,Eligibility_Sampling_Method,Secondary_Outcome_Measure_Information,Source,Sponsor,Study_Start_Date,Eligibility_Study_Population_Description,Study_Type,Time_Perspective,URL,Record_Verification_Date,Why_Stopped
0,Non-Randomized|,[OrderedDict([('arm_group_label'  'Arm 1 Standard Risk')  ('arm_group_type'  'Experimental')  ('description'  '6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin')])  OrderedDict([('arm_group_label'  'Arm 2 High Risk')  ('arm_group_type'  'Experimental')  ('description'  '6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C')])]|,[OrderedDict([('@group_id'  'B1')  ('@value'  '21')])  OrderedDict([('@group_id'  'B2')  ('@value'  '39')])  OrderedDict([('@group_id'  'B3')  ('@value'  '60')])]|,[OrderedDict([('@group_id'  'B1')  ('title'  'Arm 1 Standard Risk')  ('description'  '6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin')])  OrderedDict([('@group_id'  'B2')  ('title'  'Arm 2 High Risk')  ('description'  '6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C')])  OrderedDict([('@group_id'  'B3')  ('title'  'Total')  ('description'  'Total of all reporting groups')])]|,[OrderedDict([('title'  'Age')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  '<=18 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '21')])  OrderedDict([('@group_id'  'B2')  ('@value'  '30')])  OrderedDict([('@group_id'  'B3')  ('@value'  '51')])])]))]))]))])  OrderedDict([('title'  'Between 18 and 65 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '9')])  OrderedDict([('@group_id'  'B3')  ('@value'  '9')])])]))]))]))])  OrderedDict([('title'  '>=65 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '0')])  OrderedDict([('@group_id'  'B3')  ('@value'  '0')])])]))]))]))])])]))])  OrderedDict([('title'  'Age')  ('units'  'years')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '3.71')  ('@spread'  '1.77')])  OrderedDict([('@group_id'  'B2')  ('@value'  '16')  ('@spread'  '9.8')])  OrderedDict([('@group_id'  'B3')  ('@value'  '11.7')  ('@spread'  '9.89')])])]))]))]))]))]))])  OrderedDict([('title'  'Gender')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Female')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '11')])  OrderedDict([('@group_id'  'B2')  ('@value'  '18')])  OrderedDict([('@group_id'  'B3')  ('@value'  '29')])])]))]))]))])  OrderedDict([('title'  'Male')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '10')])  OrderedDict([('@group_id'  'B2')  ('@value'  '21')])  OrderedDict([('@group_id'  'B3')  ('@value'  '31')])])]))]))]))])])]))])  OrderedDict([('title'  'Region of Enrollment')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  OrderedDict([('title'  'United States')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '21')])  OrderedDict([('@group_id'  'B2')  ('@value'  '39')])  OrderedDict([('@group_id'  'B3')  ('@value'  '60')])])]))]))]))]))]))])]|,The purpose of this research study is to identify better ways to treat children and young adults with acute lymphocytic leukemia (ALL). At the same time  doctors hope to define methods to identify those patients at higher risk for certain side effects  as well as those who are at higher risk for relapse of their leukemia.|,CINJALL: Treatment for Children With Acute Lymphocytic Leukemia|,There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|,NIH|,September 2008|,['Leukemia'  'Leukemia  Lymphoid'  'Precursor Cell Lymphoblastic Leukemia-Lymphoma']|,,Inclusion: - Newly Diagnosed ALL  excluding mature B-cell ALL (surface Ig positive) - Patients with overt CNS (central nervous system) or testicular disease are eligible - Informed consent according to institutional and FDA guidelines. - Adequate organ function is required. - HIV seropositive patients will not be excluded from this study. - Patients greater than 1 year of age and less than 29.99 years of age are eligible. Exclusion Criteria - Patients with medical  psychological  or psychiatric problems that are likely to compromise their ability to tolerate intensive therapy will be ineligible. - All patients with evidence of significant organ dysfunction not thought to be attributable to ALL (patients with clinically significant congestive heart failure  cardiac ejection fraction <40%  total bilirubin >2  serum creatinine >2) will be ineligible. Note: echocardiogram or MUGA are required prior to therapy ONLY for those patients with history or physical findings suggestive of cardiac dysfunction not directly attributable to anemia or ALL. Note: Patients with total bilirubin >2 but direct (conjugated) bilirubin less than the upper limit of normal will still be eligible. These patients should be evaluated for deficiency of the enzyme glucuronyl transferase.|,Outline of Therapy: Combinations of chemotherapy drugs will be given orally  intravenously and intrathecally (directly into the cerebrospinal fluid by spinal tap) over a period of roughly two and a half years. Therapy will be divided into five phases: Induction (4 weeks): chemotherapy given to produce a clinical remission (defined by normal blood counts  with the absence of leukemia cells in the blood and fewer than 5% leukemia cells in the bone marrow). Consolidation (11 weeks): chemotherapy given to consolidate the remission. Delayed Intensification (7 weeks) Intensive chemotherapy aimed at killing any resistant leukemia cells will be given only for patients at high risk of relapse. Intensive Continuation (approximately 1 year): Eight week cycles of chemotherapy  given eight times. Continuation (final year of therapy): Eight week cycles of largely oral chemotherapy  with one clinic visit for a lumbar puncture every eight weeks. Irradiation: radiation will be given in the middle of intensive continuation to the head and spine of those patients who have leukemia cells found in the cerebrospinal fluid at the time of diagnosis. Follow-up: After the conclusion of therapy  there will be periodic office visits  initially monthly  then gradually spaced out to annual visits. The purpose of these visits is to evaluate for late side-effects of therapy.|,ClinicalTrials.gov processed this data on May 19  2017|,Inclusion: - Newly Diagnosed ALL  excluding mature B-cell ALL (surface Ig positive) - Patients with overt CNS (central nervous system) or testicular disease are eligible - Informed consent according to institutional and FDA guidelines. - Adequate organ function is required. - HIV seropositive patients will not be excluded from this study. - Patients greater than 1 year of age and less than 29.99 years of age are eligible. Exclusion Criteria - Patients with medical  psychological  or psychiatric problems that are likely to compromise their ability to tolerate intensive therapy will be ineligible. - All patients with evidence of significant organ dysfunction not thought to be attributable to ALL (patients with clinically significant congestive heart failure  cardiac ejection fraction <40%  total bilirubin >2  serum creatinine >2) will be ineligible. Note: echocardiogram or MUGA are required prior to therapy ONLY for those patients with history or physical findings suggestive of cardiac dysfunction not directly attributable to anemia or ALL. Note: Patients with total bilirubin >2 but direct (conjugated) bilirubin less than the upper limit of normal will still be eligible. These patients should be evaluated for deficiency of the enzyme glucuronyl transferase.|,All|,No|,30 Years|,1 Year|,60|,September 12  2005|,November 15  2013|,,All|,,,No|,,['Dexamethasone acetate'  'Hydrocortisone 17-butyrate 21-propionate'  'Cortisol succinate'  'Hydrocortisone acetate'  'Dexamethasone'  'Hydrocortisone'  'Dexamethasone 21-phosphate'  'Methotrexate'  'Cyclophosphamide'  'Cytarabine'  'Vincristine'  'Asparaginase'  '6-Mercaptopurine'  'Thioguanine'  'Daunorubicin'  'BB 1101'  'Aminopterin']|,,,,,['Acute Lymphocytic Leukemia'  'Leukemia']|,May 12  2014|,Other|,Antifolate therapy was non-randomly assigned  therefore  we do not have a statistical basis to compare the toxicity observed among patients on the standard risk and high risk treatment arms.|,Link to the current ClinicalTrials.gov record.|,United States|,,Open Label|,,30 Years|,1 Year|,NCT00176462|,2|,,,CINJALL: Treatment for Children With Acute Lymphocytic Leukemia|,020101|,[OrderedDict([('type'  'Primary')  ('title'  'Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years')  ('description'  'This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years  where relapse is defined as the presence of progressive disease after the achievement of a complete remission.')  ('time_frame'  '5 years')  ('population'  'Number of high risk ALL patients treated.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Arm 2 High Risk')  ('description'  '6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C')]))]))  ('measure'  OrderedDict([('title'  'Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years')  ('description'  'This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years  where relapse is defined as the presence of progressive disease after the achievement of a complete remission.')  ('population'  'Number of high risk ALL patients treated.')  ('units'  'percentage of participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '37')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '64.9')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'To Measure 5-methyltetrahydrofolate  Aminopterin and Methotrexate Uptake in Leukemic Blasts Isolated at Diagnosis')  ('time_frame'  '5 years')  ('population'  'We did not analyze this outcome measure. The laboratory analysis was not performed. The Principal Investigator left the institution.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Arm 1 Standard Risk')  ('description'  '6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin')])  OrderedDict([('@group_id'  'O2')  ('title'  'Arm 2 High Risk')  ('description'  '6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C')])])]))  ('measure'  OrderedDict([('title'  'To Measure 5-methyltetrahydrofolate  Aminopterin and Methotrexate Uptake in Leukemic Blasts Isolated at Diagnosis')  ('population'  'We did not analyze this outcome measure. The laboratory analysis was not performed. The Principal Investigator left the institution.')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '0')])])]))]))]))]))])]|,Rutgers  The State University of New Jersey|,Completed|,No|,[OrderedDict([('title'  'Induction (4 Weeks)')  ('milestone_list'  OrderedDict([('milestone'  [OrderedDict([('title'  'STARTED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '21')])  OrderedDict([('@group_id'  'P2')  ('@count'  '39')])])]))])  OrderedDict([('title'  'COMPLETED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '20')])  OrderedDict([('@group_id'  'P2')  ('@count'  '34')])])]))])  OrderedDict([('title'  'NOT COMPLETED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '1')])  OrderedDict([('@group_id'  'P2')  ('@count'  '5')])])]))])])]))  ('drop_withdraw_reason_list'  OrderedDict([('drop_withdraw_reason'  [OrderedDict([('title'  'Withdrawal by Subject')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '2')])])]))])  OrderedDict([('title'  'Death')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '1')])  OrderedDict([('@group_id'  'P2')  ('@count'  '2')])])]))])  OrderedDict([('title'  'Lack of Efficacy')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '1')])])]))])])]))])  OrderedDict([('title'  'Consolidation (12 Weeks)')  ('milestone_list'  OrderedDict([('milestone'  [OrderedDict([('title'  'STARTED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '20')])  OrderedDict([('@group_id'  'P2')  ('@count'  '34')])])]))])  OrderedDict([('title'  'COMPLETED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '20')])  OrderedDict([('@group_id'  'P2')  ('@count'  '29')])])]))])  OrderedDict([('title'  'NOT COMPLETED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '5')])])]))])])]))  ('drop_withdraw_reason_list'  OrderedDict([('drop_withdraw_reason'  [OrderedDict([('title'  'Patient moved to another state')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '1')])])]))])  OrderedDict([('title'  'Adverse Event')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '1')])])]))])  OrderedDict([('title'  'Lack of Efficacy')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '2')])])]))])  OrderedDict([('title'  'Not documented')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '1')])])]))])])]))])  OrderedDict([('title'  'Delayed Intensification (8 Weeks)')  ('milestone_list'  OrderedDict([('milestone'  [OrderedDict([('title'  'STARTED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '20')])  OrderedDict([('@group_id'  'P2')  ('@count'  '29')])])]))])  OrderedDict([('title'  'COMPLETED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '20')])  OrderedDict([('@group_id'  'P2')  ('@count'  '29')])])]))])  OrderedDict([('title'  'NOT COMPLETED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '0')])])]))])])]))])  OrderedDict([('title'  'Intensive Continuation (8X8-week Cycles)')  ('milestone_list'  OrderedDict([('milestone'  [OrderedDict([('title'  'STARTED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '20')])  OrderedDict([('@group_id'  'P2')  ('@count'  '29')])])]))])  OrderedDict([('title'  'COMPLETED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '19')])  OrderedDict([('@group_id'  'P2')  ('@count'  '26')])])]))])  OrderedDict([('title'  'NOT COMPLETED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '1')])  OrderedDict([('@group_id'  'P2')  ('@count'  '3')])])]))])])]))  ('drop_withdraw_reason_list'  OrderedDict([('drop_withdraw_reason'  [OrderedDict([('title'  'Death')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '1')])  OrderedDict([('@group_id'  'P2')  ('@count'  '0')])])]))])  OrderedDict([('title'  'Lack of Efficacy')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '3')])])]))])])]))])  OrderedDict([('title'  'Continuation -up to 30mos Post Remission')  ('milestone_list'  OrderedDict([('milestone'  [OrderedDict([('title'  'STARTED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '19')])  OrderedDict([('@group_id'  'P2')  ('@count'  '26')])])]))])  OrderedDict([('title'  'COMPLETED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '19')])  OrderedDict([('@group_id'  'P2')  ('@count'  '26')])])]))])  OrderedDict([('title'  'NOT COMPLETED')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '0')])])]))])])]))])]|,,,,Phase 2|,drachtri@cinj.rutgers.edu; zelinsta@cinj.rutgers.edu; rizzoji@cinj.rutgers.edu|,,,This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years  where relapse is defined as the presence of progressive disease after the achievement of a complete remission.|,Treatment|,,,,[OrderedDict([('@group_id'  'E1')  ('title'  'Arm 1 Standard Risk')  ('description'  '6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin')])  OrderedDict([('@group_id'  'E2')  ('title'  'Arm 2 High Risk')  ('description'  '6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C')])]|,[OrderedDict([('title'  'Total')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Total  other adverse events')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '21')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '39')  ('@subjects_at_risk'  '39')])])]))]))])  OrderedDict([('title'  'Blood and lymphatic system disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Platelets')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Pancytopenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Hypokalemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Hemoglobin')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Hyperammonemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Hyperglycemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Hypercalcemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Hyperbilirubinemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '39')])])])])]))])  OrderedDict([('title'  'Cardiac disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Tachycardia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Ventricular arrythmia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Hypotension')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])])]))])  OrderedDict([('title'  'Ear and labyrinth disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Otitis middle ear')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])]))]))])  OrderedDict([('title'  'Gastrointestinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Dehydration')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '6')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Nausea')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '9')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Vomiting')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '17')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Gastritis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Abdominal pain or cramping')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Stomatitis / pharyngitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '5')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Appendicitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Bowel obstruction')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Pancreatitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Weight gain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'GI other (Elevated liver enzymes)')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Diarrhea')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Excessive thirst')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Amylase')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])])]))])  OrderedDict([('title'  'General disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Fever')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '22')  ('@subjects_affected'  '12')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '21')  ('@subjects_affected'  '15')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Headache - Pain-Head')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '10')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Other Toxicity')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '5')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Chest pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Rigors')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])])]))])  OrderedDict([('title'  'Immune system disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Allergic reaction/hypersensitivity')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '39')])])]))]))])  OrderedDict([('title'  'Infections and infestations')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Infection with unknown ANC')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Infection without neutropenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Infection / Febrile neutropenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '39')])])])])]))])  OrderedDict([('title'  'Musculoskeletal and connective tissue disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Extremity pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Joint pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Muscle Pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Fracture')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])])]))])  OrderedDict([('title'  'Neoplasms benign  malignant and unspecified (incl cysts and polyps)')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Ascites')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])]))]))])  OrderedDict([('title'  'Nervous system disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Neuropathy')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Speech impairment')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Seizure(s)')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Neurology - Mood Alteration')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])])]))])  OrderedDict([('title'  'Renal and urinary disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Urinary freqency')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])]))]))])  OrderedDict([('title'  'Respiratory  thoracic and mediastinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Cough')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Rhinitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Upper respiratory infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Edema (Pulmonary)')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Tachypnea')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Pneumothorax')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Wheezing')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Fever & pneumonia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '39')])])])])]))])  OrderedDict([('title'  'Skin and subcutaneous tissue disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Rash/desquamation')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])  OrderedDict([('sub_title'  'Phlebitis (superficial)')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])])])]))])  OrderedDict([('title'  'Vascular disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Cerebrovascular accident')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@events'  '0')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '21')])  OrderedDict([('@group_id'  'E2')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '39')])])]))]))])]|,Sponsor|,,5 years|,Rutgers  The State University of New Jersey|,,February 2001|,,Interventional|,,https://clinicaltrials.gov/show/NCT00176462|,May 2014|,
1,,All participants|,63|,This includes all study participants.|,[OrderedDict([('title'  'Age')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  '<=18 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '61')]))]))]))]))])  OrderedDict([('title'  'Between 18 and 65 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '2')]))]))]))]))])  OrderedDict([('title'  '>=65 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))]))]))])])]))])  OrderedDict([('title'  'Age')  ('units'  'years')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '9.9')  ('@spread'  '5.3')]))]))]))]))]))]))])  OrderedDict([('title'  'Gender')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Female')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '25')]))]))]))]))])  OrderedDict([('title'  'Male')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '38')]))]))]))]))])])]))])  OrderedDict([('title'  'Region of Enrollment')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  OrderedDict([('title'  'United States')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '63')]))]))]))]))]))]))])]|,Objectives: Primary objective: Evaluate toxicity of rapamycin when used for post-bone marrow transplant graft vs. host disease prophylaxis in children with acute lymphoblastic leukemia (ALL). Investigator initiated; four participating institutions; Phase II pilot study|,Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)|,There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|,Other|,March 2010|,['Leukemia'  'Precursor Cell Lymphoblastic Leukemia-Lymphoma'  'Leukemia  Lymphoid']|,,Inclusion Criteria: 1. Pediatric patients' ages (0 - 21 years) with lymphoid malignancies considered for allogeneic bone marrow transplant from HLA-identical sibling donor  single antigen mismatched related or unrelated donor marrow /peripheral blood stem cell (PBSC) or cord blood available for marrow donation. First remission: - if remission not achieved by day28 - high risk cytogenetic features  including t(9;22) or t(4;11) Second or third remission 2. Signed informed consent. Exclusion Criteria: 1. Organ criteria: 1. Cardiac: ECHO shortening fraction <27% 2. Renal: Creatinine clearance <60 ml/min/1.73 m2 3. Hepatic: Bilirubin >1.5 mg/dl  transaminases <3x normal 4. Infection: active viral  fungal or bacterial infection including HIV.|,"Objectives: Primary objective: Evaluate toxicity of rapamycin when used for post-bone marrow transplant graft vs. host disease prophylaxis in children with acute lymphoblastic leukemia (ALL). Rapamycin Rapamycin (RAPA  RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506  FKBP1 2 3  but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506  RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen  thus preventing proliferation among T and B lymphocytes3 4. This action is at a later stage in T cell mediated response than that of CSA or FK506. Important cyclin-dependent signaling kinases are blocked  which results in cell cycle arrest between G1 and S phase. RAPA prevents factor dependent growth of activated T cells  but does not prevent the autocrine production or release of growth factors from activated T cells. Rapamycin has been studied in clinical trials of solid organ allografts  and have been shown to prolong allograft survival by inhibiting host CD4+ and CD8+ T cell expansion5  6. RAPA has synergistic immunosuppressive properties when used with CSA or FK506  and its use allows lower doses of the more nephrotoxic calcineurin inhibitors to accomplish decreased rejection. The use of full dose calcineurin inhibitors with RAPA can result in nephrotoxicity  but these agents can be safely used at a reduced dose with RAPA. Our goal with Rapamycin is to achieve two necessary ends with one medication: a leukemic precursor effect (see above)  and prevention of graft vs. host disease (GVHD). With CSA OR FK506  acute GVHD develops in approximately 40% of pediatric matched related donor recipients  and the majority is mild and easily controllable by the addition of methylprednisolone or prednisone. At Children's hospital of Philadelphia (CHOP)  ""short course"" methotrexate in addition to CSA OR FK506 is given only to patients >14 years  or those with older donors. Chronic GVHD occurs in approximately 20% of pediatric matched related donor recipients  and 75% of this is limited to skin. Therefore  the use of RAPA in this group may accomplish adequate immunosuppression so as to prevent GVHD  as well as provide anti- B and anti-T cell malignancy effect. RAPA may also prove less toxic than the calcineurin inhibitors as well  in which both nephrotoxicity and neurotoxicity remain serious side effects. Allogeneic bone marrow transplantation for children with ALL Children who have very high-risk features  such as t(4;11) or t(9;22)  or those who relapse while on chemotherapy are rarely cured by chemotherapy alone. These patients  as well as those beyond second remission  are generally referred for allogeneic stem cell transplantation. Approximately 25-30% of these patients will have a matched sibling donor. Matched sibling  matched unrelated  and cord blood donor bone marrow transplant results in approximately 40-60% of patients surviving disease free  but relapse remains the largest obstacle to cure. Rapamycin  with its apoptotic effects upon B cell precursor malignancies  may prove effective in decreasing the incidence of relapse in these patients  particularly when used in a state of minimal residual disease post transplant. We expect to treat approximately 10 patients with ALL yearly with matched related donor BMT between the four centers involved in this study. Rapamycin studies in conjunction with a calcineurin inhibitor (CSA or FK506) At the Dana Farber Cancer Institute (DFCI)  50 patients with related  human leukocyte antigen (HLA) matched peripheral stem cell transplants were studied using the combination of FK506 and repaying. The hypothesis tested was that the omission of methotrexate would not increase the rate of GVHD  and would reduce toxicity. The rate of grade II-IV acute GVHD was 16%  and III-IV 5%  which is extremely favorable for adults. Transplant related mortality at 100 days was 5%. This study was done following an earlier study of low dose methotrexate in the higher risk unrelated donor transplant patient. This study showed that rapamycin provided excellent GVHD prevention in the high-risk cohort. We will substitute FK506 for cyclosporine as per the Boston experience. This will be considered a standard practice within our division to increase patient compliance and comfort. This does not increase risk to patients  as oral FK506 is better tolerated RAPA and FK506 appear to be synergistic which may result in better GVHD prophylaxis. Study Procedures: Conditioning: 1. Thiotepa 5 mg/kg days -7  -6. Given IV over 4 hours. Cyclophosphamide 60 mg/kg days -5  -4. Given over 1 hour IV with routine supportive care. 2. Total body irradiation (TBI) 200 cGy/fraction x 6 fractions given over 3 days*. Testicular boost 400 cGy may be given for males. Patients with prior CNS disease and no prior central nervous system (CNS) irradiation: 600 cGy prior to starting conditioning. *TBI may be given before or after Thiotepa and cyclophosphamide. If given before Stem cells are to be given 48 hours after the end of cyclosphosphamide. Graft vs. Host Disease Prophylaxis: 1. Tacrolimus IV by continuous infusion .03mg/kg per day beginning day -3. Target serum levels between 5-10 patients will switch to oral form when tolerating PO's (""Per Os"" or ""By mouth"". 2. Methotrexate 5mg/m2 will be given IV on days 1  3  and 6 for all patients and on day 11 for patients receiving unrelated donor marrow. 3. Rapamycin day 0 with dosing as follows: 2.5 mg/m2/d (4mg/d max) PO daily. Absent GVHD Immune Suppression Weaning: 1. Tacrolimus: Matched sibling donor allograft taper at day +42 over 6-8wks. Mismatched or unrelated allograft or cord blood taper at day +100 to be off by day +180. 2. Sirolimus: At day + 180 wean over 4 weeks.|",ClinicalTrials.gov processed this data on May 19  2017|,Inclusion Criteria: 1. Pediatric patients' ages (0 - 21 years) with lymphoid malignancies considered for allogeneic bone marrow transplant from HLA-identical sibling donor  single antigen mismatched related or unrelated donor marrow /peripheral blood stem cell (PBSC) or cord blood available for marrow donation. First remission: - if remission not achieved by day28 - high risk cytogenetic features  including t(9;22) or t(4;11) Second or third remission 2. Signed informed consent. Exclusion Criteria: 1. Organ criteria: 1. Cardiac: ECHO shortening fraction <27% 2. Renal: Creatinine clearance <60 ml/min/1.73 m2 3. Hepatic: Bilirubin >1.5 mg/dl  transaminases <3x normal 4. Infection: active viral  fungal or bacterial infection including HIV.|,All|,No|,21 Years|,N/A|,63|,November 19  2008|,March 1  2011|,,All|,,,No|,,['Sirolimus'  'Everolimus']|,,,,,['ALL'  'Cancer'  'Stem Cell Transplant']|,July 23  2013|,Other|,,Link to the current ClinicalTrials.gov record.|,United States|,,Open Label|,,21 Years|,N/A|,NCT00795886|,1|,,,CHP-753  Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)|,HCI14044|,"[OrderedDict([('type'  'Primary')  ('title'  'Number of Participants With Transplant-related Mortality')  ('description'  'Death not associated with relapse. We determined that if transplant related mortality(TRM) 25% at day 100 or if Grade III-IV (severe  life threatening  or disabling) acute GVHD was >30% a stopping rule would be triggered.')  ('time_frame'  '24 months after transplant')  ('population'  'All participants enrolled in the trial.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Rate of Transplant Related Mortality')  ('description'  'All participants enrolled in the trial')]))]))  ('measure'  OrderedDict([('title'  'Number of Participants With Transplant-related Mortality')  ('description'  'Death not associated with relapse. We determined that if transplant related mortality(TRM) 25% at day 100 or if Grade III-IV (severe  life threatening  or disabling) acute GVHD was >30% a stopping rule would be triggered.')  ('population'  'All participants enrolled in the trial.')  ('units'  'participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '63')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '8')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Percentage of Patients Developing Acute Graft vs. Host Disease (GVHD)')  ('description'  'Cumulative incidence of Grade 2-4 acute GVHD at 180 days.')  ('time_frame'  '180 days')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Rapamycin')  ('description'  'This includes all study participants.')]))]))  ('measure'  OrderedDict([('title'  'Percentage of Patients Developing Acute Graft vs. Host Disease (GVHD)')  ('description'  'Cumulative incidence of Grade 2-4 acute GVHD at 180 days.')  ('units'  'percentage of participants')  ('param'  'Number')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '63')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '38')  ('@lower_limit'  '26')  ('@upper_limit'  '50')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Primary')  ('title'  'Two Year Overall Survival')  ('description'  ""The probability that a given patient will be alive two years after transplantation. The Kaplan-Meier product limit method was used to compute the probability of overall survival to 2 years. Greenwood's formula was used to compute the standard error."")  ('time_frame'  '24 months after transplant')  ('population'  'All patients enrolled in study.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Rapamycin')  ('description'  'This includes all study participants.')]))]))  ('measure'  OrderedDict([('title'  'Two Year Overall Survival')  ('description'  ""The probability that a given patient will be alive two years after transplantation. The Kaplan-Meier product limit method was used to compute the probability of overall survival to 2 years. Greenwood's formula was used to compute the standard error."")  ('population'  'All patients enrolled in study.')  ('units'  'probability')  ('param'  'Mean')  ('dispersion'  'Standard Error')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '63')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.73')  ('@spread'  '0.058')]))]))]))]))]))]))]))])]|",Primary Children's Hospital|,Completed|,Yes|,10|,,,,Phase 2|,Michael.Pulsipher@hsc.utah.edu|,,,"[OrderedDict([('measure'  'Number of Participants With Transplant-related Mortality')  ('time_frame'  '24 months after transplant')  ('description'  'Death not associated with relapse. We determined that if transplant related mortality(TRM) 25% at day 100 or if Grade III-IV (severe  life threatening  or disabling) acute GVHD was >30% a stopping rule would be triggered.')])  OrderedDict([('measure'  'Two Year Overall Survival')  ('time_frame'  '24 months after transplant')  ('description'  ""The probability that a given patient will be alive two years after transplantation. The Kaplan-Meier product limit method was used to compute the probability of overall survival to 2 years. Greenwood's formula was used to compute the standard error."")])]|",Treatment|,,,,This includes all study participants.|,[OrderedDict([('title'  'Total')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Total  other adverse events')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '63')]))]))]))])  OrderedDict([('title'  'Hepatobiliary disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Venoocclusive Disease')  ('description'  'Looking at non-severe VOD. Important to understand this as it has been noted in a portion of patients using sirolimus.')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '63')]))]))]))])]|,Sponsor|,,Cumulative incidence of Grade 2-4 acute GVHD at 180 days.|,University of Utah|,,August 2005|,,Interventional|,,https://clinicaltrials.gov/show/NCT00795886|,July 2013|,
2,Randomized|,[OrderedDict([('arm_group_label'  'rotating-platform design TKA')  ('arm_group_type'  'Active Comparator')  ('description'  'patients who were randomized to receive the rotating platform mobile-bearing TKA design')])  OrderedDict([('arm_group_label'  'all-polyethylene tibia design TKA')  ('arm_group_type'  'Active Comparator')  ('description'  'patients who were randomized to receive the all-polyethylene tibial component design')])]|,[OrderedDict([('@group_id'  'B1')  ('@value'  '200')])  OrderedDict([('@group_id'  'B2')  ('@value'  '200')])  OrderedDict([('@group_id'  'B3')  ('@value'  '400')])]|,[OrderedDict([('@group_id'  'B1')  ('title'  'Rotating-platform Design Total Knee Arthroplasty (TKA)')  ('description'  'patients who were randomized to receive the rotating platform mobile-bearing total knee arthroplasty (TKA) design')])  OrderedDict([('@group_id'  'B2')  ('title'  'All-polyethylene Tibia Design Total Knee Arthroplasty (TKA)')  ('description'  'patients who were randomized to receive the all-polyethylene tibial component design')])  OrderedDict([('@group_id'  'B3')  ('title'  'Total')  ('description'  'Total of all reporting groups')])]|,[OrderedDict([('title'  'Age')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  '<=18 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '0')])  OrderedDict([('@group_id'  'B3')  ('@value'  '0')])])]))]))]))])  OrderedDict([('title'  'Between 18 and 65 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '79')])  OrderedDict([('@group_id'  'B2')  ('@value'  '74')])  OrderedDict([('@group_id'  'B3')  ('@value'  '153')])])]))]))]))])  OrderedDict([('title'  '>=65 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '121')])  OrderedDict([('@group_id'  'B2')  ('@value'  '126')])  OrderedDict([('@group_id'  'B3')  ('@value'  '247')])])]))]))]))])])]))])  OrderedDict([('title'  'Gender')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Female')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '5')])  OrderedDict([('@group_id'  'B2')  ('@value'  '7')])  OrderedDict([('@group_id'  'B3')  ('@value'  '12')])])]))]))]))])  OrderedDict([('title'  'Male')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '195')])  OrderedDict([('@group_id'  'B2')  ('@value'  '193')])  OrderedDict([('@group_id'  'B3')  ('@value'  '388')])])]))]))]))])])]))])  OrderedDict([('title'  'Region of Enrollment')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  OrderedDict([('title'  'United States')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '200')])  OrderedDict([('@group_id'  'B2')  ('@value'  '200')])  OrderedDict([('@group_id'  'B3')  ('@value'  '400')])])]))]))]))]))]))])  OrderedDict([('title'  'range of motion of knee')  ('units'  'degrees')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '113.7')  ('@spread'  '1.0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '111.9')  ('@spread'  '1.1')])  OrderedDict([('@group_id'  'B3')  ('@value'  '112.8')  ('@spread'  '1.2')])])]))]))]))]))]))])]|,This study will be designed to compare prospectively  in a randomized fashion  the clinical  functional  and radiographic results of a nonmodular (all-polyethylene tibi/AP) fixed-bearing posterior cruciate substituting design with a modular posterior cruciate substituting rotating platform (RP) design for total knee arthroplasty. Comparing these two designs will afford the investigators information in the following areas: 1. Does a RP design offer improvement in range of motion over a AP design? 2. Does a RP design have improved wear characteristics over a nonmodular AP design? 3. Is there a clear clinical advantage to the RP design that justifies its increased cost? Answering these questions will allow surgeons to use RP designs appropriately in different demand populations. This study was designed to address the questions of whether an RP design offers improvement in ROM  Knee Society scores  Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) scores  selected Medical Outcomes Short-Form Health Survey Short Form-36 (SF-36) scores or radiographic measures  over an APT design. The investigators' primary hypothesis was that there would be no difference in these outcome measures at a minimum two year followup. A secondary hypothesis based on the anticipated long-term followup of this group was that there would be no difference in implant survival.|,Comparison of Mobile-Bearing and Fixed-Bearing All-Polyethylene Tibia Total Knee Designs|,There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|,Industry|,January 2007|,['Osteoarthritis'  'Osteoarthritis  Knee']|,,Inclusion Criteria: - generally accepted clinical and radiographic criteria for primary total knee arthroplasty Exclusion Criteria: - substantial angular deformity or bony deformity requiring structural grafting or modular augmentation were excluded at the discretion of the principle investigator - patients whose mental function precluded them from responding to our standard questionnaires|,,ClinicalTrials.gov processed this data on May 19  2017|,Inclusion Criteria: - generally accepted clinical and radiographic criteria for primary total knee arthroplasty Exclusion Criteria: - substantial angular deformity or bony deformity requiring structural grafting or modular augmentation were excluded at the discretion of the principle investigator - patients whose mental function precluded them from responding to our standard questionnaires|,All|,Accepts Healthy Volunteers|,85 Years|,60 Years|,400|,March 24  2009|,March 24  2009|,,All|,,,No|,,[OrderedDict([('intervention_type'  'Procedure')  ('intervention_name'  'TKA surgery with the rotating platform mobile-bearing knee design')  ('description'  'Depuy Sigma RP rotating platform design')  ('arm_group_label'  'rotating-platform design TKA')])  OrderedDict([('intervention_type'  'Procedure')  ('intervention_name'  'TKA surgery with the all-polyethylene tibia knee design')  ('description'  'Depuy Sigma fixed-bearing design with all-polyethylene tibia')  ('arm_group_label'  'all-polyethylene tibia design TKA')])]|,,,,Chief  Dept. of Orthopaedic Surgery  Minneapolis VAMC|,['knee arthritis'  'total knee arthroplasty'  'total knee replacement'  'mobile bearing design'  'all-polyethylene tibia']|,June 24  2013|,U.S. Fed|,Mean 43 month followup with minimum 2 year followup; survival analysis will follow at long-term followup; multiple outcome measures also recorded other than range of motion (ROM)|,Link to the current ClinicalTrials.gov record.|,United States|,,Single Blind (Participant)|,,85 Years|,60 Years|,NCT00894361|,2|,,,A Randomized Prospective Comparison of Mobile-Bearing and Fixed-Bearing (All-Polyethylene Tibia) Cruciate-Substituting Total Knee Arthroplasty (TKA) Designs|,MVA-3028|,[OrderedDict([('type'  'Secondary')  ('title'  'Survival of the Implants to Subject Death or Implant Removal')  ('time_frame'  '10 or more years')])  OrderedDict([('type'  'Primary')  ('title'  'Knee Postoperative Range of Motion (ROM) at 2 Years')  ('description'  'range of motion of the knee postoperatively at 2 years')  ('time_frame'  '2 years')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Rotating-platform Design Total Knee Arthroplasty (TKA)')  ('description'  'patients who were randomized to receive the rotating platform mobile-bearing TKA design')])  OrderedDict([('@group_id'  'O2')  ('title'  'All-polyethylene Tibia Design Total Knee Arthroplasty (TKA)')  ('description'  'patients who were randomized to receive the all-polyethylene tibial component design')])])]))  ('measure'  OrderedDict([('title'  'Knee Postoperative Range of Motion (ROM) at 2 Years')  ('description'  'range of motion of the knee postoperatively at 2 years')  ('units'  'degrees')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '176')])  OrderedDict([('@group_id'  'O2')  ('@value'  '136')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '110.4')  ('@spread'  '0.8')])  OrderedDict([('@group_id'  'O2')  ('@value'  '111.9')  ('@spread'  '0.9')])])]))]))]))]))]))]))])]|,Minneapolis VAMC  Dept. of Orthopaedic Surgery|,Completed|,Yes|,[OrderedDict([('@group_id'  'P1')  ('@count'  '24')])  OrderedDict([('@group_id'  'P2')  ('@count'  '64')])]|,,,,Phase 4|,tjgioe@gmail.com|,,,range of motion of the knee postoperatively at 2 years|,Treatment|,,,,[OrderedDict([('@group_id'  'E1')  ('title'  'Rotating-platform Design Total Knee Arthroplasty (TKA)')  ('description'  'patients who were randomized to receive the rotating platform mobile-bearing total knee arthroplasty (TKA) design')])  OrderedDict([('@group_id'  'E2')  ('title'  'All-polyethylene Tibia Design Total Knee Arthroplasty (TKA)')  ('description'  'patients who were randomized to receive the all-polyethylene tibial component design')])]|,[OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '200')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '200')])]|,Principal Investigator|,,10 or more years|,Minneapolis Veterans Affairs Medical Center|,,October 2001|,,Interventional|,,https://clinicaltrials.gov/show/NCT00894361|,June 2013|,
3,,All patients treated on same arm|,30|,All patients treated on same armPrednisone: Orally during Induction  Consolidation 1  CNS  Consolidation 2  and Continuation therapy.Vincristine: Intravenously during Induction  CNS  Consolidation 2 and Continuation TherapyDoxorubicin: Intravenously during Induction  CNS  and Consolidation 2 therapyPEG-asparaginase: Intravenously during Induction  Consolidation 1  CNS  and Consolidation 2 therapyCytarabine: Intrathecally during Induction and CNS therapyMethotrexate: Intrathecally during Induction  CNS  and Continuation TherapyImatinib: Orally during Induction  Consolidation 1  CNS  Consolidation 2 and Continuation TherapyClofarabine: Intravenously during Consolidation 1 Therapy6 Mercaptopurine: Orally during CNS  Consolidation 2 and Continuation Therapy|,[OrderedDict([('title'  'Age')  ('units'  'years')  ('param'  'Median')  ('dispersion'  'Full Range')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '58')  ('@lower_limit'  '51')  ('@upper_limit'  '72')]))]))]))]))]))]))])  OrderedDict([('title'  'Sex: Female  Male')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  [OrderedDict([('title'  'Female')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '18')]))]))])  OrderedDict([('title'  'Male')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '12')]))]))])])]))]))]))])  OrderedDict([('title'  'Race/Ethnicity  Customized')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Caucasian')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '27')]))]))]))]))])  OrderedDict([('title'  'Not Available')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '3')]))]))]))]))])])]))])  OrderedDict([('title'  'Region of Enrollment')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  OrderedDict([('title'  'United States')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '30')]))]))]))]))]))]))])  OrderedDict([('title'  'White blood cell count')  ('units'  '10^3 cell per μL')  ('param'  'Median')  ('dispersion'  'Full Range')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '10.4')  ('@lower_limit'  '0.7')  ('@upper_limit'  '570')]))]))]))]))]))]))])  OrderedDict([('title'  'Performance status')  ('description'  'Eastern Cooperative Oncology Group Performance Status 0 Fully active  able to carry on all pre-disease performance without restriction\nRestricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature\nAmbulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours\nCapable of only limited selfcare; confined to bed or chair more than 50% of waking hours\nCompletely disabled; cannot carry on any self-care totally confined to bed or chair\nDead')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'ECOG 0')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '14')]))]))]))]))])  OrderedDict([('title'  'ECOG 1')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '11')]))]))]))]))])  OrderedDict([('title'  'ECOG 2')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '5')]))]))]))]))])])]))])  OrderedDict([('title'  'Chromosomal alterations')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Philadelphia chromosome positive')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '12')]))]))]))]))])  OrderedDict([('title'  'Mixed lineage leukemia rearrangement')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '2')]))]))]))]))])])]))])  OrderedDict([('title'  'Immunophenotype')  ('description'  'acute lymphoblastic leukemia (ALL) immunophenotype')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'B-cell ALL')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '29')]))]))]))]))])  OrderedDict([('title'  'T-cell ALL')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '1')]))]))]))]))])])]))])]|,The purpose of this study is to determine the safety and effectiveness of a multi-drug regimen (which includes prednisone  vincristine  cytarabine  doxorubicin  6 mercaptopurine  and methotrexate) which is considered standard treatment for children and young adults with acute lymphoblastic leukemia (ALL)  in combination with PEG-asparaginase and clofarabine to treat older adults with ALL. PEG-asparaginase has been used in chemotherapy treatment regimens for both children and adults with ALL. Clofarabine has been used in chemotherapy treatment regimens for children with ALL and has been shown to decrease the number of leukemia cells. Participants with leukemia that has an abnormal chromosome  called the Philadelphia chromosome  will also be given imatinib.|,Treatment of Older Adults With Acute Lymphoblastic Leukemia|,There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|,[OrderedDict([('agency'  'Dana-Farber Cancer Institute')  ('agency_class'  'Other')])  OrderedDict([('agency'  'Beth Israel Deaconess Medical Center')  ('agency_class'  'Other')])  OrderedDict([('agency'  'Enzon Pharmaceuticals  Inc.')  ('agency_class'  'Industry')])  OrderedDict([('agency'  'Genzyme  a Sanofi Company')  ('agency_class'  'Industry')])]|,December 2014|,['Leukemia'  'Precursor Cell Lymphoblastic Leukemia-Lymphoma'  'Leukemia  Lymphoid']|,,Inclusion Criteria: - Acute lymphoblastic leukemia  excluding known mature B-cell ALL by the presence of any of the following: surface immunoglobulin  L3 morphology  t(8;14)(q24;q32)  t(8;22)  or t(2;8). - Patients with mature B-cell ALL will be removed from the protocol as soon as the diagnosis is made and should be treated on a B-cell leukemia protocol. - Patients with lymphoblastic lymphoma are also eligible - No prior anti-leukemic therapy except <1 week of steroids  and/or emergent radiation therapy to the mediastinum  or hydroxyurea or emergent leukopheresis. Longer steroid use for diseases other than leukemia is permitted. - Age 51-75 years - Ejection fraction > 45% - Creatinine < 2.0 mg/dl - Total bilirubin < 3.0 mg/dl - ECOG (Eastern Cooperative Oncology Group) Performance Status of 0  1  2 - Non-pregnant and non lactating Exclusion Criteria: - Known HIV positive - Comorbid medical condition  in the investigator's opinion  would make participation in this trial and adherence to the protocol guidelines difficult - Active psychiatric or mental illness making informed consent or careful clinical follow-up unlikely|,- This research study has stages of treatment as follows: 1) Induction 2) Consolidation 1 3) Stem cell of Bone Marrow Transplant (if the participant is eligible). If the participant does not have a transplant: 4) CNS Therapy 5) Consolidation 2 6) Continuation Therapy. - During all phases of study treatment  participants will have additional tests and procedures to monitor their health and for research purposes. These tests will include: physical exams  blood tests  bone marrow aspirate/biopsy and EKGs (electrocardiogram) and/or ECHOs (echo-cardiogram). - INDUCTION STAGE: This stage lasts for about one month. The study drugs and the way they are administered are as follows: Prednisone orally on days 1-21 for participants less than 60 and days 1-7 for participants 60 or greater; Vincristine intravenously on days 1  8  15 and 22; Doxorubicin intravenously on days 1 and 2; PEG-Asparaginase intravenously on days 7 and 21; Cytarabine intrathecally on day 1; Methotrexate intrathecally on day 29; Imatinib orally on days 14-29 if participant has the Philadelphia Chromosome. - After induction  if there is evidence of ALL in the spinal fluid  participants may need to receive more intrathecal therapy. - CONSOLIDATION 1 Therapy: This stage will last about one month. Participants will receive Consolidation 1 Therapy  regardless of whether or not their ALL is in full remission after Induction. The study drugs and the way they are administered are as follows: Prednisone orally days 1-5; Clofarabine intravenously days 1-5; PEG-Asparaginase intravenously days 1 and 15; Imatinib continues orally for participants with the Philadelphia Chromosome. - After the participants blood counts return to normal  their bone marrow will be tested. If the bone marrow shows remission  participants will proceed to the next stage of the study. If the bone marrow does not show remission  the participants will no longer continue on this study. - STEM CELL or BONE MARROW TRANSPLANTATION: The next stage is stem cell or bone marrow transplantation if the participant is eligible. If the participant receives a stem cell transplant  they will receive additional chemotherapy (separate from the study drugs) followed by an infusion of stem cells. If the participant receives a bone marrow transplant  they will have a bone marrow aspirate and biopsy 3 months after the transplant and 12 months from the start fo the induction to monitor the status of the ALL. If the participant receives a bone marrow or stem cell transplant  they will continue to be a part of the study  but will not proceed with CNS Therapy  Consolidation 2 Therapy  and Continuation Therapy. - CENTRAL NERVOUS SYSTEM (CNS) THERAPY: CNS therapy will begin between 2 and 6 weeks following the end of Consolidation 1. This stage will last about one month. The study drugs and the way they are administered are as follows: vincristine intravenously on day 1; doxorubicin intravenously on day 1; 6 mercaptopurine orally on days 1-14; prednisone orally on days 1-5; PEG-asparaginase intravenously on days 1 and 15; methotrexate/cytarabine/prednisone intrathecally weekly for 3 weeks; imatinib orally continues daily if the participant has the Philadelphia Chromosome. - Radiation therapy will also be given during this stage of the participant is under 60 years old. The purpose of radiation therapy is to prevent ALL from coming back in the brain. Radiation will be given in 8 treatments  given once a day  and will be scheduled with other study treatment. - CONSOLIDATION 2 THERAPY: This stage begins as soon as CNS Therapy ends and lasts about 8 months. Participants will receive repeated cycles of the study drug treatment about every 4 weeks. The study drugs and the way they are administered are as follows: vincristine intravenously on day 1; doxorubicin intravenously on day 1; 6 mercaptopurine orally on days 1-14; prednisone orally days 1-5; PEG-asparaginase orally on days 1 and 15 (first cycle only); imatinib orally continues daily if the participant has Philadelphia chromosome. - CONTINUATION THERAPY: This stage begins at the end of Consolidation 2 Therapy. The goal of this stage is to get rid of all of the ALL in the body. Participants will receive repeated cycles of the study drug treatment every 4 weeks. It will last until the participant has been in remission for 2 years. The study drugs and the way they are administered are as follows: vincristine intravenously on day 1; mercaptopurine orally on days 1-14; prednisone orally on days 1-5; methotrexate intravenously on day 15; imatinib orally continues daily if the participant has Philadelphia chromosome.|,ClinicalTrials.gov processed this data on May 19  2017|,Inclusion Criteria: - Acute lymphoblastic leukemia  excluding known mature B-cell ALL by the presence of any of the following: surface immunoglobulin  L3 morphology  t(8;14)(q24;q32)  t(8;22)  or t(2;8). - Patients with mature B-cell ALL will be removed from the protocol as soon as the diagnosis is made and should be treated on a B-cell leukemia protocol. - Patients with lymphoblastic lymphoma are also eligible - No prior anti-leukemic therapy except <1 week of steroids  and/or emergent radiation therapy to the mediastinum  or hydroxyurea or emergent leukopheresis. Longer steroid use for diseases other than leukemia is permitted. - Age 51-75 years - Ejection fraction > 45% - Creatinine < 2.0 mg/dl - Total bilirubin < 3.0 mg/dl - ECOG (Eastern Cooperative Oncology Group) Performance Status of 0  1  2 - Non-pregnant and non lactating Exclusion Criteria: - Known HIV positive - Comorbid medical condition  in the investigator's opinion  would make participation in this trial and adherence to the protocol guidelines difficult - Active psychiatric or mental illness making informed consent or careful clinical follow-up unlikely|,All|,No|,75 Years|,51 Years|,30|,September 8  2009|,December 16  2016|,,All|,,,No|,,['Methotrexate'  'Cytarabine'  'Clofarabine'  '6-Mercaptopurine'  'Doxorubicin'  'Pegaspargase'  'Prednisone'  'Vincristine'  'Asparaginase']|,,,,Principal Investigator|,ALL|,February 10  2017|,Other|,,Link to the current ClinicalTrials.gov record.|,United States|,,No masking|,,75 Years|,51 Years|,NCT00973752|,1|,,,Treatment of Older Adults With Acute Lymphoblastic Leukemia|,08-356|,19|,Massachusetts General Hospital|,Completed|,Yes|,[OrderedDict([('title'  'STARTED')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '30')]))]))])  OrderedDict([('title'  'COMPLETED')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '30')]))]))])  OrderedDict([('title'  'NOT COMPLETED')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '0')]))]))])]|,,,,Phase 2|,afathi@partners.org|,,,The number of participants alive one year after baseline.|,Treatment|,,,,All patients treated on same armPrednisone: Orally during Induction  Consolidation 1  CNS  Consolidation 2  and Continuation therapy.Vincristine: Intravenously during Induction  CNS  Consolidation 2 and Continuation TherapyDoxorubicin: Intravenously during Induction  CNS  and Consolidation 2 therapyPEG-asparaginase: Intravenously during Induction  Consolidation 1  CNS  and Consolidation 2 therapyCytarabine: Intrathecally during Induction and CNS therapyMethotrexate: Intrathecally during Induction  CNS  and Continuation TherapyImatinib: Orally during Induction  Consolidation 1  CNS  Consolidation 2 and Continuation TherapyClofarabine: Intravenously during Consolidation 1 Therapy6 Mercaptopurine: Orally during CNS  Consolidation 2 and Continuation Therapy|,[OrderedDict([('title'  'Total')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Total  other adverse events')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '18')  ('@subjects_at_risk'  '30')]))]))]))])  OrderedDict([('title'  'Blood and lymphatic system disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Grade 2 Anemia')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '12')  ('@subjects_at_risk'  '30')]))]))]))])  OrderedDict([('title'  'Cardiac disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Grade 2 Hypertension')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 hypotension')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Gastrointestinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Grade 2 anorexia')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 colitis')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 constipation')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 diarrhea')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 stomatitis')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 nausea')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '11')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 taste alteration')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 vomiting')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 Abdominal pain')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'General disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Grade 2 fatigue')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '18')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 Insomnia')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 weight loss')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 Edema')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '9')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 hypoalbuminemia')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 weakness')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 mental status change')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 back pain')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 pain  other')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Hepatobiliary disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Grade 2 transaminitis')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 Elevated alkaline phosphatase')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 Hyperbilirubinemia')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Immune system disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Grade 2 Allergic reaction')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))]))]))])  OrderedDict([('title'  'Infections and infestations')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Grade 2 febrile neutropenia')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 Infection')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '9')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Metabolism and nutrition disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Grade 2 hyperglycemia')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 hypocalcemia')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Nervous system disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Grade 2 neuropathy')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))]))]))])  OrderedDict([('title'  'Renal and urinary disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Grade 2 azotemia')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 ureteral obstruction')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Respiratory  thoracic and mediastinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Grade 2 dyspnea')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 hypoxia')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Skin and subcutaneous tissue disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Grade 2 erythema multiforme')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 pruritis')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 rash')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Grade 2 decubitus ulcer')  ('description'  'Grade 1 toxicities were not required to be reported per protocol')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '30')]))])])]))])]|,Principal Investigator|,,,Massachusetts General Hospital|,,August 2009|,,Interventional|,,https://clinicaltrials.gov/show/NCT00973752|,February 2017|,
4,Non-Randomized|,['Group 1'  'Group 2']|,[OrderedDict([('@group_id'  'B1')  ('@value'  '8')])  OrderedDict([('@group_id'  'B2')  ('@value'  '7')])  OrderedDict([('@group_id'  'B3')  ('@value'  '15')])]|,[OrderedDict([('@group_id'  'B1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'B2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])  OrderedDict([('@group_id'  'B3')  ('title'  'Total')  ('description'  'Total of all reporting groups')])]|,[OrderedDict([('title'  'Age')  ('units'  'Years')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '6.8')  ('@spread'  '1.16')])  OrderedDict([('@group_id'  'B2')  ('@value'  '13.7')  ('@spread'  '2.81')])  OrderedDict([('@group_id'  'B3')  ('@value'  '10.0')  ('@spread'  '4.12')])])]))]))]))]))]))])  OrderedDict([('title'  'Gender')  ('units'  'Participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Female')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '3')])  OrderedDict([('@group_id'  'B2')  ('@value'  '4')])  OrderedDict([('@group_id'  'B3')  ('@value'  '7')])])]))]))]))])  OrderedDict([('title'  'Male')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '5')])  OrderedDict([('@group_id'  'B2')  ('@value'  '3')])  OrderedDict([('@group_id'  'B3')  ('@value'  '8')])])]))]))]))])])]))])  OrderedDict([('title'  'Weight')  ('units'  'kg')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '24.60')  ('@spread'  '4.739')])  OrderedDict([('@group_id'  'B2')  ('@value'  '48.89')  ('@spread'  '17.533')])  OrderedDict([('@group_id'  'B3')  ('@value'  '35.93')  ('@spread'  '17.328')])])]))]))]))]))]))])  OrderedDict([('title'  'Height')  ('units'  'cm')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '119.9')  ('@spread'  '7.49')])  OrderedDict([('@group_id'  'B2')  ('@value'  '158.0')  ('@spread'  '16.32')])  OrderedDict([('@group_id'  'B3')  ('@value'  '137.7')  ('@spread'  '23.02')])])]))]))]))]))]))])  OrderedDict([('title'  'Body Mass Index (BMI)')  ('units'  'kg/m^2')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '16.962')  ('@spread'  '1.7654')])  OrderedDict([('@group_id'  'B2')  ('@value'  '18.944')  ('@spread'  '3.4563')])  OrderedDict([('@group_id'  'B3')  ('@value'  '17.887')  ('@spread'  '2.7795')])])]))]))]))]))]))])]|,This study will assess the pharmacokinetics of nilotinib in Ph+ CML pediatric patients that are newly diagnosed or resistant or intolerant to imatinib or dasatinib or refractory or relapsed Ph+ ALL compared to the adult populations. It will also evaluate safety and activity of nilotinib as secondary objectives.|,A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)|,The terms and conditions of Novartis' agreements with its investigators may vary. However  Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e. data from all sites) in clinical trial or disclosure of trial results in their entirety.|,,July 2015|,['Leukemia'  'Leukemia  Myeloid'  'Precursor Cell Lymphoblastic Leukemia-Lymphoma'  'Leukemia  Lymphoid'  'Leukemia  Myelogenous  Chronic  BCR-ABL Positive'  'Philadelphia Chromosome']|,,Inclusion Criteria: - Must have one of the following: newly diagnosed CP Ph+CML  CP or AP resistant/ intolerant to imatinib and/or dasatinib  or Ph+ ALL either relapsed after or refractory to standard therapy - adequate renal  hepatic and pancreatic function Exclusion Criteria: - patients receiving therapy with strong CYP3A4 inhibitors and/or inducers and treatments cannot be stopped or changed to a different medication at least 14 days prior to starting study drug - patients receiving therapy with any medications with a known risk or possible risk to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. - gastrointestinal impairment or disease that may interfere with drug absorption - liver  pancreatic or severe renal disease unrelated to disease under study - impaired cardiac function - patients who received dasatinib within 3 days of starting study drug - patients who received imatinib within 5 days of starting study drug - patients receiving hydroxyurea or corticosteroids that has not been discontinued at least 1 week after initiation of nilotinib - patients who received hematopoietic growth factors within 7 days of starting study drug or Pegfilgrastim (Neulasta®) within 14 days of starting study drug - patients with Stem Cell Transplant (SCT) or Rescue without TBI: Evidence of active graft vs. host disease and < 3 months since SCT Other protocol-defined inclusion/exclusion criteria may apply|,,ClinicalTrials.gov processed this data on May 19  2017|,Inclusion Criteria: - Must have one of the following: newly diagnosed CP Ph+CML  CP or AP resistant/ intolerant to imatinib and/or dasatinib  or Ph+ ALL either relapsed after or refractory to standard therapy - adequate renal  hepatic and pancreatic function Exclusion Criteria: - patients receiving therapy with strong CYP3A4 inhibitors and/or inducers and treatments cannot be stopped or changed to a different medication at least 14 days prior to starting study drug - patients receiving therapy with any medications with a known risk or possible risk to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. - gastrointestinal impairment or disease that may interfere with drug absorption - liver  pancreatic or severe renal disease unrelated to disease under study - impaired cardiac function - patients who received dasatinib within 3 days of starting study drug - patients who received imatinib within 5 days of starting study drug - patients receiving hydroxyurea or corticosteroids that has not been discontinued at least 1 week after initiation of nilotinib - patients who received hematopoietic growth factors within 7 days of starting study drug or Pegfilgrastim (Neulasta®) within 14 days of starting study drug - patients with Stem Cell Transplant (SCT) or Rescue without TBI: Evidence of active graft vs. host disease and < 3 months since SCT Other protocol-defined inclusion/exclusion criteria may apply|,All|,No|,18 Years|,1 Year|,15|,February 26  2010|,December 18  2015|,,All|,,,No|,,['Imatinib Mesylate'  'Dasatinib']|,,,,,['Chronic Myeloid Leukemia'  'Acute Lymphoblastic Leukemia'  'Ph+ CML'  'Ph+ ALL'  'pediatric'  'nilotinib'  'imatinib'  'chronic phase'  'accelerated phase'  'newly diagnosed Ph+ CML'  'dasatinib']|,December 18  2015|,Industry|,,Link to the current ClinicalTrials.gov record.|,['Brazil'  'France'  'Italy'  'Korea  Republic of'  'Netherlands'  'Russian Federation'  'United Kingdom'  'United States']|,,Open Label|,,18 Years|,1 Year|,NCT01077544|,2|,,,A Multi-center  Open-label  Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML  With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib  or With Refractory/Relapsed Ph+ ALL|,CAMN107A2120|,[OrderedDict([('type'  'Primary')  ('title'  'Summary of Nilotinib Non-compartmental PK Parameters: Cmax')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')  ('time_frame'  'Cycle 1 Day 1')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Summary of Nilotinib Non-compartmental PK Parameters: Cmax')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('units'  'ng/mL')  ('param'  'Geometric Mean')  ('dispersion'  'Geometric Coefficient of Variation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '7')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '405.111')  ('@spread'  '42.5')])  OrderedDict([('@group_id'  'O2')  ('@value'  '402.715')  ('@spread'  '35.2')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Ph+ CML Participants With Confirmed Complete Hematologic Response (CHR)')  ('description'  'A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved at two consecutive assessments  at least 4 weeks apart: white blood cell (WBC) count < 10 × 109/L; platelet < 450 × 109/L; basophils < 5%; no blasts and promyelocytes in peripheral blood (PB); myelocytes + metamyelocytes < 5% in PB; and no extramedullary involvement. The information used for hematological assessment was to be obtained from the laboratory and extramedullary data  all merged by patient and date.')  ('time_frame'  'minimum of 12 cycles (28 days per cycle)')  ('population'  'Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Number of Ph+ CML Participants With Confirmed Complete Hematologic Response (CHR)')  ('description'  'A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved at two consecutive assessments  at least 4 weeks apart: white blood cell (WBC) count < 10 × 109/L; platelet < 450 × 109/L; basophils < 5%; no blasts and promyelocytes in peripheral blood (PB); myelocytes + metamyelocytes < 5% in PB; and no extramedullary involvement. The information used for hematological assessment was to be obtained from the laboratory and extramedullary data  all merged by patient and date.')  ('population'  'Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.')  ('units'  'Participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '5')])  OrderedDict([('@group_id'  'O2')  ('@value'  '6')])])]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Yes')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '5')])  OrderedDict([('@group_id'  'O2')  ('@value'  '5')])])]))]))]))])  OrderedDict([('title'  'No')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '1')])])]))]))]))])])]))]))])  OrderedDict([('type'  'Primary')  ('title'  'Summary of Nilotinib Non-compartmental PK Parameters: Tmax')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')  ('time_frame'  'Cycle 1 Day 1')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Summary of Nilotinib Non-compartmental PK Parameters: Tmax')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('units'  'h')  ('param'  'Median')  ('dispersion'  'Full Range')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '7')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '2.000')  ('@spread'  '163.1050')  ('@lower_limit'  '1.02')  ('@upper_limit'  '7.08')])  OrderedDict([('@group_id'  'O2')  ('@value'  '3.000')  ('@spread'  '140.8314')  ('@lower_limit'  '2.00')  ('@upper_limit'  '7.88')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Primary')  ('title'  'Summary of Nilotinib Non-compartmental PK Parameters: AUClast (Last = 24h)')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')  ('time_frame'  'Cycle 1 Day 1')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Summary of Nilotinib Non-compartmental PK Parameters: AUClast (Last = 24h)')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('units'  'ng*h/mL')  ('param'  'Geometric Mean')  ('dispersion'  'Geometric Coefficient of Variation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '7')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '4160.969')  ('@spread'  '38.5')])  OrderedDict([('@group_id'  'O2')  ('@value'  '5707.368')  ('@spread'  '51.2')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Primary')  ('title'  'Summary of Nilotinib Non-compartmental PK Parameters: AUC0-12h')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')  ('time_frame'  'Cycle 1 Day 1')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Summary of Nilotinib Non-compartmental PK Parameters: AUC0-12h')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('units'  'ng*h/mL')  ('param'  'Geometric Mean')  ('dispersion'  'Geometric Coefficient of Variation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '7')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '2795.782')  ('@spread'  '35.7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '3393.296')  ('@spread'  '30.4')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Primary')  ('title'  'Summary of Nilotinib Steady-state PK Parameters: AUCss')  ('description'  'The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses')  ('time_frame'  'Cycle 1 Day 8 - Cycle 1 Day 28')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Summary of Nilotinib Steady-state PK Parameters: AUCss')  ('description'  'The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('units'  'ng*h/mL')  ('param'  'Geometric Mean')  ('dispersion'  'Geometric Coefficient of Variation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '7')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '15129.182')  ('@spread'  '38.0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '14383.076')  ('@spread'  '33.6')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Primary')  ('title'  'Summary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted)')  ('description'  'The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses')  ('time_frame'  'Cycle 1 Day 8 - Cycle 1 day 28')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Summary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted)')  ('description'  'The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('units'  'L/h/m^2)')  ('param'  'Geometric Mean')  ('dispersion'  'Geometric Coefficient of Variation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '7')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '15.356')  ('@spread'  '38.7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '15.922')  ('@spread'  '37.0')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Primary')  ('title'  'Summary of Nilotinib Steady-state PK Parameters: Cmin')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose.')  ('time_frame'  'Cycle 1 Day 8 - Cycle 1 Day 28')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Summary of Nilotinib Steady-state PK Parameters: Cmin')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose.')  ('population'  'Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1  had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.')  ('units'  'ng/mL')  ('param'  'Geometric Mean')  ('dispersion'  'Geometric Coefficient of Variation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '7')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '804.791')  ('@spread'  '33.7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '1072.850')  ('@spread'  '20.5')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Ph+ CML Participants With Cytogenic Response')  ('description'  'Cytogenetic response was initially assessed as the percentage of Ph+ metaphases in the bone marrow (BM) and performed within 21 days prior to study entry. A major cytogenetic response (0% to 35% Ph+ metaphases test positive for the Philadelphia chromosome) combines both complete cytogenetic (CCyR) and partial cytogenetic response (PCyR). CCyR implies 0% Ph+ metaphases in the BM  PCyR is > 0% to 35%  minor cytogenetic response (mCyR) is > 35% to 65%  minimal response is > 65% to 95% and no response is > 95% Ph+ metaphases in the BM.')  ('time_frame'  'minimum of 12 cycles (28 days per cycle)')  ('population'  'FAS consist of all patients (pts) who passed screening & are enrolled into study. Patients may or may not have taken study drug. One (1) Ph+ CML patient in Group 2 was Ph+ at baseline & discontinued study prior to subsequent cytogenetic assessment. This pt doesn’t appear in any cytogenic response category.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Number of Ph+ CML Participants With Cytogenic Response')  ('description'  'Cytogenetic response was initially assessed as the percentage of Ph+ metaphases in the bone marrow (BM) and performed within 21 days prior to study entry. A major cytogenetic response (0% to 35% Ph+ metaphases test positive for the Philadelphia chromosome) combines both complete cytogenetic (CCyR) and partial cytogenetic response (PCyR). CCyR implies 0% Ph+ metaphases in the BM  PCyR is > 0% to 35%  minor cytogenetic response (mCyR) is > 35% to 65%  minimal response is > 65% to 95% and no response is > 95% Ph+ metaphases in the BM.')  ('population'  'FAS consist of all patients (pts) who passed screening & are enrolled into study. Patients may or may not have taken study drug. One (1) Ph+ CML patient in Group 2 was Ph+ at baseline & discontinued study prior to subsequent cytogenetic assessment. This pt doesn’t appear in any cytogenic response category.')  ('units'  'Participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '5')])  OrderedDict([('@group_id'  'O2')  ('@value'  '6')])])]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Complete cytogenic response (CCyR)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '2')])  OrderedDict([('@group_id'  'O2')  ('@value'  '2')])])]))]))]))])  OrderedDict([('title'  'Partial cytogenic response (PCyR)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '1')])])]))]))]))])  OrderedDict([('title'  'Minor cytogenic response (mCyR)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '1')])])]))]))]))])  OrderedDict([('title'  'Minimal')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '0')])])]))]))]))])  OrderedDict([('title'  'None')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '0')])])]))]))]))])  OrderedDict([('title'  'Absence of Ph+ at baseline')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '3')])  OrderedDict([('@group_id'  'O2')  ('@value'  '1')])])]))]))]))])])]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Ph+ CML Participants With Major Molecular Response (MMR)')  ('description'  'The bcr-abl gene fusion encodes for a BCR-ABL fusion protein. Depending on the precise location of the fusion  the molecular weight of this protein can range from 185 to 210 kDa. Consequently BCR-ABL is referred to as p185 or p210 transcript. For the patients expressing the major BCR-ABL transcript p210  molecular response was defined and reported as the percent ratio of BCR-ABL transcripts/control gene transcripts converted to a reference standard according to the International Scale (IS). A major molecular response (MMR) is defined as a BCR-ABL/control gene ratio ≤ 0.1% (equal to a 3 log reduction in BCR-ABL transcripts) on the IS. In this study  the control gene was abl.')  ('time_frame'  'minimum of 12 cycles (28 days per cycle)')  ('population'  'Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Number of Ph+ CML Participants With Major Molecular Response (MMR)')  ('description'  'The bcr-abl gene fusion encodes for a BCR-ABL fusion protein. Depending on the precise location of the fusion  the molecular weight of this protein can range from 185 to 210 kDa. Consequently BCR-ABL is referred to as p185 or p210 transcript. For the patients expressing the major BCR-ABL transcript p210  molecular response was defined and reported as the percent ratio of BCR-ABL transcripts/control gene transcripts converted to a reference standard according to the International Scale (IS). A major molecular response (MMR) is defined as a BCR-ABL/control gene ratio ≤ 0.1% (equal to a 3 log reduction in BCR-ABL transcripts) on the IS. In this study  the control gene was abl.')  ('population'  'Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.')  ('units'  'Participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '5')])  OrderedDict([('@group_id'  'O2')  ('@value'  '6')])])]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Yes')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '1')])  OrderedDict([('@group_id'  'O2')  ('@value'  '2')])])]))]))]))])  OrderedDict([('title'  'No')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '4')])  OrderedDict([('@group_id'  'O2')  ('@value'  '4')])])]))]))]))])])]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Efficacy Endpoints for Ph+ ALL Patients')  ('description'  'Best Response in Ph+ ALL patients was defined as either Complete Remission (CR) with platelet recovery  Complete Remission (CR) with incomplete platelet recovery  Partial Remission (PR) or Stable disease. Stable disease was defined is defined as failure to qualify for either CR  PR  or progressive disease.')  ('time_frame'  'minimum of 12 cycles (28 days per cycle)')  ('population'  'Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'O2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])])]))  ('measure'  OrderedDict([('title'  'Efficacy Endpoints for Ph+ ALL Patients')  ('description'  'Best Response in Ph+ ALL patients was defined as either Complete Remission (CR) with platelet recovery  Complete Remission (CR) with incomplete platelet recovery  Partial Remission (PR) or Stable disease. Stable disease was defined is defined as failure to qualify for either CR  PR  or progressive disease.')  ('population'  'Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.')  ('units'  'Participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '3')])  OrderedDict([('@group_id'  'O2')  ('@value'  '1')])])]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Complete Remission with platelet recovery')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '2')])  OrderedDict([('@group_id'  'O2')  ('@value'  '1')])])]))]))]))])  OrderedDict([('title'  'Complete Remission w/incomplete platelet recovery')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '0')])])]))]))]))])  OrderedDict([('title'  'Partial remission')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '0')])])]))]))]))])  OrderedDict([('title'  'Stable disease')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '1')])  OrderedDict([('@group_id'  'O2')  ('@value'  '0')])])]))]))]))])  OrderedDict([('title'  'Progressive disease')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '0')])])]))]))]))])])]))]))])]|,Novartis Pharmaceuticals|,Completed|,Yes|,[OrderedDict([('title'  'New Cancer Therapy')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '3')])  OrderedDict([('@group_id'  'P2')  ('@count'  '3')])])]))])  OrderedDict([('title'  'Adverse Event')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '1')])])]))])  OrderedDict([('title'  'Disease Progression')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '1')])])]))])]|,,,,Phase 1|,trialandresults.registries@novartis.com|,,,[OrderedDict([('measure'  'Summary of Nilotinib Non-compartmental PK Parameters: Cmax')  ('time_frame'  'Cycle 1 Day 1')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')])  OrderedDict([('measure'  'Summary of Nilotinib Non-compartmental PK Parameters: Tmax')  ('time_frame'  'Cycle 1 Day 1')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')])  OrderedDict([('measure'  'Summary of Nilotinib Non-compartmental PK Parameters: AUClast (Last = 24h)')  ('time_frame'  'Cycle 1 Day 1')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')])  OrderedDict([('measure'  'Summary of Nilotinib Non-compartmental PK Parameters: AUC0-12h')  ('time_frame'  'Cycle 1 Day 1')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.')])  OrderedDict([('measure'  'Summary of Nilotinib Steady-state PK Parameters: AUCss')  ('time_frame'  'Cycle 1 Day 8 - Cycle 1 Day 28')  ('description'  'The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses')])  OrderedDict([('measure'  'Summary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted)')  ('time_frame'  'Cycle 1 Day 8 - Cycle 1 day 28')  ('description'  'The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses')])  OrderedDict([('measure'  'Summary of Nilotinib Steady-state PK Parameters: Cmin')  ('time_frame'  'Cycle 1 Day 8 - Cycle 1 Day 28')  ('description'  'The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose.')])]|,Treatment|,,['Germany'  'Thailand']|,,[OrderedDict([('@group_id'  'E1')  ('title'  'Group 1')  ('description'  '1 year to < 10 years pediatric patients')])  OrderedDict([('@group_id'  'E2')  ('title'  'Group 2')  ('description'  '>= 10 years to <18 years pediatric patients')])]|,[OrderedDict([('title'  'Total')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Total  other adverse events')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '7')])])]))]))])  OrderedDict([('title'  'Blood and lymphatic system disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Haemolytic anaemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Leukopenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Lymphopenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Neutropenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Thrombocytopenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])])]))])  OrderedDict([('title'  'Ear and labyrinth disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Ear pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])]))]))])  OrderedDict([('title'  'Gastrointestinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Abdominal pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Abdominal pain upper')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Constipation')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Diarrhoea')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Nausea')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Odynophagia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Toothache')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Vomiting')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])])])])]))])  OrderedDict([('title'  'General disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Asthenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Catheter site pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Fatigue')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Malaise')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Mucosal inflammation')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Pyrexia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Xerosis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])])]))])  OrderedDict([('title'  'Hepatobiliary disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Hyperbilirubinaemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])]))]))])  OrderedDict([('title'  'Infections and infestations')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Bronchitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Device related infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Ear infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Folliculitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Fungal skin infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Hand-foot-and-mouth disease')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Lip infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Nasopharyngitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Oral candidiasis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Otitis media')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Rhinitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Skin infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Tinea pedis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Tonsillitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Upper respiratory tract infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])])]))])  OrderedDict([('title'  'Investigations')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Alanine aminotransferase increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Aspartate aminotransferase increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Bilirubin conjugated increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Blood bilirubin increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Blood bilirubin unconjugated increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Blood creatinine increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Blood phosphorus decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Blood sodium decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Blood urea increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Blood uric acid increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Electrocardiogram QT prolonged')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Haematocrit decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Haemoglobin decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Neutrophil count increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Platelet count decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Red blood cell count decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Weight decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'White blood cell count decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'White blood cell count increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])])]))])  OrderedDict([('title'  'Metabolism and nutrition disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Hypoalbuminaemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])]))]))])  OrderedDict([('title'  'Musculoskeletal and connective tissue disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Arthralgia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Back pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Bone pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Muscle spasms')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Musculoskeletal pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Neck pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Pain in extremity')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Tendon pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])])]))])  OrderedDict([('title'  'Neoplasms benign  malignant and unspecified (incl cysts and polyps)')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Skin papilloma')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])]))]))])  OrderedDict([('title'  'Nervous system disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Headache')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Paraesthesia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Peripheral sensory neuropathy')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Presyncope')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Syncope')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])])]))])  OrderedDict([('title'  'Reproductive system and breast disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Vulvovaginal pruritus')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])]))]))])  OrderedDict([('title'  'Respiratory  thoracic and mediastinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Cough')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Oropharyngeal pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Pharyngeal erythema')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Productive cough')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])])]))])  OrderedDict([('title'  'Skin and subcutaneous tissue disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Dermatitis atopic')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Dry skin')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Dyshidrotic eczema')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Eczema')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Exfoliative rash')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Psoriasis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Rash')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Rash erythematous')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Rash maculo-papular')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Rash papular')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])])])  OrderedDict([('sub_title'  'Skin lesion')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '8')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])])])])]))])]|,Sponsor|,,[OrderedDict([('measure'  'Number of Ph+ CML Participants With Confirmed Complete Hematologic Response (CHR)')  ('time_frame'  'minimum of 12 cycles (28 days per cycle)')  ('description'  'A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved at two consecutive assessments  at least 4 weeks apart: white blood cell (WBC) count < 10 × 109/L; platelet < 450 × 109/L; basophils < 5%; no blasts and promyelocytes in peripheral blood (PB); myelocytes + metamyelocytes < 5% in PB; and no extramedullary involvement. The information used for hematological assessment was to be obtained from the laboratory and extramedullary data  all merged by patient and date.')])  OrderedDict([('measure'  'Number of Ph+ CML Participants With Cytogenic Response')  ('time_frame'  'minimum of 12 cycles (28 days per cycle)')  ('description'  'Cytogenetic response was initially assessed as the percentage of Ph+ metaphases in the bone marrow (BM) and performed within 21 days prior to study entry. A major cytogenetic response (0% to 35% Ph+ metaphases test positive for the Philadelphia chromosome) combines both complete cytogenetic (CCyR) and partial cytogenetic response (PCyR). CCyR implies 0% Ph+ metaphases in the BM  PCyR is > 0% to 35%  minor cytogenetic response (mCyR) is > 35% to 65%  minimal response is > 65% to 95% and no response is > 95% Ph+ metaphases in the BM.')])  OrderedDict([('measure'  'Number of Ph+ CML Participants With Major Molecular Response (MMR)')  ('time_frame'  'minimum of 12 cycles (28 days per cycle)')  ('description'  'The bcr-abl gene fusion encodes for a BCR-ABL fusion protein. Depending on the precise location of the fusion  the molecular weight of this protein can range from 185 to 210 kDa. Consequently BCR-ABL is referred to as p185 or p210 transcript. For the patients expressing the major BCR-ABL transcript p210  molecular response was defined and reported as the percent ratio of BCR-ABL transcripts/control gene transcripts converted to a reference standard according to the International Scale (IS). A major molecular response (MMR) is defined as a BCR-ABL/control gene ratio ≤ 0.1% (equal to a 3 log reduction in BCR-ABL transcripts) on the IS. In this study  the control gene was abl.')])  OrderedDict([('measure'  'Efficacy Endpoints for Ph+ ALL Patients')  ('time_frame'  'minimum of 12 cycles (28 days per cycle)')  ('description'  'Best Response in Ph+ ALL patients was defined as either Complete Remission (CR) with platelet recovery  Complete Remission (CR) with incomplete platelet recovery  Partial Remission (PR) or Stable disease. Stable disease was defined is defined as failure to qualify for either CR  PR  or progressive disease.')])]|,Novartis|,,April 2011|,,Interventional|,,https://clinicaltrials.gov/show/NCT01077544|,December 2015|,
5,Non-Randomized|,['Blinatumomab 15 μg'  'Blinatumomab 5/15 μg'  'Blinatumomab 5/15/30 μg']|,[OrderedDict([('@group_id'  'B1')  ('@value'  '7')])  OrderedDict([('@group_id'  'B2')  ('@value'  '23')])  OrderedDict([('@group_id'  'B3')  ('@value'  '6')])  OrderedDict([('@group_id'  'B4')  ('@value'  '36')])]|,[OrderedDict([('@group_id'  'B1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'B2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'B3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'B4')  ('title'  'Total')  ('description'  'Total of all reporting groups')])]|,[OrderedDict([('title'  'Age')  ('units'  'years')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '44.0')  ('@spread'  '21.5')])  OrderedDict([('@group_id'  'B2')  ('@value'  '38.1')  ('@spread'  '16.7')])  OrderedDict([('@group_id'  'B3')  ('@value'  '42.5')  ('@spread'  '23.2')])  OrderedDict([('@group_id'  'B4')  ('@value'  '40.0')  ('@spread'  '18.4')])])]))]))]))]))]))])  OrderedDict([('title'  'Sex: Female  Male')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  [OrderedDict([('title'  'Female')  ('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '3')])  OrderedDict([('@group_id'  'B2')  ('@value'  '9')])  OrderedDict([('@group_id'  'B3')  ('@value'  '2')])  OrderedDict([('@group_id'  'B4')  ('@value'  '14')])])]))])  OrderedDict([('title'  'Male')  ('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '4')])  OrderedDict([('@group_id'  'B2')  ('@value'  '14')])  OrderedDict([('@group_id'  'B3')  ('@value'  '4')])  OrderedDict([('@group_id'  'B4')  ('@value'  '22')])])]))])])]))]))]))])  OrderedDict([('title'  'Race (NIH/OMB)')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  [OrderedDict([('title'  'American Indian or Alaska Native')  ('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '0')])  OrderedDict([('@group_id'  'B3')  ('@value'  '0')])  OrderedDict([('@group_id'  'B4')  ('@value'  '0')])])]))])  OrderedDict([('title'  'Asian')  ('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '1')])  OrderedDict([('@group_id'  'B3')  ('@value'  '0')])  OrderedDict([('@group_id'  'B4')  ('@value'  '1')])])]))])  OrderedDict([('title'  'Native Hawaiian or Other Pacific Islander')  ('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '0')])  OrderedDict([('@group_id'  'B3')  ('@value'  '0')])  OrderedDict([('@group_id'  'B4')  ('@value'  '0')])])]))])  OrderedDict([('title'  'Black or African American')  ('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '0')])  OrderedDict([('@group_id'  'B3')  ('@value'  '0')])  OrderedDict([('@group_id'  'B4')  ('@value'  '0')])])]))])  OrderedDict([('title'  'White')  ('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '7')])  OrderedDict([('@group_id'  'B2')  ('@value'  '22')])  OrderedDict([('@group_id'  'B3')  ('@value'  '6')])  OrderedDict([('@group_id'  'B4')  ('@value'  '35')])])]))])  OrderedDict([('title'  'More than one race')  ('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '0')])  OrderedDict([('@group_id'  'B3')  ('@value'  '0')])  OrderedDict([('@group_id'  'B4')  ('@value'  '0')])])]))])  OrderedDict([('title'  'Unknown or Not Reported')  ('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '0')])  OrderedDict([('@group_id'  'B3')  ('@value'  '0')])  OrderedDict([('@group_id'  'B4')  ('@value'  '0')])])]))])])]))]))]))])  OrderedDict([('title'  'Number of Prior Relapses')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  '0')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '2')])  OrderedDict([('@group_id'  'B3')  ('@value'  '1')])  OrderedDict([('@group_id'  'B4')  ('@value'  '3')])])]))]))]))])  OrderedDict([('title'  '1')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '5')])  OrderedDict([('@group_id'  'B2')  ('@value'  '15')])  OrderedDict([('@group_id'  'B3')  ('@value'  '3')])  OrderedDict([('@group_id'  'B4')  ('@value'  '23')])])]))]))]))])  OrderedDict([('title'  '2')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '2')])  OrderedDict([('@group_id'  'B2')  ('@value'  '6')])  OrderedDict([('@group_id'  'B3')  ('@value'  '1')])  OrderedDict([('@group_id'  'B4')  ('@value'  '9')])])]))]))]))])  OrderedDict([('title'  '3')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '0')])  OrderedDict([('@group_id'  'B3')  ('@value'  '1')])  OrderedDict([('@group_id'  'B4')  ('@value'  '1')])])]))]))]))])])]))])  OrderedDict([('title'  'Relapsed / refractory Status')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Primary Refractory')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '2')])  OrderedDict([('@group_id'  'B3')  ('@value'  '1')])  OrderedDict([('@group_id'  'B4')  ('@value'  '3')])])]))]))]))])  OrderedDict([('title'  'Relapsed')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '7')])  OrderedDict([('@group_id'  'B2')  ('@value'  '21')])  OrderedDict([('@group_id'  'B3')  ('@value'  '5')])  OrderedDict([('@group_id'  'B4')  ('@value'  '33')])])]))]))]))])])]))])  OrderedDict([('title'  'Prior Allogeneic Hematopoietic Stem cell Transplantation (HSCT)')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Yes  Sibling')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '1')])  OrderedDict([('@group_id'  'B2')  ('@value'  '1')])  OrderedDict([('@group_id'  'B3')  ('@value'  '1')])  OrderedDict([('@group_id'  'B4')  ('@value'  '3')])])]))]))]))])  OrderedDict([('title'  'Yes  Unrelated')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '2')])  OrderedDict([('@group_id'  'B2')  ('@value'  '9')])  OrderedDict([('@group_id'  'B3')  ('@value'  '1')])  OrderedDict([('@group_id'  'B4')  ('@value'  '12')])])]))]))]))])  OrderedDict([('title'  'Yes  Haploidentical (mother/father)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '0')])  OrderedDict([('@group_id'  'B2')  ('@value'  '0')])  OrderedDict([('@group_id'  'B3')  ('@value'  '0')])  OrderedDict([('@group_id'  'B4')  ('@value'  '0')])])]))]))]))])  OrderedDict([('title'  'No prior allogeneic HSCT')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'B1')  ('@value'  '4')])  OrderedDict([('@group_id'  'B2')  ('@value'  '13')])  OrderedDict([('@group_id'  'B3')  ('@value'  '4')])  OrderedDict([('@group_id'  'B4')  ('@value'  '21')])])]))]))]))])])]))])]|,The purpose of this study is to determine whether the bispecific T-cell engager blinatumomab is effective  safe and tolerable in the treatment of patients with relapsed/refractory B-precursor ALL.|,Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)|,The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information  but authors have final control and approval of publication content. For multicenter studies  the investigator agrees not to publish any results before the first multi-center publication.|,,March 2012|,['Leukemia'  'Precursor Cell Lymphoblastic Leukemia-Lymphoma'  'Leukemia  Lymphoid']|,,Inclusion Criteria: - Patients with B-precursor ALL relapsed after at least induction and consolidation or having refractory disease - More than 5% blasts in bone marrow - Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 - Life expectancy of ≥ 12 weeks Exclusion Criteria: - History or presence of clinically relevant central nervous system (CNS) pathology - Infiltration of cerebrospinal fluid (CSF) by ALL - Autologous/allogeneic hematopoietic stem cell transplantation (HSCT) within six weeks/three months prior to start of blinatumomab treatment - Active Graft-versus-Host Disease (GvHD) - Patients with Philadelphia chromosome (Ph)+ ALL eligible for treatment with dasatinib or imatinib - Cancer chemotherapy within two weeks prior to start of blinatumomab treatment - Immunotherapy (e.g. rituximab) within four weeks prior to start of blinatumomab treatment - Infection with human immunodeficiency virus (HIV) or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive) - Pregnant or nursing women - Previous treatment with blinatumomab|,Relapsed/refractory B-precursor ALL in adult patients is an aggressive malignant disease with dismal prognosis and unmet medical need. Additional therapeutic approaches are urgently needed. Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against CD19 expressing cells. The purpose of this study is to investigate the efficacy  safety and tolerability of different doses of the bispecific T-cell engager blinatumomab in adult patients with relapsed/refractory B-precursor ALL. Patrticipants will receive up to five 4-week cycles of intravenous blinatumomab treatment.|,ClinicalTrials.gov processed this data on May 19  2017|,Inclusion Criteria: - Patients with B-precursor ALL relapsed after at least induction and consolidation or having refractory disease - More than 5% blasts in bone marrow - Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 - Life expectancy of ≥ 12 weeks Exclusion Criteria: - History or presence of clinically relevant central nervous system (CNS) pathology - Infiltration of cerebrospinal fluid (CSF) by ALL - Autologous/allogeneic hematopoietic stem cell transplantation (HSCT) within six weeks/three months prior to start of blinatumomab treatment - Active Graft-versus-Host Disease (GvHD) - Patients with Philadelphia chromosome (Ph)+ ALL eligible for treatment with dasatinib or imatinib - Cancer chemotherapy within two weeks prior to start of blinatumomab treatment - Immunotherapy (e.g. rituximab) within four weeks prior to start of blinatumomab treatment - Infection with human immunodeficiency virus (HIV) or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive) - Pregnant or nursing women - Previous treatment with blinatumomab|,All|,No|,N/A|,18 Years|,36|,September 23  2010|,December 23  2014|,,All|,,,No|,,['Blinatumomab'  'Antibodies  Bispecific']|,,,,,['Blinatumomab'  'B-ALL'  'adult ALL'  'relapsed ALL'  'refractory ALL'  'Leukemia'  'ALL'  'Lymphatic diseases'  'Lymphoproliferative disorders'  'bispecific antibody'  'anti-CD19'  'Immunotherapeutic treatment']|,January 23  2017|,Industry|,,Link to the current ClinicalTrials.gov record.|,Germany|,,No masking|,,N/A|,18 Years|,NCT01209286|,3|,,,An Open Label  Multicenter  Exploratory Phase II Study to Evaluate the Efficacy  Safety  and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)|,MT103-206|,"[OrderedDict([('type'  'Primary')  ('title'  'Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria:\nComplete Response/Remission (CR):\nLess than or equal to 5% blasts in the bone marrow\nNo evidence of circulating blasts or extramedullar disease\nFull recovery of peripheral blood counts:\nPlatelets > 100 000/μL\nHemoglobin ≥ 11 g/dL\nAbsolute neutrophil count (ANC) > 1 500/μL\nComplete Remission with only Partial Hematological Recovery (CRh*):\nLess than or equal to 5% blasts in the bone marrow\nNo evidence of circulating blasts or extramedullar disease\nPartial recovery of peripheral blood counts:\nPlatelets > 50 000/μL\nHemoglobin ≥ 7 g/dL\nANC > 500/μL.')  ('time_frame'  'Within the first 2 cycles of treatment  12 weeks')  ('population'  'Full analysis set (FAS)  defined as participants who received any infusion of the assigned study medication  who completed at least the first treatment cycle and for whom at least one response assessment was available after the start of treatment.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'O3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'O4')  ('title'  'Blinatumomab Overall')  ('description'  'Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])])]))  ('measure'  OrderedDict([('title'  'Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria:\nComplete Response/Remission (CR):\nLess than or equal to 5% blasts in the bone marrow\nNo evidence of circulating blasts or extramedullar disease\nFull recovery of peripheral blood counts:\nPlatelets > 100 000/μL\nHemoglobin ≥ 11 g/dL\nAbsolute neutrophil count (ANC) > 1 500/μL\nComplete Remission with only Partial Hematological Recovery (CRh*):\nLess than or equal to 5% blasts in the bone marrow\nNo evidence of circulating blasts or extramedullar disease\nPartial recovery of peripheral blood counts:\nPlatelets > 50 000/μL\nHemoglobin ≥ 7 g/dL\nANC > 500/μL.')  ('population'  'Full analysis set (FAS)  defined as participants who received any infusion of the assigned study medication  who completed at least the first treatment cycle and for whom at least one response assessment was available after the start of treatment.')  ('units'  'percentage of participants')  ('param'  'Number')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '23')])  OrderedDict([('@group_id'  'O3')  ('@value'  '6')])  OrderedDict([('@group_id'  'O4')  ('@value'  '36')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '71.4')  ('@lower_limit'  '29.0')  ('@upper_limit'  '96.3')])  OrderedDict([('@group_id'  'O2')  ('@value'  '69.6')  ('@lower_limit'  '47.1')  ('@upper_limit'  '86.8')])  OrderedDict([('@group_id'  'O3')  ('@value'  '66.7')  ('@lower_limit'  '22.3')  ('@upper_limit'  '95.7')])  OrderedDict([('@group_id'  'O4')  ('@value'  '69.4')  ('@lower_limit'  '51.9')  ('@upper_limit'  '83.7')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete Response/Remission (CR) was defined by the following criteria:\nLess than or equal to 5% blasts in the bone marrow\nNo evidence of circulating blasts or extramedullar disease\nFull recovery of peripheral blood counts:\nPlatelets > 100 000/μL\nHemoglobin ≥ 11 g/dL\nAbsolute neutrophil count (ANC) > 1 500/μL')  ('time_frame'  'Within the first 2 cycles of treatment  12 weeks')  ('population'  'Full analysis set')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'O3')  ('title'  'ABlinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'O4')  ('title'  'Blinatumomab Overall')  ('description'  'Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])])]))  ('measure'  OrderedDict([('title'  'Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete Response/Remission (CR) was defined by the following criteria:\nLess than or equal to 5% blasts in the bone marrow\nNo evidence of circulating blasts or extramedullar disease\nFull recovery of peripheral blood counts:\nPlatelets > 100 000/μL\nHemoglobin ≥ 11 g/dL\nAbsolute neutrophil count (ANC) > 1 500/μL')  ('population'  'Full analysis set')  ('units'  'percentage of participants')  ('param'  'Number')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '23')])  OrderedDict([('@group_id'  'O3')  ('@value'  '6')])  OrderedDict([('@group_id'  'O4')  ('@value'  '36')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '14.3')  ('@lower_limit'  '0.4')  ('@upper_limit'  '57.9')])  OrderedDict([('@group_id'  'O2')  ('@value'  '43.5')  ('@lower_limit'  '23.2')  ('@upper_limit'  '65.5')])  OrderedDict([('@group_id'  'O3')  ('@value'  '66.7')  ('@lower_limit'  '22.3')  ('@upper_limit'  '95.7')])  OrderedDict([('@group_id'  'O4')  ('@value'  '41.7')  ('@lower_limit'  '25.5')  ('@upper_limit'  '59.2')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete remission with only partial hematological recovery (CRh*) was defined by the following criteria:\nLess than or equal to 5% blasts in the bone marrow\nNo evidence of circulating blasts or extramedullar disease\nPartial recovery of peripheral blood counts:\nPlatelets > 50 000/μL\nHemoglobin ≥ 7 g/dL\nANC > 500/μL.')  ('time_frame'  'Within the first 2 cycles of treatment  12 weeks')  ('population'  'Full analysis set')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'O3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'O4')  ('title'  'Blinatumomab Overall')  ('description'  'Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])])]))  ('measure'  OrderedDict([('title'  'Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete remission with only partial hematological recovery (CRh*) was defined by the following criteria:\nLess than or equal to 5% blasts in the bone marrow\nNo evidence of circulating blasts or extramedullar disease\nPartial recovery of peripheral blood counts:\nPlatelets > 50 000/μL\nHemoglobin ≥ 7 g/dL\nANC > 500/μL.')  ('population'  'Full analysis set')  ('units'  'percentage of participants')  ('param'  'Number')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '23')])  OrderedDict([('@group_id'  'O3')  ('@value'  '6')])  OrderedDict([('@group_id'  'O4')  ('@value'  '36')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '57.1')  ('@lower_limit'  '18.4')  ('@upper_limit'  '90.1')])  OrderedDict([('@group_id'  'O2')  ('@value'  '26.1')  ('@lower_limit'  '10.2')  ('@upper_limit'  '48.4')])  OrderedDict([('@group_id'  'O3')  ('@value'  '0.0')  ('@lower_limit'  '0.0')  ('@upper_limit'  '45.9')])  OrderedDict([('@group_id'  'O4')  ('@value'  '27.8')  ('@lower_limit'  '14.2')  ('@upper_limit'  '45.2')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Partial remission was defined by the following criteria:\n• Bone marrow blasts ≤ 25%')  ('time_frame'  'Within the first 2 cycles of treatment  12 weeks')  ('population'  'Full analysis set')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'O3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'O4')  ('title'  'Blinatumomab Overall')  ('description'  'Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])])]))  ('measure'  OrderedDict([('title'  'Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Partial remission was defined by the following criteria:\n• Bone marrow blasts ≤ 25%')  ('population'  'Full analysis set')  ('units'  'percentage of participants')  ('param'  'Number')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '23')])  OrderedDict([('@group_id'  'O3')  ('@value'  '6')])  OrderedDict([('@group_id'  'O4')  ('@value'  '36')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '0.0')  ('@lower_limit'  '0.0')  ('@upper_limit'  '41.0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '8.7')  ('@lower_limit'  '1.1')  ('@upper_limit'  '28.0')])  OrderedDict([('@group_id'  'O3')  ('@value'  '0.0')  ('@lower_limit'  '0.0')  ('@upper_limit'  '45.9')])  OrderedDict([('@group_id'  'O4')  ('@value'  '5.6')  ('@lower_limit'  '0.7')  ('@upper_limit'  '18.7')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Percentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study')  ('description'  'A minimal residual disease (MRD) response is defined as MRD < 10^-4 blasts/nucleated cells based on polymerase chain reaction (PCR) evaluation of individual rearrangements of immunoglobulin or T cell receptor genes.')  ('time_frame'  'During the core study treatment period (up to 30 weeks).')  ('population'  'Full analysis set (FAS)')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'O3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'O4')  ('title'  'Blinatumomab Overall')  ('description'  'Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])])]))  ('measure'  OrderedDict([('title'  'Percentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study')  ('description'  'A minimal residual disease (MRD) response is defined as MRD < 10^-4 blasts/nucleated cells based on polymerase chain reaction (PCR) evaluation of individual rearrangements of immunoglobulin or T cell receptor genes.')  ('population'  'Full analysis set (FAS)')  ('units'  'percentage of participants')  ('param'  'Number')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '23')])  OrderedDict([('@group_id'  'O3')  ('@value'  '6')])  OrderedDict([('@group_id'  'O4')  ('@value'  '36')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '71.4')  ('@lower_limit'  '29.0')  ('@upper_limit'  '96.3')])  OrderedDict([('@group_id'  'O2')  ('@value'  '73.9')  ('@lower_limit'  '51.6')  ('@upper_limit'  '89.8')])  OrderedDict([('@group_id'  'O3')  ('@value'  '50.0')  ('@lower_limit'  '11.8')  ('@upper_limit'  '88.2')])  OrderedDict([('@group_id'  'O4')  ('@value'  '69.4')  ('@lower_limit'  '51.9')  ('@upper_limit'  '83.7')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab')  ('description'  'The percentage of participants who underwent immediate allogeneic HSCT (defined as those in remission who undergo HSCT without receiving any other treatments) after having discontinued or completed the core study.')  ('time_frame'  'Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days')  ('population'  'Full analysis set')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'O3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'O4')  ('title'  'Blinatumomab')  ('description'  'Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])])]))  ('measure'  OrderedDict([('title'  'Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab')  ('description'  'The percentage of participants who underwent immediate allogeneic HSCT (defined as those in remission who undergo HSCT without receiving any other treatments) after having discontinued or completed the core study.')  ('population'  'Full analysis set')  ('units'  'percentage of participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '23')])  OrderedDict([('@group_id'  'O3')  ('@value'  '6')])  OrderedDict([('@group_id'  'O4')  ('@value'  '36')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '42.9')])  OrderedDict([('@group_id'  'O2')  ('@value'  '60.9')])  OrderedDict([('@group_id'  'O3')  ('@value'  '16.7')])  OrderedDict([('@group_id'  'O4')  ('@value'  '50.0')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Time to Hematological Relapse')  ('description'  'Time to hematological relapse was measured for participants who achieved a CR or CRh* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their day of death.\nHematological Relapse was defined as:\nProportion of blasts in bone marrow > 5%\nExtramedullary relapse.\nTime to hematological relapse was analyzed by Kaplan-Meier methods.')  ('time_frame'  'Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days.')  ('population'  'Participants who reached complete remission or complete remission with partial hematological recovery during the core study.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'O3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'O4')  ('title'  'Blinatumimab Overall')  ('description'  'Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])])]))  ('measure'  OrderedDict([('title'  'Time to Hematological Relapse')  ('description'  'Time to hematological relapse was measured for participants who achieved a CR or CRh* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their day of death.\nHematological Relapse was defined as:\nProportion of blasts in bone marrow > 5%\nExtramedullary relapse.\nTime to hematological relapse was analyzed by Kaplan-Meier methods.')  ('population'  'Participants who reached complete remission or complete remission with partial hematological recovery during the core study.')  ('units'  'days')  ('param'  'Median')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '5')])  OrderedDict([('@group_id'  'O2')  ('@value'  '16')])  OrderedDict([('@group_id'  'O3')  ('@value'  '4')])  OrderedDict([('@group_id'  'O4')  ('@value'  '25')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '240.0')  ('@lower_limit'  '63.0')  ('@upper_limit'  '270.0')])  OrderedDict([('@group_id'  'O2')  ('@value'  'NA')  ('@lower_limit'  '227.0')  ('#text'  'median was not reached during the core study')])  OrderedDict([('@group_id'  'O3')  ('@value'  'NA')  ('@lower_limit'  '15.0')  ('#text'  'Median was not reached during the core study')])  OrderedDict([('@group_id'  'O4')  ('@value'  '270.0')  ('@lower_limit'  '227.0')  ('#text'  'Could not be estimated due to the low number of events')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Relapse-free Survival')  ('description'  'Relapse-free survival was measured only for participants who achieved a CR or CRh* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse-free survival was estimated using Kaplan-Meier methods.')  ('time_frame'  'Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days.')  ('population'  'Participants who reached complete remission or complete remission with partial hematological recovery during the core study.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'O3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'O4')  ('title'  'Blinatumomab Overall')  ('description'  'Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])])]))  ('measure'  OrderedDict([('title'  'Relapse-free Survival')  ('description'  'Relapse-free survival was measured only for participants who achieved a CR or CRh* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse-free survival was estimated using Kaplan-Meier methods.')  ('population'  'Participants who reached complete remission or complete remission with partial hematological recovery during the core study.')  ('units'  'days')  ('param'  'Median')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '5')])  OrderedDict([('@group_id'  'O2')  ('@value'  '16')])  OrderedDict([('@group_id'  'O3')  ('@value'  '4')])  OrderedDict([('@group_id'  'O4')  ('@value'  '25')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '137.0')  ('@lower_limit'  '63.0')  ('@upper_limit'  '270.0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '268.0')  ('@lower_limit'  '226.0')  ('@upper_limit'  '403.0')])  OrderedDict([('@group_id'  'O3')  ('@value'  'NA')  ('@lower_limit'  '15.0')  ('#text'  'Median was not reached during the core study')])  OrderedDict([('@group_id'  'O4')  ('@value'  '233.0')  ('@lower_limit'  '175.0')  ('@upper_limit'  '291.0')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Overall Survival')  ('description'  'Overall survival was measured for all participants from the date of first infusion of blinatumomab until the date of death due to any cause. Participants who did not die were censored on the last documented visit date. Overall survival was estimated using Kaplan-Meier methods.')  ('time_frame'  'Up to the data cut-off date of 15 October 2012; maximum follow up time was 667 days.')  ('population'  'Full analysis set')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'O3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'O4')  ('title'  'Blinatumomab Overall')  ('description'  'Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])])]))  ('measure'  OrderedDict([('title'  'Overall Survival')  ('description'  'Overall survival was measured for all participants from the date of first infusion of blinatumomab until the date of death due to any cause. Participants who did not die were censored on the last documented visit date. Overall survival was estimated using Kaplan-Meier methods.')  ('population'  'Full analysis set')  ('units'  'days')  ('param'  'Median')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '23')])  OrderedDict([('@group_id'  'O3')  ('@value'  '6')])  OrderedDict([('@group_id'  'O4')  ('@value'  '36')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '269.0')  ('@lower_limit'  '165.0')  ('@upper_limit'  '482.0')])  OrderedDict([('@group_id'  'O2')  ('@value'  '300.0')  ('@lower_limit'  '254.0')  ('@upper_limit'  '431.0')])  OrderedDict([('@group_id'  'O3')  ('@value'  'NA')  ('@lower_limit'  '276.0')  ('#text'  'Median was not reached during the core study')])  OrderedDict([('@group_id'  'O4')  ('@value'  '300.0')  ('@lower_limit'  '258.0')  ('@upper_limit'  '455.0')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Participants With Treatment-emergent Adverse Events')  ('description'  ""Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)  version 3.0 and according to the following:\nGrade I (mild); Grade 2 (moderate); Grade 3 (severe - significantly limits the patient's ability to perform routine activities despite symptomatic therapy; Grade 4 (life-threatening); Grade 5 (death).\nThe investigator used medical judgment to determine if there was a causal relationship (ie  certain  probable  possible  unlikely  not related) between an adverse event and blinatumomab.\nA serious adverse event is any untoward medical occurrence or effect  that at any dose:\nresulted in death  was life-threatening  required or prolonged hospitalization  resulted in persistent or significant disability or incapacity  is a congenital anomaly or birth defect or is a medically important condition."")  ('time_frame'  'From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle; median treatment duration was 55.7 days.')  ('population'  'Safety analysis set  defined as all participants who received any infusion of blinatumomab.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'O3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'O4')  ('title'  'Blinatumomab Overall')  ('description'  'Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])])]))  ('measure'  OrderedDict([('title'  'Number of Participants With Treatment-emergent Adverse Events')  ('description'  ""Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)  version 3.0 and according to the following:\nGrade I (mild); Grade 2 (moderate); Grade 3 (severe - significantly limits the patient's ability to perform routine activities despite symptomatic therapy; Grade 4 (life-threatening); Grade 5 (death).\nThe investigator used medical judgment to determine if there was a causal relationship (ie  certain  probable  possible  unlikely  not related) between an adverse event and blinatumomab.\nA serious adverse event is any untoward medical occurrence or effect  that at any dose:\nresulted in death  was life-threatening  required or prolonged hospitalization  resulted in persistent or significant disability or incapacity  is a congenital anomaly or birth defect or is a medically important condition."")  ('population'  'Safety analysis set  defined as all participants who received any infusion of blinatumomab.')  ('units'  'participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '23')])  OrderedDict([('@group_id'  'O3')  ('@value'  '6')])  OrderedDict([('@group_id'  'O4')  ('@value'  '36')])])]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Any adverse event (AE)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '23')])  OrderedDict([('@group_id'  'O3')  ('@value'  '6')])  OrderedDict([('@group_id'  'O4')  ('@value'  '36')])])]))]))]))])  OrderedDict([('title'  'Adverse events of at least CTC grade 3')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '15')])  OrderedDict([('@group_id'  'O3')  ('@value'  '5')])  OrderedDict([('@group_id'  'O4')  ('@value'  '27')])])]))]))]))])  OrderedDict([('title'  'Treatment-related adverse events')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '23')])  OrderedDict([('@group_id'  'O3')  ('@value'  '6')])  OrderedDict([('@group_id'  'O4')  ('@value'  '36')])])]))]))]))])  OrderedDict([('title'  'Related adverse events of at least CTC grade 3')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '7')])  OrderedDict([('@group_id'  'O2')  ('@value'  '12')])  OrderedDict([('@group_id'  'O3')  ('@value'  '4')])  OrderedDict([('@group_id'  'O4')  ('@value'  '23')])])]))]))]))])  OrderedDict([('title'  'Serious adverse events')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '6')])  OrderedDict([('@group_id'  'O2')  ('@value'  '13')])  OrderedDict([('@group_id'  'O3')  ('@value'  '5')])  OrderedDict([('@group_id'  'O4')  ('@value'  '24')])])]))]))]))])  OrderedDict([('title'  'Serious adverse events of at least CTC grade 3')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '6')])  OrderedDict([('@group_id'  'O2')  ('@value'  '12')])  OrderedDict([('@group_id'  'O3')  ('@value'  '4')])  OrderedDict([('@group_id'  'O4')  ('@value'  '22')])])]))]))]))])  OrderedDict([('title'  'Serious related adverse events')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '4')])  OrderedDict([('@group_id'  'O2')  ('@value'  '8')])  OrderedDict([('@group_id'  'O3')  ('@value'  '4')])  OrderedDict([('@group_id'  'O4')  ('@value'  '16')])])]))]))]))])  OrderedDict([('title'  'AEs leading to interruption of blinatumomab')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '3')])  OrderedDict([('@group_id'  'O2')  ('@value'  '6')])  OrderedDict([('@group_id'  'O3')  ('@value'  '3')])  OrderedDict([('@group_id'  'O4')  ('@value'  '12')])])]))]))]))])  OrderedDict([('title'  'AEs leading to discontinuation of blinatumomab')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '4')])  OrderedDict([('@group_id'  'O2')  ('@value'  '4')])  OrderedDict([('@group_id'  'O3')  ('@value'  '1')])  OrderedDict([('@group_id'  'O4')  ('@value'  '9')])])]))]))]))])  OrderedDict([('title'  'AEs leading to death')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '1')])  OrderedDict([('@group_id'  'O2')  ('@value'  '4')])  OrderedDict([('@group_id'  'O3')  ('@value'  '1')])  OrderedDict([('@group_id'  'O4')  ('@value'  '6')])])]))]))]))])])]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Steady State Blinatumomab Concentration')  ('description'  'The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the intravenous infusion was started for cycle 1 and cycle 2  respectively. Actual doses administered were used in the analysis.\nConcentrations below the limit of detection (3 pg/mL) were set to zero before data analysis and concentrations below the lower limit of quantitation (50 pg/mL) were excluded from analysis.')  ('time_frame'  'Samples were collected at predose and at 48 hours following start of infusion  when dose is escalated and on Days 8  15  22  and 29 of the first 2 cycles.')  ('population'  'Participants who received blinatumomab and who had available pharmacokinetic data.')  ('group_list'  OrderedDict([('group'  [OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab 5 μg')  ('description'  'Participants receiving blinatumomab 5 μg/m²/day.')])  OrderedDict([('@group_id'  'O2')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants receiving blinatumomab 15 μg/m²/day.')])  OrderedDict([('@group_id'  'O3')  ('title'  'Blinatumomab 30 μg')  ('description'  'Participants receiving blinatumomab 30 μg/m²/day.')])])]))  ('measure'  OrderedDict([('title'  'Steady State Blinatumomab Concentration')  ('description'  'The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the intravenous infusion was started for cycle 1 and cycle 2  respectively. Actual doses administered were used in the analysis.\nConcentrations below the limit of detection (3 pg/mL) were set to zero before data analysis and concentrations below the lower limit of quantitation (50 pg/mL) were excluded from analysis.')  ('population'  'Participants who received blinatumomab and who had available pharmacokinetic data.')  ('units'  'pg/mL')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  [OrderedDict([('@group_id'  'O1')  ('@value'  '31')])  OrderedDict([('@group_id'  'O2')  ('@value'  '34')])  OrderedDict([('@group_id'  'O3')  ('@value'  '5')])])]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  [OrderedDict([('@group_id'  'O1')  ('@value'  '167')  ('@spread'  '66')])  OrderedDict([('@group_id'  'O2')  ('@value'  '553')  ('@spread'  '238')])  OrderedDict([('@group_id'  'O3')  ('@value'  '1180')  ('@spread'  '820')])])]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Clearance of Blinatumomab')  ('description'  'Clearance was calculated as R0/Css; where R0 is the infusion rate (μg/m^2/hr) and Css is the steady state concentration.')  ('time_frame'  'Samples were collected at predose and at 48 hours following start of infusion  when dose is escalated and on Days 8  15  22  and 29 of the first 2 cycles.')  ('population'  'Participants who received blinatumomab and who had available pharmacokinetic data.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab')  ('description'  'All participants who received blinatumomab.')]))]))  ('measure'  OrderedDict([('title'  'Clearance of Blinatumomab')  ('description'  'Clearance was calculated as R0/Css; where R0 is the infusion rate (μg/m^2/hr) and Css is the steady state concentration.')  ('population'  'Participants who received blinatumomab and who had available pharmacokinetic data.')  ('units'  'L/m^2/hr')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '36')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1.34')  ('@spread'  '0.61')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Serum Cytokine Peak Levels')  ('description'  'The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2  IL-6  IL-10  tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) is 125 pg/mL and the limit of detection (LOD) is 20 pg/mL.')  ('time_frame'  'Samples were collected prior to treatment start (baseline)  and at 2  6  24  and 48 hours after drug infusion start  and at these same time points when dose is escalated in each treatment cycle.')  ('population'  'Participants who received blinatumomab and who had evaluable pharmacodynamic data.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Blinatumomab')  ('description'  'All participants who received blinatumomab.')]))]))  ('measure'  OrderedDict([('title'  'Serum Cytokine Peak Levels')  ('description'  'The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2  IL-6  IL-10  tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) is 125 pg/mL and the limit of detection (LOD) is 20 pg/mL.')  ('population'  'Participants who received blinatumomab and who had evaluable pharmacodynamic data.')  ('units'  'pg/mL')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '36')]))]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'IL-6: Cycle 1 (N=35)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '2563')  ('@spread'  '5231')]))]))]))]))])  OrderedDict([('title'  'IL-6: Cycle 2 (N=22)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '212')  ('@spread'  '477')]))]))]))]))])  OrderedDict([('title'  'IL-6: Cycle 3 (N=11)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '21')  ('@spread'  '26')]))]))]))]))])  OrderedDict([('title'  'IL-10: Cycle 1 (N=35)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1302')  ('@spread'  '2563')]))]))]))]))])  OrderedDict([('title'  'IL-10: Cycle 2 (N=22)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '351')  ('@spread'  '582')]))]))]))]))])  OrderedDict([('title'  'IL-10: Cycle 3 (N=11)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '419')  ('@spread'  '730')]))]))]))]))])  OrderedDict([('title'  'IFN-Ɣ: Cycle 1 (N=35)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '467')  ('@spread'  '1824')]))]))]))]))])  OrderedDict([('title'  'IFN-Ɣ: Cycle 2 (N=22)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '25')  ('@spread'  '28')]))]))]))]))])  OrderedDict([('title'  'IFN-Ɣ: Cycle 3 (N=11)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  'NA')  ('#text'  'Data below detection level of the assay')]))]))]))]))])  OrderedDict([('title'  'IL-2: Cycle 1 (N=35)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '36')  ('@spread'  '49')]))]))]))]))])  OrderedDict([('title'  'IL-2: Cycle 2 (N=22)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  'NA')  ('#text'  'Data below detection level of the assay')]))]))]))]))])  OrderedDict([('title'  'IL-2: Cycle 3 (N=11)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  'NA')  ('#text'  'Data below detection level of the assay')]))]))]))]))])  OrderedDict([('title'  'TNF-α: Cycle 1 (N=35)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '60')  ('@spread'  '122')]))]))]))]))])  OrderedDict([('title'  'TNF-α: Cycle 2 (N=22)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  'NA')  ('#text'  'Data below detection level of the assay')]))]))]))]))])  OrderedDict([('title'  'TNF-α: Cycle 3 (N=11)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  'NA')  ('#text'  'Data below detection level of the assay')]))]))]))]))])])]))]))])]|",University of Wuerzburg|,Completed|,Yes|,[OrderedDict([('title'  'Adverse Event')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '4')])  OrderedDict([('@group_id'  'P2')  ('@count'  '3')])  OrderedDict([('@group_id'  'P3')  ('@count'  '1')])])]))])  OrderedDict([('title'  'Hematological Relapse After Remission')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '1')])  OrderedDict([('@group_id'  'P3')  ('@count'  '1')])])]))])  OrderedDict([('title'  'Remission Not Achieved in 2 Cycles')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '1')])  OrderedDict([('@group_id'  'P2')  ('@count'  '3')])  OrderedDict([('@group_id'  'P3')  ('@count'  '1')])])]))])  OrderedDict([('title'  'Physician Decision')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '2')])  OrderedDict([('@group_id'  'P3')  ('@count'  '0')])])]))])  OrderedDict([('title'  'Other')  ('participants_list'  OrderedDict([('participants'  [OrderedDict([('@group_id'  'P1')  ('@count'  '0')])  OrderedDict([('@group_id'  'P2')  ('@count'  '1')])  OrderedDict([('@group_id'  'P3')  ('@count'  '0')])])]))])]|,,,,Phase 2|,866-572-6436|,,,At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria:Complete Response/Remission (CR):Less than or equal to 5% blasts in the bone marrowNo evidence of circulating blasts or extramedullar diseaseFull recovery of peripheral blood counts:Platelets > 100 000/μLHemoglobin ≥ 11 g/dLAbsolute neutrophil count (ANC) > 1 500/μLComplete Remission with only Partial Hematological Recovery (CRh*):Less than or equal to 5% blasts in the bone marrowNo evidence of circulating blasts or extramedullar diseasePartial recovery of peripheral blood counts:Platelets > 50 000/μLHemoglobin ≥ 7 g/dLANC > 500/μL.|,Treatment|,,,,[OrderedDict([('@group_id'  'E1')  ('title'  'Blinatumomab 15 μg')  ('description'  'Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.')])  OrderedDict([('@group_id'  'E2')  ('title'  'Blinatumomab 5/15 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  followed by 15 μg/m²/day starting from Week 2 of treatment.')])  OrderedDict([('@group_id'  'E3')  ('title'  'Blinatumomab 5/15/30 μg')  ('description'  'Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment  a dose of 15 μg/m²/day in the subsequent 7 days  followed by 30 μg/m²/day starting from Week 3 of treatment.')])  OrderedDict([('@group_id'  'E4')  ('title'  'Blinatumomab Overall')  ('description'  'All participants who received blinatumomab by continuous intravenous infusion during the core study.')])]|,[OrderedDict([('title'  'Total')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Total  other adverse events')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '23')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '36')  ('@subjects_at_risk'  '36')])])]))]))])  OrderedDict([('title'  'Blood and lymphatic system disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Anaemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Coagulopathy')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Disseminated intravascular coagulation')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Febrile neutropenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Leukocytosis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Leukopenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Lymphopenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Monocytosis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Splenomegaly')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Thrombocytopenia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Cardiac disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Arrhythmia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Bradycardia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Sinus tachycardia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Tachycardia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '9')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Ear and labyrinth disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Vertigo')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])]))]))])  OrderedDict([('title'  'Eye disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Conjunctival haemorrhage')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Conjunctivitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Dry eye')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Eye pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Eyelid oedema')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Lacrimation increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Periorbital oedema')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Visual acuity reduced')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Gastrointestinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Abdominal distension')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Abdominal pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Abdominal pain upper')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Aphthous stomatitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Constipation')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Diarrhoea')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '12')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Dry mouth')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Dyspepsia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Dysphagia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Faecal incontinence')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Gastrooesophageal reflux disease')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Gingival bleeding')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Nausea')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Proctitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Stomatitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Vomiting')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'General disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Catheter site haematoma')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Catheter site haemorrhage')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Catheter site pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Chest pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Chills')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Fatigue')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '18')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'General physical health deterioration')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Influenza like illness')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Localised oedema')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Malaise')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Mucosal inflammation')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Oedema peripheral')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '14')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Pyrexia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '18')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '29')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Hepatobiliary disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Hepatic failure')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Hepatotoxicity')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Immune system disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Acute graft versus host disease in skin')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])]))]))])  OrderedDict([('title'  'Infections and infestations')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Adenovirus infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Candidiasis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Cystitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Cytomegalovirus chorioretinitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'JC virus infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Nasopharyngitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Oral herpes')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Otitis media')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Paronychia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Pharyngitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Pneumonia fungal')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Respiratory syncytial virus infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Rhinitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Sinusitis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Staphylococcal infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Urinary tract infection')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Injury  poisoning and procedural complications')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Allergic transfusion reaction')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Skin laceration')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Investigations')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Alanine aminotransferase increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Aspartate aminotransferase increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood albumin decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood amylase increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood bilirubin increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood calcium decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood fibrinogen decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood fibrinogen increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood immunoglobulin A decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood immunoglobulin G decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood immunoglobulin M decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood lactate dehydrogenase increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood magnesium decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Blood potassium decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'C-reactive protein increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '9')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Electrocardiogram QT prolonged')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Fibrin D dimer increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '9')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Gamma-glutamyltransferase increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Immunoglobulins decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Lipase increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Oxygen saturation decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Prothrombin time prolonged')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Reticulocyte count increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Vital capacity abnormal')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Weight decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Weight increased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '13')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'pH urine decreased')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Metabolism and nutrition disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Decreased appetite')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Hyperglycaemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Hypokalaemia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Musculoskeletal and connective tissue disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Arthralgia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Back pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Bone pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Intervertebral disc protrusion')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Muscle spasms')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Musculoskeletal pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Myopathy')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Neck pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Pain in extremity')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Nervous system disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Aphasia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Apraxia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Balance disorder')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Dizziness')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Formication')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Headache')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '11')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '17')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Intention tremor')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Memory impairment')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Neurotoxicity')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Paraesthesia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Polyneuropathy')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Tremor')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '12')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Psychiatric disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Anxiety')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Depression')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Disorientation')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Fear')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Insomnia')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Mental disorder due to a general medical condition')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Sleep disorder')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Renal and urinary disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Incontinence')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Proteinuria')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Renal failure')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Renal failure acute')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Urinary tract pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Reproductive system and breast disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Breast mass')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Vulvovaginal dryness')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Respiratory  thoracic and mediastinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Cough')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '7')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Dry throat')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Dyspnoea')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Epistaxis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '9')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Haemoptysis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Hyperventilation')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Mediastinal haemorrhage')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Oropharyngeal pain')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Pleural effusion')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Respiratory failure')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Rhinitis allergic')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Skin and subcutaneous tissue disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Cold sweat')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Dry skin')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Erythema')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Hirsutism')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Hyperhidrosis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Petechiae')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Pruritus')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Psoriasis')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Rash')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Rash generalised')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '36')])])])])]))])  OrderedDict([('title'  'Vascular disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Circulatory collapse')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Flushing')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Haematoma')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Hypertension')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '36')])])])  OrderedDict([('sub_title'  'Hypotension')  ('counts'  [OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '7')])  OrderedDict([('@group_id'  'E2')  ('@subjects_affected'  '0')  ('@subjects_at_risk'  '23')])  OrderedDict([('@group_id'  'E3')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '6')])  OrderedDict([('@group_id'  'E4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '36')])])])])]))])]|,Sponsor|,,"[OrderedDict([('measure'  'Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment')  ('time_frame'  'Within the first 2 cycles of treatment  12 weeks')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete Response/Remission (CR) was defined by the following criteria:\nLess than or equal to 5% blasts in the bone marrow\nNo evidence of circulating blasts or extramedullar disease\nFull recovery of peripheral blood counts:\nPlatelets > 100 000/μL\nHemoglobin ≥ 11 g/dL\nAbsolute neutrophil count (ANC) > 1 500/μL')])  OrderedDict([('measure'  'Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment')  ('time_frame'  'Within the first 2 cycles of treatment  12 weeks')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete remission with only partial hematological recovery (CRh*) was defined by the following criteria:\nLess than or equal to 5% blasts in the bone marrow\nNo evidence of circulating blasts or extramedullar disease\nPartial recovery of peripheral blood counts:\nPlatelets > 50 000/μL\nHemoglobin ≥ 7 g/dL\nANC > 500/μL.')])  OrderedDict([('measure'  'Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment')  ('time_frame'  'Within the first 2 cycles of treatment  12 weeks')  ('description'  'At the end of each infusion period  a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Partial remission was defined by the following criteria:\n• Bone marrow blasts ≤ 25%')])  OrderedDict([('measure'  'Percentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study')  ('time_frame'  'During the core study treatment period (up to 30 weeks).')  ('description'  'A minimal residual disease (MRD) response is defined as MRD < 10^-4 blasts/nucleated cells based on polymerase chain reaction (PCR) evaluation of individual rearrangements of immunoglobulin or T cell receptor genes.')])  OrderedDict([('measure'  'Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab')  ('time_frame'  'Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days')  ('description'  'The percentage of participants who underwent immediate allogeneic HSCT (defined as those in remission who undergo HSCT without receiving any other treatments) after having discontinued or completed the core study.')])  OrderedDict([('measure'  'Time to Hematological Relapse')  ('time_frame'  'Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days.')  ('description'  'Time to hematological relapse was measured for participants who achieved a CR or CRh* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their day of death.\nHematological Relapse was defined as:\nProportion of blasts in bone marrow > 5%\nExtramedullary relapse.\nTime to hematological relapse was analyzed by Kaplan-Meier methods.')])  OrderedDict([('measure'  'Relapse-free Survival')  ('time_frame'  'Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days.')  ('description'  'Relapse-free survival was measured only for participants who achieved a CR or CRh* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse-free survival was estimated using Kaplan-Meier methods.')])  OrderedDict([('measure'  'Overall Survival')  ('time_frame'  'Up to the data cut-off date of 15 October 2012; maximum follow up time was 667 days.')  ('description'  'Overall survival was measured for all participants from the date of first infusion of blinatumomab until the date of death due to any cause. Participants who did not die were censored on the last documented visit date. Overall survival was estimated using Kaplan-Meier methods.')])  OrderedDict([('measure'  'Number of Participants With Treatment-emergent Adverse Events')  ('time_frame'  'From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle; median treatment duration was 55.7 days.')  ('description'  ""Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)  version 3.0 and according to the following:\nGrade I (mild); Grade 2 (moderate); Grade 3 (severe - significantly limits the patient's ability to perform routine activities despite symptomatic therapy; Grade 4 (life-threatening); Grade 5 (death).\nThe investigator used medical judgment to determine if there was a causal relationship (ie  certain  probable  possible  unlikely  not related) between an adverse event and blinatumomab.\nA serious adverse event is any untoward medical occurrence or effect  that at any dose:\nresulted in death  was life-threatening  required or prolonged hospitalization  resulted in persistent or significant disability or incapacity  is a congenital anomaly or birth defect or is a medically important condition."")])  OrderedDict([('measure'  'Steady State Blinatumomab Concentration')  ('time_frame'  'Samples were collected at predose and at 48 hours following start of infusion  when dose is escalated and on Days 8  15  22  and 29 of the first 2 cycles.')  ('description'  'The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the intravenous infusion was started for cycle 1 and cycle 2  respectively. Actual doses administered were used in the analysis.\nConcentrations below the limit of detection (3 pg/mL) were set to zero before data analysis and concentrations below the lower limit of quantitation (50 pg/mL) were excluded from analysis.')])  OrderedDict([('measure'  'Clearance of Blinatumomab')  ('time_frame'  'Samples were collected at predose and at 48 hours following start of infusion  when dose is escalated and on Days 8  15  22  and 29 of the first 2 cycles.')  ('description'  'Clearance was calculated as R0/Css; where R0 is the infusion rate (μg/m^2/hr) and Css is the steady state concentration.')])  OrderedDict([('measure'  'Serum Cytokine Peak Levels')  ('time_frame'  'Samples were collected prior to treatment start (baseline)  and at 2  6  24  and 48 hours after drug infusion start  and at these same time points when dose is escalated in each treatment cycle.')  ('description'  'The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2  IL-6  IL-10  tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) is 125 pg/mL and the limit of detection (LOD) is 20 pg/mL.')])]|",Amgen Research (Munich) GmbH|,,October 2010|,,Interventional|,,https://clinicaltrials.gov/show/NCT01209286|,July 2016|,
6,,Glucarpidase arm|,47|,In the NOPHO ALL-2008 protocol patients with delayed methotrexate elimination (DME) in high-dose methotrexate treatments should be given Glucarpidase (50 ie/kg) with-in 60 hours from start of the methotrexate treatment.Glucarpidase: Patients treated with Glucarpidase if the 24 hour levels of MTX is >250 µM  36 hour levels >30 µM or 42 hours levels >10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.|,[OrderedDict([('title'  'Age')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  [OrderedDict([('title'  '<=18 years')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '47')]))]))])  OrderedDict([('title'  'Between 18 and 65 years')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))])  OrderedDict([('title'  '>=65 years')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))])])]))]))]))])  OrderedDict([('title'  'Age')  ('description'  'Children 1-18 years')  ('units'  'years')  ('param'  'Median')  ('dispersion'  'Standard Deviation')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '7.5')  ('@spread'  '4.89')]))]))]))]))]))]))])  OrderedDict([('title'  'Gender')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  [OrderedDict([('title'  'Female')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '20')]))]))])  OrderedDict([('title'  'Male')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '27')]))]))])])]))]))]))])  OrderedDict([('title'  'Region of Enrollment')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Sweden')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '14')]))]))]))]))])  OrderedDict([('title'  'Norway')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '16')]))]))]))]))])  OrderedDict([('title'  'Finland')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Denmark')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '11')]))]))]))]))])  OrderedDict([('title'  'Iceland')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '2')]))]))]))]))])  OrderedDict([('title'  'Lithuania')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '3')]))]))]))]))])])]))])]|,Early intervention in children and adolescents who experience delayed MTX-clearance and renal dysfunction in ALL treatments with the enzyme Glucarpidase which rapidly hydrolyses MTX to non-toxic metabolites to avoid life threatening complications.|,Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL|,There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|,Other|,December 2014|,['Leukemia'  'Precursor Cell Lymphoblastic Leukemia-Lymphoma'  'Leukemia  Lymphoid']|,,Inclusion Criteria: Children and adolescents who experience delayed MTX-clearance and renal dysfunction during high-dose methotrexate treatment in NOPHO ALL-2008. Exclusion Criteria: Children and adolescents with earlier anaphylactic reaction to Glucarpidase. Pregnant patients.|,The NOPHO ALL-2008 protocol is a treatment and research protocol that aims to improve the overall outcome of Nordic children and adolescents with ALL in comparison with the ALL-2000 protocol and with the aim to reduce and prevent toxic treatment complications with high-dose methotrexate (HD-MTX). The specific and primary objectives of the randomized study is: 1. Early intervention in children and adolescents who experience delayed MTX-clearance and renal dysfunction with the enzyme Glucarpidase which rapidly hydrolyses MTX to non-toxic metabolites and lowers the serum concentration to avoid life threatening complications. Glucarpidase should be given if the 24 hour levels of MTX is > 250 µM  36 hour levels > 30 µM or 42 hours levels > 10 µM together with a reduced kidney function. Glucarpidase treatment should take place within 48 hours from the start of HD-MTX treatment. 2. To evaluate if the early intervention with Glucarpidase reduce the number of days the patients have to stay at the hospital. 3. Evaluate the reduction of health costs of early intervention in patients with delayed MTX-clearance and renal dysfunction.|,ClinicalTrials.gov processed this data on May 19  2017|,Inclusion Criteria: Children and adolescents who experience delayed MTX-clearance and renal dysfunction during high-dose methotrexate treatment in NOPHO ALL-2008. Exclusion Criteria: Children and adolescents with earlier anaphylactic reaction to Glucarpidase. Pregnant patients.|,All|,No|,18 Years|,1 Year|,47|,February 28  2011|,October 17  2016|,,All|,,,No|,,Methotrexate|,,,,MD|,Drug: Glucarpidase|,December 10  2016|,Other|,,Link to the current ClinicalTrials.gov record.|,['Denmark'  'Finland'  'Iceland'  'Norway'  'Sweden']|,,Open Label|,,18 Years|,1 Year|,NCT01305655|,1|,,,Glucarpidase (CPG2) Effect on Severe Delayed Methotrexate-clearance in Children Treated With High-dose Methotrexate in Acute Lymphoblastic Leukemia (ALL)|,NOPHO2008CPG2|,[OrderedDict([('type'  'Primary')  ('title'  'Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood  Nephrotoxicity  Hepatotoxicity  Mucositis  MTX Elimination Time and Permanent Kidney Damage.')  ('description'  'Glucarpidase was used in case of predefined toxic MTX values at defined time points and/or in combination with decreased renal function.\nA total of 47 patients of the 1286 ALL-patients included in the protocol (3.7 %) were treated with Glucarpidase.')  ('time_frame'  '6 years 6 months')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Glucarpidase Arm')  ('description'  '47 children treated with high dose MTX (HDMTX) according to the NOPHO ALL 2008 protocol  Glucarpidase was used in case of predefined toxic MTX values at defined time points in combination with decreased renal function.')]))]))  ('measure'  OrderedDict([('title'  'Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood  Nephrotoxicity  Hepatotoxicity  Mucositis  MTX Elimination Time and Permanent Kidney Damage.')  ('description'  'Glucarpidase was used in case of predefined toxic MTX values at defined time points and/or in combination with decreased renal function.\nA total of 47 patients of the 1286 ALL-patients included in the protocol (3.7 %) were treated with Glucarpidase.')  ('units'  'participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '47')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '47')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Evaluate Time at Hospital and Health Costs')  ('time_frame'  '6 years 6 months')  ('posting_date'  '01/2017')])]|,University Childrens hospital  Lund  Sweden|,Completed|,Yes|,[OrderedDict([('title'  'STARTED')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '47')  ('#text'  'July 2008')]))]))])  OrderedDict([('title'  'COMPLETED')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '47')  ('#text'  'December 31  2014')]))]))])  OrderedDict([('title'  'NOT COMPLETED')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '0')]))]))])]|,,,Publication in preparation in Pediatric Blood and Cancer|,Phase 3|,jesper.heldrup@skane.se|,,,Glucarpidase was used in case of predefined toxic MTX values at defined time points and/or in combination with decreased renal function.A total of 47 patients of the 1286 ALL-patients included in the protocol (3.7 %) were treated with Glucarpidase.|,Treatment|,,,,In the NOPHO ALL-2008 protocol patients with delayed methotrexate elimination (DME) in high-dose methotrexate treatments should be given Glucarpidase (50 ie/kg) with-in 60 hours from start of the methotrexate treatment.Glucarpidase: Patients treated with Glucarpidase if the 24 hour levels of MTX is >250 µM  36 hour levels >30 µM or 42 hours levels >10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.No serious effect reported.|,47|,Principal Investigator|,,6 years 6 months|,Nordic Society for Pediatric Hematology and Oncology|,,July 2008|,,Interventional|,,http://nopho.org|,December 2016|,
7,,Bortezomib IV Vorinostat PO Dexamethasone PO Intrathecal Methotrexate Imatinib Mesylate PO (for Ph+ ALL patients only)|,2|,bortezomib  vorinostat and dexamethasone combination  as well as intrathecal methotrexate and imatinib mesylate.Bortezomib: 1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1  4  8 and 11.Vorinostat: 180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14Dexamethasone: 6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.Methotrexate: Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)Imatinib mesylate: For Ph+ acute lymphoblastic leukemia (ALL) patients only:Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16.|,[OrderedDict([('title'  'Age')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  '<=18 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '2')]))]))]))]))])  OrderedDict([('title'  'Between 18 and 65 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))]))]))])  OrderedDict([('title'  '>=65 years')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))]))]))])])]))])  OrderedDict([('title'  'Gender')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Female')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))]))]))])  OrderedDict([('title'  'Male')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '2')]))]))]))]))])])]))])  OrderedDict([('title'  'Region of Enrollment')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  OrderedDict([('title'  'United States')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '2')]))]))]))]))]))]))])]|,Both of bortezomib and vorinostat have identified Phase II doses for pediatric and adult patients of which no grade 4 dose limiting toxicities have been observed in prior studies. The pre-clinical synergy of these 2 agents when used in combination along with the lack of over-riding toxicities and different mechanisms of action provide strong rationale for a clinical trial investigating bortezomib and vorinostat in combination. This trial will use the identified Phase II dose which is at or below the maximum tolerated dose for both agents which have very acceptable toxicity profiles and such should prove feasible and tolerable in this relapsed/refractory ALL population.|,Bortezomib  Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)|,There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|,Industry|,January 2013|,['Leukemia'  'Precursor Cell Lymphoblastic Leukemia-Lymphoma'  'Leukemia  Lymphoid']|,,Inclusion Criteria: - Diagnosis of lymphoblastic lymphoma or acute lymphoblastic leukemia (ALL) with ≥ 5% blasts in the bone marrow (M2/M3) with or without extramedullary disease that meets one of the following criteria: - Refractory Disease/Induction Failure: Failure to achieve initial remission after 2 attempts of standard induction therapy - Relapsed Disease: Patients in relapse #1 or higher for whom standard curative therapies or therapies to prolong survival do not exist. Patients who are Philadelphia chromosome-positive (Ph + ALL) are eligible provided they are not imatinib resistant or intolerant. Patients with CNS positive disease will be eligible. - Age 2 to 30 years - Karnofsky ≥ 50% for patients 16 years and older and Lansky status ≥ 50 for patients under 16 years of age. - Patients must have a life expectancy ≥ 8 weeks as determined by the enrolling investigator. - Have acceptable organ function as defined within 7 days of starting treatment: - Renal: creatinine clearance ≥ 70ml/min/1.73m^2 or serum creatinine based on age/gender as follows: Maximum serum creatinine (mg/dl) 0.8 for 2 years to <6 years; 1.0 for 6 years to <10 years; 1.2 for 10 years to <13 years; 1.5 male and 1.4 female for 13 years to <16 years; 1.7 male and 1.4 female for ≥ 16 years - Hepatic: ALT < 5 x upper limit of normal (ULN) and total bilirubin ≤ 1.5x upper limit of normal (ULN) for age. - Cardiac: left ventricular ejection fraction ≥ 40% by echocardiogram/multi gated acquisition scan (ECHO/MUGA). Normal QTc on electrocardiogram (EKG) (not to exceed upper limit of normal - men: 430 milliseconds (ms); women: 450 ms; children up to 15 years: 440 ms). - Prior Therapy: - Patients must have recovered from the non-hematologic toxic effects of all prior therapy before entry onto this trial. Recovery is defined as a Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0 toxicity grade <2  unless otherwise specified in the Inclusion and Exclusion Criteria. Cytotoxic therapy: Patients must have had their last dose of chemotherapy at least two weeks prior to study entry. - Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor and at least 14 days since pegfilgrastim (Neulasta®) administration. - Biologic (anti-neoplastic) therapy: At least 7 days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration  this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair. - Monoclonal antibodies: At least 3 half-lives of the antibody after the last administration of a monoclonal antibody. - Hematopoietic Stem Cell Transplant (HSCT): Patients who have experienced their relapse after a HSCT are eligible  provided they have no evidence of Graft-versus-Host Disease (GVHD). - Women of child bearing potential must agree to use adequate contraception (diaphragm  birth control pills  injections  intrauterine device [IUD]  surgical sterilization  subcutaneous implants  or abstinence  etc.) for the duration of treatment and for 2 months after the last dose of chemotherapy. Sexually active men must agree to use barrier contraceptive for the duration of treatment and for 2 months after the last dose of chemotherapy. - Voluntary written consent before performance of any study-related procedure not part of normal medical care  with the understanding that consent may be withdrawn by the subject/guardian at any time without prejudice to future medical care. Exclusion Criteria: - Pregnant or lactating. The agents used in this study are known to be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for surgically sterilized women. - Known hypersensitivity to bortezomib  boron or mannitol or any of the agents or their ingredients used in this study. - Inability to swallow capsules. - Grade 2 or greater peripheral neuropathy within 14 days before study registration. - Patients with untreated positive blood cultures or progressive infections as assessed by radiographic studies. - Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (appendix VI)  uncontrolled angina  severe uncontrolled ventricular arrhythmias  or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry  any ECG abnormality at Screening has to be documented by the investigator as not medically relevant. - Serious concomitant medical or psychiatric disorders (e.g.  active infection  uncontrolled diabetes) that  in the opinion of the investigator  would compromise the safety of the patient or likely to interfere with participation in this clinical study. - Diagnosed or treated for another malignancy within 3 years of enrollment  with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin  an in situ malignancy  or low-risk prostate cancer after curative therapy. - Patient has received investigational drugs within the 14 days before study registration. - Radiation therapy within 3 weeks before registration. Enrollment of patients who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.|,This is a phase II study of bortezomib 1.3 mg/m^2 by intravenous pyelogram (IVP) on days 1  4  8  and 11  vorinostat 180 mg/m^2 by mouth (PO) per day (not to exceed 400 mg per day) days 1-14  and dexamethasone 6 mg/m^2 PO days 4-15 for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). No more than 3 treatment courses may be given.|,ClinicalTrials.gov processed this data on May 19  2017|,Inclusion Criteria: - Diagnosis of lymphoblastic lymphoma or acute lymphoblastic leukemia (ALL) with ≥ 5% blasts in the bone marrow (M2/M3) with or without extramedullary disease that meets one of the following criteria: - Refractory Disease/Induction Failure: Failure to achieve initial remission after 2 attempts of standard induction therapy - Relapsed Disease: Patients in relapse #1 or higher for whom standard curative therapies or therapies to prolong survival do not exist. Patients who are Philadelphia chromosome-positive (Ph + ALL) are eligible provided they are not imatinib resistant or intolerant. Patients with CNS positive disease will be eligible. - Age 2 to 30 years - Karnofsky ≥ 50% for patients 16 years and older and Lansky status ≥ 50 for patients under 16 years of age. - Patients must have a life expectancy ≥ 8 weeks as determined by the enrolling investigator. - Have acceptable organ function as defined within 7 days of starting treatment: - Renal: creatinine clearance ≥ 70ml/min/1.73m^2 or serum creatinine based on age/gender as follows: Maximum serum creatinine (mg/dl) 0.8 for 2 years to <6 years; 1.0 for 6 years to <10 years; 1.2 for 10 years to <13 years; 1.5 male and 1.4 female for 13 years to <16 years; 1.7 male and 1.4 female for ≥ 16 years - Hepatic: ALT < 5 x upper limit of normal (ULN) and total bilirubin ≤ 1.5x upper limit of normal (ULN) for age. - Cardiac: left ventricular ejection fraction ≥ 40% by echocardiogram/multi gated acquisition scan (ECHO/MUGA). Normal QTc on electrocardiogram (EKG) (not to exceed upper limit of normal - men: 430 milliseconds (ms); women: 450 ms; children up to 15 years: 440 ms). - Prior Therapy: - Patients must have recovered from the non-hematologic toxic effects of all prior therapy before entry onto this trial. Recovery is defined as a Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0 toxicity grade <2  unless otherwise specified in the Inclusion and Exclusion Criteria. Cytotoxic therapy: Patients must have had their last dose of chemotherapy at least two weeks prior to study entry. - Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor and at least 14 days since pegfilgrastim (Neulasta®) administration. - Biologic (anti-neoplastic) therapy: At least 7 days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration  this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair. - Monoclonal antibodies: At least 3 half-lives of the antibody after the last administration of a monoclonal antibody. - Hematopoietic Stem Cell Transplant (HSCT): Patients who have experienced their relapse after a HSCT are eligible  provided they have no evidence of Graft-versus-Host Disease (GVHD). - Women of child bearing potential must agree to use adequate contraception (diaphragm  birth control pills  injections  intrauterine device [IUD]  surgical sterilization  subcutaneous implants  or abstinence  etc.) for the duration of treatment and for 2 months after the last dose of chemotherapy. Sexually active men must agree to use barrier contraceptive for the duration of treatment and for 2 months after the last dose of chemotherapy. - Voluntary written consent before performance of any study-related procedure not part of normal medical care  with the understanding that consent may be withdrawn by the subject/guardian at any time without prejudice to future medical care. Exclusion Criteria: - Pregnant or lactating. The agents used in this study are known to be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for surgically sterilized women. - Known hypersensitivity to bortezomib  boron or mannitol or any of the agents or their ingredients used in this study. - Inability to swallow capsules. - Grade 2 or greater peripheral neuropathy within 14 days before study registration. - Patients with untreated positive blood cultures or progressive infections as assessed by radiographic studies. - Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (appendix VI)  uncontrolled angina  severe uncontrolled ventricular arrhythmias  or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry  any ECG abnormality at Screening has to be documented by the investigator as not medically relevant. - Serious concomitant medical or psychiatric disorders (e.g.  active infection  uncontrolled diabetes) that  in the opinion of the investigator  would compromise the safety of the patient or likely to interfere with participation in this clinical study. - Diagnosed or treated for another malignancy within 3 years of enrollment  with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin  an in situ malignancy  or low-risk prostate cancer after curative therapy. - Patient has received investigational drugs within the 14 days before study registration. - Radiation therapy within 3 weeks before registration. Enrollment of patients who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.|,All|,No|,30 Years|,2 Years|,2|,March 9  2011|,April 22  2015|,,All|,,,No|,,['Dexamethasone acetate'  'Dexamethasone'  'Dexamethasone 21-phosphate'  'Vorinostat'  'Methotrexate'  'Bortezomib'  'Imatinib Mesylate'  'BB 1101']|,,,,,,June 9  2016|,Other|,,Link to the current ClinicalTrials.gov record.|,United States|,,Open Label|,,30 Years|,2 Years|,NCT01312818|,1|,,,A Therapeutic Trial of Bortezomib (Velcade)  Vorinostat (SAHA) and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)|,2008LS113|,[OrderedDict([('type'  'Primary')  ('title'  'Number of Subjects Who Achieved Complete Remission of Their Disease')  ('description'  'Complete Remission (CR): A CR requires that the following be recorded concurrently: an absolute neutrophil count (segs and bands) > 1000/μL  no circulating blasts  platelets > 100 000/μL; adequate bone marrow cellularity with trilineage hematopoiesis  and < 5% marrow leukemia blast cells. All previous extramedullary manifestations of disease must be absent. If patients continue on with treatment  there can be no evidence of recurrence of ALL for at least 4 weeks.')  ('time_frame'  'Day 30')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'ALL Treated Patients')  ('description'  'bortezomib  vorinostat and dexamethasone combination  as well as intrathecal methotrexate and imatinib mesylate.\nBortezomib: 1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1  4  8 and 11.\nVorinostat: 180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14\nDexamethasone: 6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.\nMethotrexate: Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)\nImatinib mesylate: For Ph+ acute lymphoblastic leukemia (ALL) patients only:\nImatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16.')]))]))  ('measure'  OrderedDict([('title'  'Number of Subjects Who Achieved Complete Remission of Their Disease')  ('description'  'Complete Remission (CR): A CR requires that the following be recorded concurrently: an absolute neutrophil count (segs and bands) > 1000/μL  no circulating blasts  platelets > 100 000/μL; adequate bone marrow cellularity with trilineage hematopoiesis  and < 5% marrow leukemia blast cells. All previous extramedullary manifestations of disease must be absent. If patients continue on with treatment  there can be no evidence of recurrence of ALL for at least 4 weeks.')  ('units'  'participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '2')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Subjects Experiencing Drug Related Adverse Events')  ('description'  'To characterize the toxicities of bortezomib  vorinostat and dexamethasone when used in combination. Toxicity will be graded using the NCI’s Common Terminology Criteria for Adverse Events (CTCAE 4.0).')  ('time_frame'  'Day 1 of Treatment to 30 Days Post Treatment')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'ALL Treated Patients')  ('description'  'List of toxicities in acute lymphoblastic leukemia (ALL) patients treated with bortezomib  vorinostat and dexamethasone combination  as well as intrathecal methotrexate and imatinib mesylate.\nBortezomib: 1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1  4  8 and 11.\nVorinostat: 180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14\nDexamethasone: 6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.\nMethotrexate: Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)\nImatinib mesylate: For Ph+ acute lymphoblastic leukemia (ALL) patients only:\nImatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16.')]))]))  ('measure'  OrderedDict([('title'  'Number of Subjects Experiencing Drug Related Adverse Events')  ('description'  'To characterize the toxicities of bortezomib  vorinostat and dexamethasone when used in combination. Toxicity will be graded using the NCI’s Common Terminology Criteria for Adverse Events (CTCAE 4.0).')  ('units'  'participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '2')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Subjects With Activated Caspases and Other Regulators of Apoptosis')  ('description'  'Activation of caspases and other regulators of apoptosis in treated blast cells will be determined by Western analysis (correlative lab analysis).')  ('time_frame'  'From Day 1 to 30 Days After Last Dose')  ('population'  'The trial was terminated early with only 2 patients so caspase samples were not sent for analysis.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Chemotherapy')  ('description'  'Bortezomib IV Vorinostat PO Dexamethasone PO Intrathecal Methotrexate Imatinib Mesylate PO (for Ph+ ALL patients only)\nBortezomib: 1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1  4  8 and 11.\nVorinostat: 180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14\nDexamethasone: 6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.\nMethotrexate: Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)\nImatinib mesylate: For Ph+ acute lymphoblastic leukemia (ALL) patients only:\nImatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16.')]))]))  ('measure'  OrderedDict([('title'  'Number of Subjects With Activated Caspases and Other Regulators of Apoptosis')  ('description'  'Activation of caspases and other regulators of apoptosis in treated blast cells will be determined by Western analysis (correlative lab analysis).')  ('population'  'The trial was terminated early with only 2 patients so caspase samples were not sent for analysis.')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))]))])]|,Masonic Cancer Center  University of Minnesota|,Terminated|,Yes|,[OrderedDict([('title'  'STARTED')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '2')]))]))])  OrderedDict([('title'  'COMPLETED')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '2')]))]))])  OrderedDict([('title'  'NOT COMPLETED')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '0')]))]))])]|,,,,Phase 2|,612-672-7422|,,,Complete Remission (CR): A CR requires that the following be recorded concurrently: an absolute neutrophil count (segs and bands) > 1000/μL  no circulating blasts  platelets > 100 000/μL; adequate bone marrow cellularity with trilineage hematopoiesis  and < 5% marrow leukemia blast cells. All previous extramedullary manifestations of disease must be absent. If patients continue on with treatment  there can be no evidence of recurrence of ALL for at least 4 weeks.|,Treatment|,,,,bortezomib  vorinostat and dexamethasone combination  as well as intrathecal methotrexate and imatinib mesylate.Bortezomib: 1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1  4  8 and 11.Vorinostat: 180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14Dexamethasone: 6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.Methotrexate: Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)Imatinib mesylate: For Ph+ acute lymphoblastic leukemia (ALL) patients only:Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16.|,[OrderedDict([('title'  'Total')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Total  other adverse events')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '2')]))]))]))])  OrderedDict([('title'  'Gastrointestinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Gastric hemorrhage')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))])  OrderedDict([('sub_title'  'Gastric ulcer')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))])])]))])  OrderedDict([('title'  'General disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Fever')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))]))]))])  OrderedDict([('title'  'Investigations')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Alanine aminotransferase increased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))])  OrderedDict([('sub_title'  'Aspartate aminotransferase increased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))])  OrderedDict([('sub_title'  'Investigations - Other  specify: hyperphosphatemia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))])])]))])  OrderedDict([('title'  'Metabolism and nutrition disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Hyponatremia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))]))]))])  OrderedDict([('title'  'Respiratory  thoracic and mediastinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Dyspnea')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))])  OrderedDict([('sub_title'  'Hypoxia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))])  OrderedDict([('sub_title'  'Respiratory failure')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))])])]))])  OrderedDict([('title'  'Vascular disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Hypotension')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '2')]))]))]))])]|,Sponsor|,,"[OrderedDict([('measure'  'Number of Subjects Experiencing Drug Related Adverse Events')  ('time_frame'  'Day 1 of Treatment to 30 Days Post Treatment')  ('description'  ""To characterize the toxicities of bortezomib  vorinostat and dexamethasone when used in combination. Toxicity will be graded using the NCI's Common Terminology Criteria for Adverse Events (CTCAE 4.0)."")])  OrderedDict([('measure'  'Number of Subjects With Activated Caspases and Other Regulators of Apoptosis')  ('time_frame'  'From Day 1 to 30 Days After Last Dose')  ('description'  'Activation of caspases and other regulators of apoptosis in treated blast cells will be determined by Western analysis (correlative lab analysis).')])]|",Masonic Cancer Center  University of Minnesota|,,June 2011|,,Interventional|,,https://clinicaltrials.gov/show/NCT01312818|,January 2013|,Slow accrual|
8,,Moxetumomab Pasudotox 40 mcg/kg|,32|,Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.|,[OrderedDict([('title'  'Age')  ('units'  'Years')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '10.5')  ('@spread'  '3.9')]))]))]))]))]))]))])  OrderedDict([('title'  'Sex: Female  Male')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  [OrderedDict([('title'  'Female')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '13')]))]))])  OrderedDict([('title'  'Male')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '19')]))]))])])]))]))]))])]|,The primary objective of this study is to evaluate the efficacy of moxetumomab pasudotox in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma.|,Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma|,MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript  it being understood that results shall be published regardless of outcome.|,,November 2015|,['Lymphoma'  'Leukemia'  'Precursor Cell Lymphoblastic Leukemia-Lymphoma'  'Leukemia  Lymphoid'  'Lymphoma  Non-Hodgkin']|,,Inclusion Criteria - 1. Between the ages of greater or equal to (≥) 6 months and less than (<) 18 years of age 2. Must have histologically proven B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma with marrow involvement 3. All participants (both ALL and participants with lymphoblastic lymphoma) must have M2 or M3 bone marrow classification 4. Disease status: a) Participants must have relapsed or refractory disease b) In the event of relapse after prior allogeneic hematopoietic stem cell transplant (HSCT)  participants must be at least 3 months post-transplant and have no evidence of active graft-vs-host disease  and must have been off immunosuppression for at least 4 weeks  c) Must have resolution of the acute toxic effects to less than or equal to (≤) Grade 2 from prior chemotherapy before entry  in the opinion of the investigator 5. Participants with the following central nervous system (CNS) 1 or 2 status are eligible only in the absence of neurologic symptoms 6. Female participants of childbearing potential and post-pubertal male participants must use an approved method of contraception for the study. Exclusion Criteria 1. Concurrent enrollment in another clinical study for cancer treatment  unless the subject is in the follow-up period from a previous study. 2. Isolated testicular or CNS ALL 3. Participants with mixed-lineage leukemia (MLL) gene rearrangement 4. Inadequate Hepatic function 5. Inadequate Renal function 6. Radiologically-detected CNS lymphoma 7. Participants with clear laboratory or clinical evidence of disseminated intravascular coagulation (DIC) 8. Hyperleukocytosis or rapidly progressive disease that would compromise ability to complete study therapy 9. QT interval corrected using Fridericia's formula (QTcF) greater than or equal to a Grade 2  confirmed by 2 additional seperate electrocardiographs (ECG's) within 28 days prior to starting study drug. The initial screening ECG need not be repeated for confirmation if the QTcF interval is <481 milliseconds. 10. Pregnant or breast-feeding females 11. Prior treatment with CAT-3888 (BL22)  moxetumomab pasudotox  or any pseudomonas-exotoxin-containing compound 12. Prior treatment with any anticancer biologic therapy within 2 weeks prior to starting study drug  including but not limited to therapeutic monoclonal antibodies or antibody-drug conjugates 13. Systemic chemotherapy ≤ 2 weeks (6 weeks for nitrosoureas) and radiation therapy ≤ 3 weeks prior to starting study drug 14. Clinically significant ophthalmologic findings (evidence of retinal damage or injury) during the screening 15. Presence of a second invasive malignancy 16. Uncontrolled pulmonary infection  presence of pulmonary edema 17. Serum albumin < 2 gram per deciliter (g/dL). Albumin infusions for correction of hypoalbuminemia are allowed  but cannot have administered within 7 days prior to start of study drug 18. Radioimmunotherapy within 2 years prior to study start of study drug 19. Participants with prior history of thrombotic microangiopathy or hemolytic uremic syndrome (HUS) 20. T-cell ALL or T-cell lymphoblastic lymphoma 21. Participants currently receiving high-dose estrogen therapy defined as >0.625 milligram per day (mg/day) of an estrogen compound or within 2 weeks prior to starting study drug.|,This is a global  multicenter  open-label  single-arm Phase 2 study to evaluate the efficacy and safety of moxetumomab pasudotox monotherapy in pediatric participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Participants will be enrolled at sites in North America  Europe  and Australia. This is an approximate 35 month study.|,ClinicalTrials.gov processed this data on May 19  2017|,Inclusion Criteria - 1. Between the ages of greater or equal to (≥) 6 months and less than (<) 18 years of age 2. Must have histologically proven B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma with marrow involvement 3. All participants (both ALL and participants with lymphoblastic lymphoma) must have M2 or M3 bone marrow classification 4. Disease status: a) Participants must have relapsed or refractory disease b) In the event of relapse after prior allogeneic hematopoietic stem cell transplant (HSCT)  participants must be at least 3 months post-transplant and have no evidence of active graft-vs-host disease  and must have been off immunosuppression for at least 4 weeks  c) Must have resolution of the acute toxic effects to less than or equal to (≤) Grade 2 from prior chemotherapy before entry  in the opinion of the investigator 5. Participants with the following central nervous system (CNS) 1 or 2 status are eligible only in the absence of neurologic symptoms 6. Female participants of childbearing potential and post-pubertal male participants must use an approved method of contraception for the study. Exclusion Criteria 1. Concurrent enrollment in another clinical study for cancer treatment  unless the subject is in the follow-up period from a previous study. 2. Isolated testicular or CNS ALL 3. Participants with mixed-lineage leukemia (MLL) gene rearrangement 4. Inadequate Hepatic function 5. Inadequate Renal function 6. Radiologically-detected CNS lymphoma 7. Participants with clear laboratory or clinical evidence of disseminated intravascular coagulation (DIC) 8. Hyperleukocytosis or rapidly progressive disease that would compromise ability to complete study therapy 9. QT interval corrected using Fridericia's formula (QTcF) greater than or equal to a Grade 2  confirmed by 2 additional seperate electrocardiographs (ECG's) within 28 days prior to starting study drug. The initial screening ECG need not be repeated for confirmation if the QTcF interval is <481 milliseconds. 10. Pregnant or breast-feeding females 11. Prior treatment with CAT-3888 (BL22)  moxetumomab pasudotox  or any pseudomonas-exotoxin-containing compound 12. Prior treatment with any anticancer biologic therapy within 2 weeks prior to starting study drug  including but not limited to therapeutic monoclonal antibodies or antibody-drug conjugates 13. Systemic chemotherapy ≤ 2 weeks (6 weeks for nitrosoureas) and radiation therapy ≤ 3 weeks prior to starting study drug 14. Clinically significant ophthalmologic findings (evidence of retinal damage or injury) during the screening 15. Presence of a second invasive malignancy 16. Uncontrolled pulmonary infection  presence of pulmonary edema 17. Serum albumin < 2 gram per deciliter (g/dL). Albumin infusions for correction of hypoalbuminemia are allowed  but cannot have administered within 7 days prior to start of study drug 18. Radioimmunotherapy within 2 years prior to study start of study drug 19. Participants with prior history of thrombotic microangiopathy or hemolytic uremic syndrome (HUS) 20. T-cell ALL or T-cell lymphoblastic lymphoma 21. Participants currently receiving high-dose estrogen therapy defined as >0.625 milligram per day (mg/day) of an estrogen compound or within 2 weeks prior to starting study drug.|,All|,No|,18 Years|,6 Months|,37|,August 21  2014|,August 4  2016|,,All|,,,No|,,CAT-8015|,,,,,pediatric cancer pediatric acute lymphoblastic leukemia  lymphoblastic lymphoma  B-cell leukemia  ALL  moxetumomab pasudotox  CD22|,March 9  2017|,Industry|,The study was terminated prior to a planned interim analysis based on lack of required efficacy in the first 32 participants enrolled.|,Link to the current ClinicalTrials.gov record.|,['Australia'  'Canada'  'France'  'Italy'  'Netherlands'  'Spain'  'United Kingdom'  'United States']|,,No masking|,,18 Years|,6 Months|,NCT02227108|,1|,,,A Phase 2  Multicenter  Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin|,CD-ON-CAT-8015-1036|,"[OrderedDict([('type'  'Primary')  ('title'  'Percentage of Participants With Composite Complete Response (CRc)')  ('description'  'The CRc is defined as achieving complete response (CR)  or CR with incomplete count recovery [CRi]) in participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts. The efficacy assessments were evaluated as per investigator assessment.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Percentage of Participants With Composite Complete Response (CRc)')  ('description'  'The CRc is defined as achieving complete response (CR)  or CR with incomplete count recovery [CRi]) in participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts. The efficacy assessments were evaluated as per investigator assessment.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('units'  'percentage of participants')  ('param'  'Number')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '28')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '10.7')  ('@lower_limit'  '2.3')  ('@upper_limit'  '28.2')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Percentage of Participants With Minimal Residual Disease (MRD)-Negative CRc Rate')  ('description'  'The MRD-negative CRc rate was defined as the percentage of participants who achieved CRc and became MRD-negative as determined by flow cytometry performed by a central analysis laboratory. The CRc is defined as complete response (CR)  or complete response with incomplete count recovery (CRi). Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Percentage of Participants With Minimal Residual Disease (MRD)-Negative CRc Rate')  ('description'  'The MRD-negative CRc rate was defined as the percentage of participants who achieved CRc and became MRD-negative as determined by flow cytometry performed by a central analysis laboratory. The CRc is defined as complete response (CR)  or complete response with incomplete count recovery (CRi). Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('units'  'percentage of participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '28')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Overall Response Rate (ORR)')  ('description'  'The ORR  defined as the percentage of participants with CRc or partial response (PR)  was estimated; the Clopper Pearson (Exact) 95% CI was calculated. The CRc is defined as complete response (CR)  or complete response with incomplete count recovery (CRi). Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Overall Response Rate (ORR)')  ('description'  'The ORR  defined as the percentage of participants with CRc or partial response (PR)  was estimated; the Clopper Pearson (Exact) 95% CI was calculated. The CRc is defined as complete response (CR)  or complete response with incomplete count recovery (CRi). Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('units'  'percentage of participants')  ('param'  'Number')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '28')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '28.6')  ('@lower_limit'  '13.2')  ('@upper_limit'  '48.7')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Time to Overall Response')  ('description'  'Time to overall response was evaluated using the Kaplan-Meier method.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Time to Overall Response')  ('description'  'Time to overall response was evaluated using the Kaplan-Meier method.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('units'  'months')  ('param'  'Median')  ('dispersion'  '95% Confidence Interval')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '28')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.66')  ('@lower_limit'  '0.53')  ('@upper_limit'  '0.76')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Best Overall Response (BOR)')  ('description'  'The best overall response was calculated  based upon the disease assessments recorded during the study visits  and summarized with the number and percentage of participants for the following categories: CRc  PR  HA  SD  PD  and not evaluable. Overall best response is the best response observed for a participant during the study based on International Working Group (IWG) Response Criteria for malignant lymphoma. Complete response (CR) as per IWG is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is a minimum of 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses and no increase in the size of other nodes and in size of liver or spleen. Stable disease (SD) is when a participant fails to attain the criteria needed for a CR or PR  but does not fulfill those for PD.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Best Overall Response (BOR)')  ('description'  'The best overall response was calculated  based upon the disease assessments recorded during the study visits  and summarized with the number and percentage of participants for the following categories: CRc  PR  HA  SD  PD  and not evaluable. Overall best response is the best response observed for a participant during the study based on International Working Group (IWG) Response Criteria for malignant lymphoma. Complete response (CR) as per IWG is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is a minimum of 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses and no increase in the size of other nodes and in size of liver or spleen. Stable disease (SD) is when a participant fails to attain the criteria needed for a CR or PR  but does not fulfill those for PD.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('units'  'percentage of participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '28')]))]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Composite complete response')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '10.7')]))]))]))]))])  OrderedDict([('title'  'Partial response')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '17.9')]))]))]))]))])  OrderedDict([('title'  'Hematological activity')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '7.1')]))]))]))]))])  OrderedDict([('title'  'Stable disease')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '21.4')]))]))]))]))])  OrderedDict([('title'  'Progressive disease')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '39.3')]))]))]))]))])  OrderedDict([('title'  'No evaluation available')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '3.6')]))]))]))]))])])]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Bone Marrow Blast Percentage Change')  ('description'  'Change in bone marrow blast percentage from baseline was evaluated. If the percentage (%) blasts (at least 200 cells counted) is less than (<) 5%  it is considered as M1  5 to 25% considered as M2  greater than (>) 25% considered as M3. Stages with the higher blasts relate to worse outcomes.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'The intent to treat (ITT) population included all participants who entered the study. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Bone Marrow Blast Percentage Change')  ('description'  'Change in bone marrow blast percentage from baseline was evaluated. If the percentage (%) blasts (at least 200 cells counted) is less than (<) 5%  it is considered as M1  5 to 25% considered as M2  greater than (>) 25% considered as M3. Stages with the higher blasts relate to worse outcomes.')  ('population'  'The intent to treat (ITT) population included all participants who entered the study. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('units'  'percentage of participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '26')]))]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Baseline M1  post-baseline M1')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))])  OrderedDict([('title'  'Baseline M1  post-baseline M2')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))])  OrderedDict([('title'  'Baseline M1  post-baseline M3')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '3.8')]))]))]))]))])  OrderedDict([('title'  'Baseline M2  post-baseline M1')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))])  OrderedDict([('title'  'Baseline M2  post-baseline M2')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))])  OrderedDict([('title'  'Baseline M2  post-baseline M3')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '7.7')]))]))]))]))])  OrderedDict([('title'  'Baseline M3 post-baseline M1')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '3.8')]))]))]))]))])  OrderedDict([('title'  'Baseline M3 post-baseline M2')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '11.5')]))]))]))]))])  OrderedDict([('title'  'Baseline M3 post-baseline M3')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '73.1')]))]))]))]))])])]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Percentage of Participants Who Became Eligible to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox')  ('description'  'The percentage of participants who became eligible for SCT after treatment with moxetumomab pasudotox were provided. The Clopper Pearson (Exact) 95% CI was calculated.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Percentage of Participants Who Became Eligible to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox')  ('description'  'The percentage of participants who became eligible for SCT after treatment with moxetumomab pasudotox were provided. The Clopper Pearson (Exact) 95% CI was calculated.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('units'  'percentage of participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '28')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Time to Transplant to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox')  ('description'  'The time to SCT was defined as the duration from the start of treatment with moxetumomab pasudotox until the date when the subject became eligible for SCT. The time to SCT was to be summarized using the Kaplan-Meier method  and was only to be evaluated for the subgroup of subjects who became eligible for SCT after treatment with moxetumomab pasudotox.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy population included participants who received moxetumomab pasudotox  completed a baseline disease assessment and had at least one post-baseline assessment. Since study was terminated prematurely  no participant received SCT after treatment with moxetumomab pasudotox  hence data were not collected for this Outcome measure.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Time to Transplant to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox')  ('description'  'The time to SCT was defined as the duration from the start of treatment with moxetumomab pasudotox until the date when the subject became eligible for SCT. The time to SCT was to be summarized using the Kaplan-Meier method  and was only to be evaluated for the subgroup of subjects who became eligible for SCT after treatment with moxetumomab pasudotox.')  ('population'  'Efficacy population included participants who received moxetumomab pasudotox  completed a baseline disease assessment and had at least one post-baseline assessment. Since study was terminated prematurely  no participant received SCT after treatment with moxetumomab pasudotox  hence data were not collected for this Outcome measure.')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Percentage of Participants Who Were Neutropenic at Study Entry and Who Experienced Hematologic Activity (HA)')  ('description'  'The percentage of participants who were neutropenic at study entry and experienced HA after treatment with moxetumomab pasudotox was evaluated. The Clopper Pearson (Exact) 95% CI was calculated.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Percentage of Participants Who Were Neutropenic at Study Entry and Who Experienced Hematologic Activity (HA)')  ('description'  'The percentage of participants who were neutropenic at study entry and experienced HA after treatment with moxetumomab pasudotox was evaluated. The Clopper Pearson (Exact) 95% CI was calculated.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('units'  'percentage of participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '28')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '3.6')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Duration of Complete Response (DOCR)')  ('description'  'DOCR was defined as the duration from the first documentation of CRc to the first documented disease progression.The CRc is defined as achieving complete response (CR)  or CR with incomplete count recovery [CRi]) in participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Kaplan-Meier method was used for evaluation.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Duration of Complete Response (DOCR)')  ('description'  'DOCR was defined as the duration from the first documentation of CRc to the first documented disease progression.The CRc is defined as achieving complete response (CR)  or CR with incomplete count recovery [CRi]) in participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Kaplan-Meier method was used for evaluation.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('units'  'months')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1.97')  ('@lower_limit'  '0')  ('@upper_limit'  '0')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Duration of Overall Response (DOR)')  ('description'  'DOR was to be defined as the duration from the first documentation of overall response to the first documented disease progression. Kaplan-Meier method was used for evaluation.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Duration of Overall Response (DOR)')  ('description'  'DOR was to be defined as the duration from the first documentation of overall response to the first documented disease progression. Kaplan-Meier method was used for evaluation.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('units'  'months')  ('param'  'Median')  ('dispersion'  'Full Range')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '28')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.95')  ('@lower_limit'  '0.59')  ('@upper_limit'  '1.97')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Progression-Free Survival (PFS)')  ('description'  'PFS was measured from the start of treatment with moxetumomab pasudotox until the first documentation of disease progression or death due to any cause  whichever occurred first. Kaplan-Meier method was used for evaluation.')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Progression-Free Survival (PFS)')  ('description'  'PFS was measured from the start of treatment with moxetumomab pasudotox until the first documentation of disease progression or death due to any cause  whichever occurred first. Kaplan-Meier method was used for evaluation.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('units'  'months')  ('param'  'Median')  ('dispersion'  'Full Range')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '28')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1.4')  ('@lower_limit'  '0.3')  ('@upper_limit'  '8.4')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Overall Survival (OS)')  ('description'  'OS was determined as the time from the start of treatment with moxetumomab pasudotox until death due to any cause. For participants who were alive at the end of the study or lost to follow-up  OS was censored on the last date when the participant was known be alive. Kaplan-Meier method was used for evaluation.')  ('time_frame'  'Baseline to end of study or last contact date  up to 1 year')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Overall Survival (OS)')  ('description'  'OS was determined as the time from the start of treatment with moxetumomab pasudotox until death due to any cause. For participants who were alive at the end of the study or lost to follow-up  OS was censored on the last date when the participant was known be alive. Kaplan-Meier method was used for evaluation.')  ('population'  'Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.')  ('units'  'months')  ('param'  'Median')  ('dispersion'  'Full Range')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '28')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '3.6')  ('@lower_limit'  '0.4')  ('@upper_limit'  '9.8')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)')  ('description'  'Treatment-emergent adverse events (TEAEs)  were defined as events present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of study drug.')  ('time_frame'  'Baseline up to 30 days after the last dose of study drug  up to 1 year')  ('population'  'Safety population includes all participants who received any amount of moxetumomab pasudotox.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)')  ('description'  'Treatment-emergent adverse events (TEAEs)  were defined as events present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of study drug.')  ('population'  'Safety population includes all participants who received any amount of moxetumomab pasudotox.')  ('units'  'participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '30')]))]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'TEAEs')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '30')]))]))]))]))])  OrderedDict([('title'  'TESAEs')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '16')]))]))]))]))])])]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE)')  ('description'  'Laboratory tests were grouped according to hematology  serum chemistry  and urinalysis. Laboratory abnormalities with toxicity grades according to NCI CTCAE Version 4.03 were derived according to laboratory values and reported as treatment-emergent adverse events.')  ('time_frame'  'Baseline up to 30 days after the last dose of study drug  up to 1 year')  ('population'  'Safety population includes all participants who received any amount of moxetumomab pasudotox.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE)')  ('description'  'Laboratory tests were grouped according to hematology  serum chemistry  and urinalysis. Laboratory abnormalities with toxicity grades according to NCI CTCAE Version 4.03 were derived according to laboratory values and reported as treatment-emergent adverse events.')  ('population'  'Safety population includes all participants who received any amount of moxetumomab pasudotox.')  ('units'  'participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '30')]))]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Anaemia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '11')]))]))]))]))])  OrderedDict([('title'  'Febrile neutropenia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '7')]))]))]))]))])  OrderedDict([('title'  'Haemolytic uraemic syndrome')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '4')]))]))]))]))])  OrderedDict([('title'  'Thrombocytopenia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Platelet count decreased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '9')]))]))]))]))])  OrderedDict([('title'  'Neutrophil count decreased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '6')]))]))]))]))])  OrderedDict([('title'  'White blood cell count decreased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '5')]))]))]))]))])  OrderedDict([('title'  'Lymphocyte count decreased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '2')]))]))]))]))])  OrderedDict([('title'  'International normalised ratio increased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Alanine aminotransferase increased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '11')]))]))]))]))])  OrderedDict([('title'  'Aspartate aminotransferase increased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '8')]))]))]))]))])  OrderedDict([('title'  'Gamma-glutamyltransferase increased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '4')]))]))]))]))])  OrderedDict([('title'  'Blood bilirubin increased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '2')]))]))]))]))])  OrderedDict([('title'  'Blood creatinine increased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '2')]))]))]))]))])  OrderedDict([('title'  'Blood lactate dehydrogenase increased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '2')]))]))]))]))])  OrderedDict([('title'  'Bilirubin conjugated')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Blood albumin decreased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Blood urea increased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Glucose tolerance increased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Hypoalbuminaemia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '6')]))]))]))]))])  OrderedDict([('title'  'Hypocalcaemia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '6')]))]))]))]))])  OrderedDict([('title'  'Hypokalaemia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '5')]))]))]))]))])  OrderedDict([('title'  'Hyponatraemia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '5')]))]))]))]))])  OrderedDict([('title'  'Hyperglycaemia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '4')]))]))]))]))])  OrderedDict([('title'  'Hypophosphataemia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '3')]))]))]))]))])  OrderedDict([('title'  'Hypermagnesaemia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Hypomagnesaemia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Hepatic function abnormal')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Proteinuria')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])])]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities')  ('description'  'Participants were evaluated for ECG abnormalities.')  ('time_frame'  'Baseline up to 30 days after the last dose of study drug  up to 1 year')  ('population'  'Safety population includes all participants who received any amount of moxetumomab pasudotox.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities')  ('description'  'Participants were evaluated for ECG abnormalities.')  ('population'  'Safety population includes all participants who received any amount of moxetumomab pasudotox.')  ('units'  'participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '30')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)')  ('description'  'Participants who experienced vital signs abnormalities recorded as TEAEs were reported.')  ('time_frame'  'Baseline up to 30 days after the last dose of study drug  up to 1 year')  ('population'  'Safety population includes all participants who received any amount of moxetumomab pasudotox.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)')  ('description'  'Participants who experienced vital signs abnormalities recorded as TEAEs were reported.')  ('population'  'Safety population includes all participants who received any amount of moxetumomab pasudotox.')  ('units'  'participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '30')]))]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Pyrexia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '16')]))]))]))]))])  OrderedDict([('title'  'Dyspnoea')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '6')]))]))]))]))])  OrderedDict([('title'  'Hypoxia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '4')]))]))]))]))])  OrderedDict([('title'  'Hypertension')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '8')]))]))]))]))])  OrderedDict([('title'  'Hypotension')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '4')]))]))]))]))])  OrderedDict([('title'  'Weight decreased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Weight increased')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '10')]))]))]))]))])  OrderedDict([('title'  'Bradycardia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '7')]))]))]))]))])  OrderedDict([('title'  'Sinus bradycardia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))])  OrderedDict([('title'  'Sinus tachycardia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '3')]))]))]))]))])  OrderedDict([('title'  'Tachycardia')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '3')]))]))]))]))])])]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Number of Participants With Positive Anti-drug Antibody (ADA) and Neutralizing Antibodies (NAb)')  ('description'  'Immunogenicity assessment included determination of antidrug (moxetumomab pasudotox) antibodies and neutralizing antidrug antibodies in serum samples. Titers and specificity were determined for NAb-positive participants. Specificity were observed in participants who had ADAs directed to the PE38 domain of moxetumomab pasudotox and increase in titers were observed in participants who tested ADA-positive at baseline. Moxetumomab pasudotox ADA-titer is a validated immunoassay  which determines titers or levels of ADAs present in ADA-positive samples.')  ('time_frame'  'Prior to the Start of Each Cycle for Cycles 1  2  3  and Subsequent Odd-Numbered Cycles  End of Treatment  and 30 Day Follow-up Visit  up to 1 year')  ('population'  'Safety population includes all participants who received any amount of moxetumomab pasudotox. Here  number of participants analysed  ""N"" included participants with at least one post-baseline sample.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Number of Participants With Positive Anti-drug Antibody (ADA) and Neutralizing Antibodies (NAb)')  ('description'  'Immunogenicity assessment included determination of antidrug (moxetumomab pasudotox) antibodies and neutralizing antidrug antibodies in serum samples. Titers and specificity were determined for NAb-positive participants. Specificity were observed in participants who had ADAs directed to the PE38 domain of moxetumomab pasudotox and increase in titers were observed in participants who tested ADA-positive at baseline. Moxetumomab pasudotox ADA-titer is a validated immunoassay  which determines titers or levels of ADAs present in ADA-positive samples.')  ('population'  'Safety population includes all participants who received any amount of moxetumomab pasudotox. Here  number of participants analysed  ""N"" included participants with at least one post-baseline sample.')  ('units'  'participants')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '23')]))]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Anti-drug Antibody (ADA)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '13')]))]))]))]))])  OrderedDict([('title'  'Neutralizing Antibodies (NAb)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '13')]))]))]))]))])  OrderedDict([('title'  'Increase in Titers')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '3')]))]))]))]))])  OrderedDict([('title'  'Specificity')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '13')]))]))]))]))])])]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Area Under the Plasma Concentration Time Curve From Time 0 to Infinity (AUC0-inf) After the First Dose of Cycle 1')  ('description'  'AUC (0-infinity) = Area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (tinfinity). It was calculated by extrapolating the concentrationtime curve from time zero to infinity using the linear/log trapezoidal rule.')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion of Day 1 of Cycle 1')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Area Under the Plasma Concentration Time Curve From Time 0 to Infinity (AUC0-inf) After the First Dose of Cycle 1')  ('description'  'AUC (0-infinity) = Area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (tinfinity). It was calculated by extrapolating the concentrationtime curve from time zero to infinity using the linear/log trapezoidal rule.')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('units'  'hour*nanogram per milliliter (hr*ng/mL)')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '7')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1200')  ('@spread'  '224')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Area Under the Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC0-last] After the First Dose of Cycle 1')  ('description'  'AUC is a measure of systemic drug exposure  which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. AUC0-t is defined as AUC from time zero to the last data point above the lower limit of quantification.')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion at Day 1 of Cycle 1')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Area Under the Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC0-last] After the First Dose of Cycle 1')  ('description'  'AUC is a measure of systemic drug exposure  which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. AUC0-t is defined as AUC from time zero to the last data point above the lower limit of quantification.')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('units'  'hour*nanogram per milliliter (hr*ng/mL)')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '21')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '794')  ('@spread'  '239')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Maximum Observed Drug Concentration in Plasma (Cmax) After the First Dose of Cycle 1')  ('description'  'Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion at Day 1 of Cycle 1')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Maximum Observed Drug Concentration in Plasma (Cmax) After the First Dose of Cycle 1')  ('description'  'Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration.')  ('units'  'nanogram per milliliter')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '26')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '457')  ('@spread'  '128')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Time to Reach Maximum Drug Concentration in Plasma (Tmax) After the First Dose of Cycle 1')  ('description'  'Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing  and measuring them for drug content.')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion at Day 1 of Cycle 1')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Time to Reach Maximum Drug Concentration in Plasma (Tmax) After the First Dose of Cycle 1')  ('description'  'Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing  and measuring them for drug content.')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration.')  ('units'  'hour')  ('param'  'Mean')  ('dispersion'  'Standard Deviation')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '26')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.54')  ('@spread'  '0.05')  ('@lower_limit'  '0.50')  ('@upper_limit'  '0.75')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Terminal Phase Elimination Half Life (t1/2) After the First Dose of Cycle 1')  ('description'  'Terminal phase elimination half-life is the time measured for the serum/plasma concentration to decrease by one half  calculated as natural logarithmic (log)-transformed (ln) value of 2 divided by elimination rate constant (lambda); that is [ln(2)/lambda]. Elimination rate constant (lambda) was estimated via linear regression of the time versus log concentration.')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion at Day 1 of Cycle 1')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Terminal Phase Elimination Half Life (t1/2) After the First Dose of Cycle 1')  ('description'  'Terminal phase elimination half-life is the time measured for the serum/plasma concentration to decrease by one half  calculated as natural logarithmic (log)-transformed (ln) value of 2 divided by elimination rate constant (lambda); that is [ln(2)/lambda]. Elimination rate constant (lambda) was estimated via linear regression of the time versus log concentration.')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('units'  'hour')  ('param'  'Median')  ('dispersion'  'Full Range')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '7')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '1.02')  ('@spread'  '0.213')  ('@lower_limit'  '0.820')  ('@upper_limit'  '1.44')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'Systemic Clearance (CL) After the First Dose of Cycle 1')  ('description'  'CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]).')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion at Day 1 of Cycle 1')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg)')  ('description'  'Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.')]))]))  ('measure'  OrderedDict([('title'  'Systemic Clearance (CL) After the First Dose of Cycle 1')  ('description'  'CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]).')  ('population'  'Safety population who provided at least one measurable Pharmacokinetic concentration. Here  number of participants analysed  ""N"" included evaluable participants for this outcome measure.')  ('units'  'milliliter per hour per kilogram')  ('param'  'Mean')  ('dispersion'  'Full Range')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '7')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '34.4')  ('@spread'  '5.72')  ('@lower_limit'  '24.4')  ('@upper_limit'  '41.8')]))]))]))]))]))]))]))])]|",MedImmune LLC|,Terminated|,Yes|,[OrderedDict([('title'  'Did not receive treatment')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '2')]))]))])  OrderedDict([('title'  'Unspecified')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '3')]))]))])  OrderedDict([('title'  'Progressive disease')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '17')]))]))])  OrderedDict([('title'  'Initiation of alternative therapy')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '2')]))]))])  OrderedDict([('title'  'Investigator discretion')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '1')]))]))])  OrderedDict([('title'  'Adverse Event')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '6')]))]))])]|,,,,Phase 2|,information.center@astrazenea.com|,,,The CRc is defined as achieving complete response (CR)  or CR with incomplete count recovery [CRi]) in participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts. The efficacy assessments were evaluated as per investigator assessment.|,Treatment|,,Germany|,,Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1  3  5  7  9  and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.|,[OrderedDict([('title'  'Total')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Total  other adverse events')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '30')  ('@subjects_at_risk'  '30')]))]))]))])  OrderedDict([('title'  'Blood and lymphatic system disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Anaemia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '29')  ('@subjects_affected'  '11')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Febrile neutropenia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '13')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Cardiac disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Sinus tachycardia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '6')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Tachycardia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Eye disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Periorbital oedema')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Vision blurred')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '6')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Gastrointestinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Abdominal pain')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '5')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Constipation')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '5')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Diarrhoea')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Nausea')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '10')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Vomiting')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'General disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Face oedema')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '5')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Fatigue')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Oedema peripheral')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '8')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Pyrexia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '40')  ('@subjects_affected'  '12')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Infections and infestations')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Pneumonia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))]))]))])  OrderedDict([('title'  'Investigations')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Alanine aminotransferase increased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '45')  ('@subjects_affected'  '11')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Aspartate aminotransferase increased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '34')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Blood bilirubin increased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Blood creatinine increased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Blood lactate dehydrogenase increased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Gamma-glutamyltransferase increased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '18')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Lymphocyte count decreased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '4')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Neutrophil count decreased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '21')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Platelet count decreased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '59')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Weight increased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '21')  ('@subjects_affected'  '10')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'White blood cell count decreased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '24')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Metabolism and nutrition disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Hyperglycaemia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '12')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Hypoalbuminaemia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '11')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Hypocalcaemia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '28')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Hypokalaemia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '27')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Hyponatraemia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '12')  ('@subjects_affected'  '5')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Hypophosphataemia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '13')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Musculoskeletal and connective tissue disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Back pain')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '6')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Bone pain')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Groin pain')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Musculoskeletal chest pain')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Myalgia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Neck pain')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Pain in extremity')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '6')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Pain in jaw')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Nervous system disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Headache')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '22')  ('@subjects_affected'  '12')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Paraesthesia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Psychiatric disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Anxiety')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))]))]))])  OrderedDict([('title'  'Respiratory  thoracic and mediastinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Cough')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '3')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Dyspnoea')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '9')  ('@subjects_affected'  '6')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Epistaxis')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Hypoxia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '6')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Wheezing')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '2')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '30')]))])])]))])  OrderedDict([('title'  'Vascular disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Hypertension')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '12')  ('@subjects_affected'  '8')  ('@subjects_at_risk'  '30')]))])  OrderedDict([('sub_title'  'Hypotension')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@events'  '4')  ('@subjects_affected'  '4')  ('@subjects_at_risk'  '30')]))])])]))])]|,Sponsor|,,[OrderedDict([('measure'  'Percentage of Participants With Minimal Residual Disease (MRD)-Negative CRc Rate')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'The MRD-negative CRc rate was defined as the percentage of participants who achieved CRc and became MRD-negative as determined by flow cytometry performed by a central analysis laboratory. The CRc is defined as complete response (CR)  or complete response with incomplete count recovery (CRi). Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts.')])  OrderedDict([('measure'  'Overall Response Rate (ORR)')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'The ORR  defined as the percentage of participants with CRc or partial response (PR)  was estimated; the Clopper Pearson (Exact) 95% CI was calculated. The CRc is defined as complete response (CR)  or complete response with incomplete count recovery (CRi). Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts.')])  OrderedDict([('measure'  'Time to Overall Response')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'Time to overall response was evaluated using the Kaplan-Meier method.')])  OrderedDict([('measure'  'Best Overall Response (BOR)')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'The best overall response was calculated  based upon the disease assessments recorded during the study visits  and summarized with the number and percentage of participants for the following categories: CRc  PR  HA  SD  PD  and not evaluable. Overall best response is the best response observed for a participant during the study based on International Working Group (IWG) Response Criteria for malignant lymphoma. Complete response (CR) as per IWG is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is a minimum of 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses and no increase in the size of other nodes and in size of liver or spleen. Stable disease (SD) is when a participant fails to attain the criteria needed for a CR or PR  but does not fulfill those for PD.')])  OrderedDict([('measure'  'Bone Marrow Blast Percentage Change')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'Change in bone marrow blast percentage from baseline was evaluated. If the percentage (%) blasts (at least 200 cells counted) is less than (<) 5%  it is considered as M1  5 to 25% considered as M2  greater than (>) 25% considered as M3. Stages with the higher blasts relate to worse outcomes.')])  OrderedDict([('measure'  'Percentage of Participants Who Became Eligible to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'The percentage of participants who became eligible for SCT after treatment with moxetumomab pasudotox were provided. The Clopper Pearson (Exact) 95% CI was calculated.')])  OrderedDict([('measure'  'Time to Transplant to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'The time to SCT was defined as the duration from the start of treatment with moxetumomab pasudotox until the date when the subject became eligible for SCT. The time to SCT was to be summarized using the Kaplan-Meier method  and was only to be evaluated for the subgroup of subjects who became eligible for SCT after treatment with moxetumomab pasudotox.')])  OrderedDict([('measure'  'Percentage of Participants Who Were Neutropenic at Study Entry and Who Experienced Hematologic Activity (HA)')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'The percentage of participants who were neutropenic at study entry and experienced HA after treatment with moxetumomab pasudotox was evaluated. The Clopper Pearson (Exact) 95% CI was calculated.')])  OrderedDict([('measure'  'Duration of Complete Response (DOCR)')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'DOCR was defined as the duration from the first documentation of CRc to the first documented disease progression.The CRc is defined as achieving complete response (CR)  or CR with incomplete count recovery [CRi]) in participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Kaplan-Meier method was used for evaluation.')])  OrderedDict([('measure'  'Duration of Overall Response (DOR)')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'DOR was to be defined as the duration from the first documentation of overall response to the first documented disease progression. Kaplan-Meier method was used for evaluation.')])  OrderedDict([('measure'  'Progression-Free Survival (PFS)')  ('time_frame'  'Prior to Cycle 1  and prior to every cycle  at the end of treatment  at post-treatment follow-up visits  and at the end of the study  up to 1 year')  ('description'  'PFS was measured from the start of treatment with moxetumomab pasudotox until the first documentation of disease progression or death due to any cause  whichever occurred first. Kaplan-Meier method was used for evaluation.')])  OrderedDict([('measure'  'Overall Survival (OS)')  ('time_frame'  'Baseline to end of study or last contact date  up to 1 year')  ('description'  'OS was determined as the time from the start of treatment with moxetumomab pasudotox until death due to any cause. For participants who were alive at the end of the study or lost to follow-up  OS was censored on the last date when the participant was known be alive. Kaplan-Meier method was used for evaluation.')])  OrderedDict([('measure'  'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)')  ('time_frame'  'Baseline up to 30 days after the last dose of study drug  up to 1 year')  ('description'  'Treatment-emergent adverse events (TEAEs)  were defined as events present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of study drug.')])  OrderedDict([('measure'  'Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE)')  ('time_frame'  'Baseline up to 30 days after the last dose of study drug  up to 1 year')  ('description'  'Laboratory tests were grouped according to hematology  serum chemistry  and urinalysis. Laboratory abnormalities with toxicity grades according to NCI CTCAE Version 4.03 were derived according to laboratory values and reported as treatment-emergent adverse events.')])  OrderedDict([('measure'  'Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities')  ('time_frame'  'Baseline up to 30 days after the last dose of study drug  up to 1 year')  ('description'  'Participants were evaluated for ECG abnormalities.')])  OrderedDict([('measure'  'Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)')  ('time_frame'  'Baseline up to 30 days after the last dose of study drug  up to 1 year')  ('description'  'Participants who experienced vital signs abnormalities recorded as TEAEs were reported.')])  OrderedDict([('measure'  'Number of Participants With Positive Anti-drug Antibody (ADA) and Neutralizing Antibodies (NAb)')  ('time_frame'  'Prior to the Start of Each Cycle for Cycles 1  2  3  and Subsequent Odd-Numbered Cycles  End of Treatment  and 30 Day Follow-up Visit  up to 1 year')  ('description'  'Immunogenicity assessment included determination of antidrug (moxetumomab pasudotox) antibodies and neutralizing antidrug antibodies in serum samples. Titers and specificity were determined for NAb-positive participants. Specificity were observed in participants who had ADAs directed to the PE38 domain of moxetumomab pasudotox and increase in titers were observed in participants who tested ADA-positive at baseline. Moxetumomab pasudotox ADA-titer is a validated immunoassay  which determines titers or levels of ADAs present in ADA-positive samples.')])  OrderedDict([('measure'  'Area Under the Plasma Concentration Time Curve From Time 0 to Infinity (AUC0-inf) After the First Dose of Cycle 1')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion of Day 1 of Cycle 1')  ('description'  'AUC (0-infinity) = Area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (tinfinity). It was calculated by extrapolating the concentrationtime curve from time zero to infinity using the linear/log trapezoidal rule.')])  OrderedDict([('measure'  'Area Under the Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC0-last] After the First Dose of Cycle 1')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion at Day 1 of Cycle 1')  ('description'  'AUC is a measure of systemic drug exposure  which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. AUC0-t is defined as AUC from time zero to the last data point above the lower limit of quantification.')])  OrderedDict([('measure'  'Maximum Observed Drug Concentration in Plasma (Cmax) After the First Dose of Cycle 1')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion at Day 1 of Cycle 1')  ('description'  'Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.')])  OrderedDict([('measure'  'Time to Reach Maximum Drug Concentration in Plasma (Tmax) After the First Dose of Cycle 1')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion at Day 1 of Cycle 1')  ('description'  'Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing  and measuring them for drug content.')])  OrderedDict([('measure'  'Terminal Phase Elimination Half Life (t1/2) After the First Dose of Cycle 1')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion at Day 1 of Cycle 1')  ('description'  'Terminal phase elimination half-life is the time measured for the serum/plasma concentration to decrease by one half  calculated as natural logarithmic (log)-transformed (ln) value of 2 divided by elimination rate constant (lambda); that is [ln(2)/lambda]. Elimination rate constant (lambda) was estimated via linear regression of the time versus log concentration.')])  OrderedDict([('measure'  'Systemic Clearance (CL) After the First Dose of Cycle 1')  ('time_frame'  'Pre-infusion  end of infusion (EOI); 1  3  and 6 hours post-infusion at Day 1 of Cycle 1')  ('description'  'CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]).')])]|,MedImmune LLC|,,August 2014|,,Interventional|,,https://clinicaltrials.gov/show/NCT02227108|,March 2017|,The study was terminated prior to a planned interim analysis based on lack of required efficacy in the first 32 participants enrolled.|
9,,Pegcrisantaspase|,4|,pegcrisantaspase|,[OrderedDict([('title'  'Age')  ('units'  'years')  ('param'  'Mean')  ('dispersion'  'Full Range')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '12.95')  ('@lower_limit'  '7.8')  ('@upper_limit'  '20.3')]))]))]))]))]))]))])  OrderedDict([('title'  'Sex: Female  Male')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  [OrderedDict([('title'  'Female')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '1')]))]))])  OrderedDict([('title'  'Male')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '3')]))]))])])]))]))]))])  OrderedDict([('title'  'Ethnicity (NIH/OMB)')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  [OrderedDict([('title'  'Hispanic or Latino')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '1')]))]))])  OrderedDict([('title'  'Not Hispanic or Latino')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '3')]))]))])  OrderedDict([('title'  'Unknown or Not Reported')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))])])]))]))]))])  OrderedDict([('title'  'Race (NIH/OMB)')  ('units'  'Participants')  ('param'  'Count of Participants')  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  [OrderedDict([('title'  'American Indian or Alaska Native')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))])  OrderedDict([('title'  'Asian')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))])  OrderedDict([('title'  'Native Hawaiian or Other Pacific Islander')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))])  OrderedDict([('title'  'Black or African American')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))])  OrderedDict([('title'  'White')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '4')]))]))])  OrderedDict([('title'  'More than one race')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))])  OrderedDict([('title'  'Unknown or Not Reported')  ('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '0')]))]))])])]))]))]))])  OrderedDict([('title'  'Region of Enrollment')  ('units'  'participants')  ('param'  'Number')  ('class_list'  OrderedDict([('class'  OrderedDict([('title'  'United States')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'B1')  ('@value'  '4')]))]))]))]))]))]))])]|,The purpose of this study is to evaluate the effectiveness safety  and dosage of pegcrisantaspase in patients with Acute Lymphoblastic Leukemia (ALL) / Lymphoblastic Lymphoma (LBL).|,A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)|,There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.|,,February 2015|,['Lymphoma'  'Leukemia'  'Precursor Cell Lymphoblastic Leukemia-Lymphoma'  'Leukemia  Lymphoid'  'Lymphoma  Non-Hodgkin'  'Hypersensitivity']|,,Inclusion Criteria: 1. Have a diagnosis of ALL/LBL 2. Be > 1 to ≤ 21 years of age at study enrollment 3. Have had a ≥ Grade 2 allergic reaction (Common Terminology Criteria for Adverse Events [CTCAE] v4.03) to pegaspargase 4. Have ≥ 1 dose(s) of pegaspargase remaining in his/her treatment plan 5. Have a documented SAA level that is below the limit of quantitation per the analytical method. 6. Subjects must have  in the opinion of the investigator  fully recovered from prior allergic reaction to pegaspargase. Subjects must have completed antihistamine  epinephrine  and/or corticosteroid treatment for the allergic reaction ≥ 24 hours prior to pegcrisantaspase administration. 7. Subjects must have a performance status corresponding to: - Karnofsky ≥ 50 (for subjects > 16 years of age) - Lansky ≥ 50 (for subjects ≤ 16 years of age) 8. Adequate Renal Function Defined as: - Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2 or - A serum creatinine based on age/gender as follows: Age Maximum Serum Creatinine (mg/dL) Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 ≥ 16 years 1.7 1.4 The threshold creatinine values in this table were derived from the Schwartz formula for estimating GFR (Schwartz & Gauthier 1985) utilizing child length and stature data published by the CDC. 9. Adequate Liver Function defined as: Bilirubin levels ≤ 2.5x ULN for age  and Direct (conjugated) Bilirubin < 0.5 mg/dLSGPT (ALT) ≤ 225 U/L. For the purpose of this study  the ULN for SGPT is 45 U/L. 10. Subjects who are sexually active must agree to use a medically acceptable method of contraception throughout the entire study period and for 4 weeks after the study is completed. Medically acceptable methods of contraception that may be used by the subject and/or the partner include abstinence  birth control pills or patches  diaphragm and spermicide  condom and vaginal spermicide  surgical sterilization  postmenopausal  vasectomy (>6 months prior to baseline)  and progestin implant or injection. 11. Able to understand and to sign a written informed consent. All subjects and/or their parent or a legally authorized representative must sign a written informed consent. Assent  when appropriate  will be obtained according to institutional guidelines. Exclusion Criteria: 1. Have previously received Erwinia asparaginase 2. Are receiving another investigational agent or will receive an investigational agent in subsequent phases of protocol therapy that include asparaginase 3. Have a history of ≥ Grade 3 pancreatitis (CTCAE v4.03) 4. Prior history of a CNS thrombotic event or ≥ Grade 3 (CTCAE v4.03) thrombotic event  excluding catheter-associated clots 5. Prior history of asparaginase-associated ≥ Grade 3 (CTCAE v4.03) hemorrhagic event or asparaginase-associated thrombus requiring anticoagulation therapy 6. Blood triglyceride levels > 500 mg/dL or > 5.6 mmol/L 7. Hyperglycemia requiring insulin therapy 8. QTc prolongation ≥ 550 msec 9. Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study 10. Subjects who have any serious active disease or co-morbid medical condition (according to investigator's decision)  or psychiatric illness that would prevent the subject from signing the informed consent form  assent form or informed consent form by parents  pending institutional requirements  or per investigator's opinion  would prevent the subject from completing one course of pegcrisantaspase. Pregnant or lactating females or females of childbearing potential not willing to use an adequate method of birth control for the duration of the study. Female subjects who are lactating who do not agree to stop breast-feeding.|,The purpose of the study was to assess the response rate in children and young adults with ALL/LBL and hypersensitivity to pegaspargase defined as the proportion of subjects having a serum asparaginase activity (SAA) level of ≥ 0.1 IU/mL 14 days following the first IV pegcrisantaspase dose in Course 1. Also  to assess the safety of IV pegcrisantaspase therapy in children and young adults with ALL/LBL with hypersensitivity to pegaspargase.|,ClinicalTrials.gov processed this data on May 19  2017|,Inclusion Criteria: 1. Have a diagnosis of ALL/LBL 2. Be > 1 to ≤ 21 years of age at study enrollment 3. Have had a ≥ Grade 2 allergic reaction (Common Terminology Criteria for Adverse Events [CTCAE] v4.03) to pegaspargase 4. Have ≥ 1 dose(s) of pegaspargase remaining in his/her treatment plan 5. Have a documented SAA level that is below the limit of quantitation per the analytical method. 6. Subjects must have  in the opinion of the investigator  fully recovered from prior allergic reaction to pegaspargase. Subjects must have completed antihistamine  epinephrine  and/or corticosteroid treatment for the allergic reaction ≥ 24 hours prior to pegcrisantaspase administration. 7. Subjects must have a performance status corresponding to: - Karnofsky ≥ 50 (for subjects > 16 years of age) - Lansky ≥ 50 (for subjects ≤ 16 years of age) 8. Adequate Renal Function Defined as: - Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2 or - A serum creatinine based on age/gender as follows: Age Maximum Serum Creatinine (mg/dL) Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 ≥ 16 years 1.7 1.4 The threshold creatinine values in this table were derived from the Schwartz formula for estimating GFR (Schwartz & Gauthier 1985) utilizing child length and stature data published by the CDC. 9. Adequate Liver Function defined as: Bilirubin levels ≤ 2.5x ULN for age  and Direct (conjugated) Bilirubin < 0.5 mg/dLSGPT (ALT) ≤ 225 U/L. For the purpose of this study  the ULN for SGPT is 45 U/L. 10. Subjects who are sexually active must agree to use a medically acceptable method of contraception throughout the entire study period and for 4 weeks after the study is completed. Medically acceptable methods of contraception that may be used by the subject and/or the partner include abstinence  birth control pills or patches  diaphragm and spermicide  condom and vaginal spermicide  surgical sterilization  postmenopausal  vasectomy (>6 months prior to baseline)  and progestin implant or injection. 11. Able to understand and to sign a written informed consent. All subjects and/or their parent or a legally authorized representative must sign a written informed consent. Assent  when appropriate  will be obtained according to institutional guidelines. Exclusion Criteria: 1. Have previously received Erwinia asparaginase 2. Are receiving another investigational agent or will receive an investigational agent in subsequent phases of protocol therapy that include asparaginase 3. Have a history of ≥ Grade 3 pancreatitis (CTCAE v4.03) 4. Prior history of a CNS thrombotic event or ≥ Grade 3 (CTCAE v4.03) thrombotic event  excluding catheter-associated clots 5. Prior history of asparaginase-associated ≥ Grade 3 (CTCAE v4.03) hemorrhagic event or asparaginase-associated thrombus requiring anticoagulation therapy 6. Blood triglyceride levels > 500 mg/dL or > 5.6 mmol/L 7. Hyperglycemia requiring insulin therapy 8. QTc prolongation ≥ 550 msec 9. Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study 10. Subjects who have any serious active disease or co-morbid medical condition (according to investigator's decision)  or psychiatric illness that would prevent the subject from signing the informed consent form  assent form or informed consent form by parents  pending institutional requirements  or per investigator's opinion  would prevent the subject from completing one course of pegcrisantaspase. Pregnant or lactating females or females of childbearing potential not willing to use an adequate method of birth control for the duration of the study. Female subjects who are lactating who do not agree to stop breast-feeding.|,All|,No|,21 Years|,1 Year|,4|,September 22  2014|,January 5  2017|,,All|,,,No|,,Pegaspargase|,,,,,['ALL'  'LBL']|,March 6  2017|,Industry|,Only 1 patient achieved the predefined SAA level above the 0.1 IU/mL therapeutic threshold 14 days following IV pegcrisantaspase dose in Course 1. Therefore  the corresponding PK parameters for repeated administration were not calculated.|,Link to the current ClinicalTrials.gov record.|,United States|,,No masking|,,21 Years|,1 Year|,NCT02257684|,1|,,,A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)|,13-011|,[OrderedDict([('type'  'Primary')  ('title'  'The Response Rate in Children & Young Adults With ALL/LBL and Hypersensitivity to Pegaspargase Defined as the Proportion of Subjects Having a Serum Asparaginase Activity (SAA) Level of >= 0.1 IU/mL Following the First IV Dose in Course 1')  ('time_frame'  '15 days during Course 1')  ('population'  'Only 1 of the first 4 patients dosed achieved the predefined serum asparaginase activity (SAA) level above the 0.1 IU/mL therapeutic threshold 14 days following the first IV pegcrisantaspase dose in Course 1 (Primary Objective of the study).')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Pegcrisantaspase')  ('description'  'IV administration of pegcrisantaspase in Course 1')]))]))  ('measure'  OrderedDict([('title'  'The Response Rate in Children & Young Adults With ALL/LBL and Hypersensitivity to Pegaspargase Defined as the Proportion of Subjects Having a Serum Asparaginase Activity (SAA) Level of >= 0.1 IU/mL Following the First IV Dose in Course 1')  ('population'  'Only 1 of the first 4 patients dosed achieved the predefined serum asparaginase activity (SAA) level above the 0.1 IU/mL therapeutic threshold 14 days following the first IV pegcrisantaspase dose in Course 1 (Primary Objective of the study).')  ('units'  'SAA Level IU/mL')  ('param'  'Number')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '1')]))]))]))]))  ('class_list'  OrderedDict([('class'  [OrderedDict([('title'  'Course 1; Day 0 (Screening)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.013')]))]))]))]))])  OrderedDict([('title'  'Course 1; Day 1 (Pre-dose)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.013')]))]))]))]))])  OrderedDict([('title'  'Course 1; Day 1 (1 hour post)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.50')]))]))]))]))])  OrderedDict([('title'  'Course 1; Day 1 (3 hour post)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.44')]))]))]))]))])  OrderedDict([('title'  'Course 1; Day 1 (5 hour post)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.41')]))]))]))]))])  OrderedDict([('title'  'Course 1; Day 2 (Visit 2)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.36')]))]))]))]))])  OrderedDict([('title'  'Course 1; Day 8 (Visit 3)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.28')]))]))]))]))])  OrderedDict([('title'  'Course 1; Day 11 (Visit 4)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.24')]))]))]))]))])  OrderedDict([('title'  'Course 1; Day 15 (Visit 5)')  ('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0.26')]))]))]))]))])])]))]))])  OrderedDict([('type'  'Primary')  ('title'  'The Serum Asparaginase Activity 14 Days After the First Infusion of Study Drug and the Adverse Events in All Participants.')  ('time_frame'  '1 Year')  ('population'  'Not Applicable  as the study was terminated before this endpoint was analyzed.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Pegcrisantaspase')  ('description'  'IV administration of pegcrisantaspase in Course 1')]))]))  ('measure'  OrderedDict([('title'  'The Serum Asparaginase Activity 14 Days After the First Infusion of Study Drug and the Adverse Events in All Participants.')  ('population'  'Not Applicable  as the study was terminated before this endpoint was analyzed.')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'The Pharmakokinetic (PK) Profile of IV Pegcrisantaspase in Children and Young Adults With ALL/LBL and Hypersensitivity to Pegaspargase. Pharmakokinetic Profiles to be Assessed Are: Half Life  Elimination Rate  Tmax  Cmax  AUC.')  ('time_frame'  '14 Days')  ('population'  'Not Applicable  as the study was terminated before this endpoint was analyzed.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Pegcrisantaspase')  ('description'  'IV administration of pegcrisantaspase in Course 1')]))]))  ('measure'  OrderedDict([('title'  'The Pharmakokinetic (PK) Profile of IV Pegcrisantaspase in Children and Young Adults With ALL/LBL and Hypersensitivity to Pegaspargase. Pharmakokinetic Profiles to be Assessed Are: Half Life  Elimination Rate  Tmax  Cmax  AUC.')  ('population'  'Not Applicable  as the study was terminated before this endpoint was analyzed.')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'The SAA Levels Over Time Following Repeated Administration in Children and Young Adults ALL/LBL and Hypersensitivity to Pegaspargase')  ('time_frame'  '30 Days')  ('population'  'Not Applicable  as the study was terminated before this endpoint was analyzed.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Pegcrisantaspase')  ('description'  'IV administration of pegcrisantaspase in Course 1')]))]))  ('measure'  OrderedDict([('title'  'The SAA Levels Over Time Following Repeated Administration in Children and Young Adults ALL/LBL and Hypersensitivity to Pegaspargase')  ('population'  'Not Applicable  as the study was terminated before this endpoint was analyzed.')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))]))]))]))])  OrderedDict([('type'  'Secondary')  ('title'  'The Immunogenicity of IV Pegcristaspase by Testing Anti-pegcrisantaspase and Anti-PEG Binding and Neutralizing Antibodies')  ('time_frame'  '30 Days')  ('population'  'Not Applicable  as the study was terminated before this endpoint was analyzed.')  ('group_list'  OrderedDict([('group'  OrderedDict([('@group_id'  'O1')  ('title'  'Pegcrisantaspase')  ('description'  'IV administration of pegcrisantaspase in Course 1')]))]))  ('measure'  OrderedDict([('title'  'The Immunogenicity of IV Pegcristaspase by Testing Anti-pegcrisantaspase and Anti-PEG Binding and Neutralizing Antibodies')  ('population'  'Not Applicable  as the study was terminated before this endpoint was analyzed.')  ('analyzed_list'  OrderedDict([('analyzed'  OrderedDict([('units'  'Participants')  ('scope'  'Measure')  ('count_list'  OrderedDict([('count'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))  ('class_list'  OrderedDict([('class'  OrderedDict([('category_list'  OrderedDict([('category'  OrderedDict([('measurement_list'  OrderedDict([('measurement'  OrderedDict([('@group_id'  'O1')  ('@value'  '0')]))]))]))]))]))]))]))])]|,Jazz Pharmaceuticals|,Terminated|,Yes|,"[OrderedDict([('title'  'Adverse Event')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '2')]))]))])  OrderedDict([('title'  'Lack of Efficacy')  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '1')]))]))])  OrderedDict([('title'  ""Sponsor's Decision"")  ('participants_list'  OrderedDict([('participants'  OrderedDict([('@group_id'  'P1')  ('@count'  '1')]))]))])]|",,,No|,Phase 2|,650-496-3777|,,,[OrderedDict([('measure'  'The Response Rate in Children & Young Adults With ALL/LBL and Hypersensitivity to Pegaspargase Defined as the Proportion of Subjects Having a Serum Asparaginase Activity (SAA) Level of >= 0.1 IU/mL Following the First IV Dose in Course 1')  ('time_frame'  '15 days during Course 1')])  OrderedDict([('measure'  'The Serum Asparaginase Activity 14 Days After the First Infusion of Study Drug and the Adverse Events in All Participants.')  ('time_frame'  '1 Year')])]|,Treatment|,,,,IV administration of pegcrisantaspase in Course 1|,[OrderedDict([('title'  'Total')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Total  other adverse events')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '3')  ('@subjects_at_risk'  '4')]))]))]))])  OrderedDict([('title'  'Blood and lymphatic system disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Anaemia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '2')  ('@subjects_at_risk'  '4')]))])  OrderedDict([('sub_title'  'Neutropenia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '4')]))])])]))])  OrderedDict([('title'  'Eye disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Periorbital oedema')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '4')]))]))]))])  OrderedDict([('title'  'General disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Mucosal inflammation')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '4')]))]))]))])  OrderedDict([('title'  'Investigations')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Alanine aminotransferase increased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '4')]))])  OrderedDict([('sub_title'  'Platelet count decreased')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '4')]))])])]))])  OrderedDict([('title'  'Musculoskeletal and connective tissue disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Muscle spasms')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '4')]))]))]))])  OrderedDict([('title'  'Nervous system disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Headache')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '4')]))]))]))])  OrderedDict([('title'  'Respiratory  thoracic and mediastinal disorders')  ('event_list'  OrderedDict([('event'  [OrderedDict([('sub_title'  'Nasal congestion')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '4')]))])  OrderedDict([('sub_title'  'Rhinorrhoea')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '4')]))])])]))])  OrderedDict([('title'  'Skin and subcutaneous tissue disorders')  ('event_list'  OrderedDict([('event'  OrderedDict([('sub_title'  'Alopecia')  ('counts'  OrderedDict([('@group_id'  'E1')  ('@subjects_affected'  '1')  ('@subjects_at_risk'  '4')]))]))]))])]|,Sponsor|,,[OrderedDict([('measure'  'The Pharmakokinetic (PK) Profile of IV Pegcrisantaspase in Children and Young Adults With ALL/LBL and Hypersensitivity to Pegaspargase. Pharmakokinetic Profiles to be Assessed Are: Half Life  Elimination Rate  Tmax  Cmax  AUC.')  ('time_frame'  '14 Days')])  OrderedDict([('measure'  'The SAA Levels Over Time Following Repeated Administration in Children and Young Adults ALL/LBL and Hypersensitivity to Pegaspargase')  ('time_frame'  '30 Days')])  OrderedDict([('measure'  'The Immunogenicity of IV Pegcristaspase by Testing Anti-pegcrisantaspase and Anti-PEG Binding and Neutralizing Antibodies')  ('time_frame'  '30 Days')])]|,Jazz Pharmaceuticals|,,September 2014|,,Interventional|,,https://clinicaltrials.gov/show/NCT02257684|,March 2017|,Sponsor decision|
10,Randomized|,[OrderedDict([('arm_group_label'  'GERI+ Incubator')  ('arm_group_type'  'Other')])  OrderedDict([('arm_group_label'  'Conventional incubator')  ('arm_group_type'  'Active Comparator')])]|,,,,The main purpose of the study is to evaluate the overall clinical value of GERI+ as an integrated embryo culture and assessment system  providing an undisturbed culture environment  continuous monitoring of embryo development and automated scoring using a predictive algorithm.|,TICON-Day 3  Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment|,,,July 28  2019|,Infertility|,,"Inclusion Criteria: - Couples with <= two failed fresh In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) embryo transfer cycles. - Age >= 18 and <= 40 years. - Body mass index (BMI): 18-30 kilogram per meter square (kg/m2). - Normal uterine cavity under ultrasound. - Subject and her husband/partner must have read and signed the Informed Consent form. - At least four normally fertilized oocytes (2Pronuclear stage (PN)) in the current cycle. Exclusion Criteria: - Male with non-ejaculated sperm. - Subjects with abnormal  undiagnosed gynecological bleeding or with genitourinary malformations. - Subjects with any contraindication to Controlled Ovarian Stimulation (COS) for Assisted Reproductive Technologies (ART) or to gonadotropins. - Planned ""freeze all"" cycle (oocytes or embryos). - Planned preimplantation genetic screening (PGS) or Pre-implantation genetic diagnosis (PGD) cycle. - Concurrent participation in another clinical study.|",,ClinicalTrials.gov processed this data on May 23  2017|,"Inclusion Criteria: - Couples with <= two failed fresh In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) embryo transfer cycles. - Age >= 18 and <= 40 years. - Body mass index (BMI): 18-30 kilogram per meter square (kg/m2). - Normal uterine cavity under ultrasound. - Subject and her husband/partner must have read and signed the Informed Consent form. - At least four normally fertilized oocytes (2Pronuclear stage (PN)) in the current cycle. Exclusion Criteria: - Male with non-ejaculated sperm. - Subjects with abnormal  undiagnosed gynecological bleeding or with genitourinary malformations. - Subjects with any contraindication to Controlled Ovarian Stimulation (COS) for Assisted Reproductive Technologies (ART) or to gonadotropins. - Planned ""freeze all"" cycle (oocytes or embryos). - Planned preimplantation genetic screening (PGS) or Pre-implantation genetic diagnosis (PGD) cycle. - Concurrent participation in another clinical study.|",All|,Accepts Healthy Volunteers|,40 Years|,18 Years|,1386|,May 22  2017|,,,All|,,,No|,,[OrderedDict([('intervention_type'  'Device')  ('intervention_name'  'GERI+ incubator')  ('description'  'The embryo culture of consented subjects will be carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3  all embryos will be reviewed firstly by GERI Assess software  using bright-field imaging. A GERI Assess score will be calculated for each embryo. The three embryos with the highest GERI Assess scores of a subject are then further assessed by Early Embryo Viability Assessment (EEVA). Finally the embryo(s) with the highest EEVA grade among the three are transferred and will be followed up until the achievement of implantation and confirmation of pregnancy.')  ('arm_group_label'  'GERI+ Incubator')])  OrderedDict([('intervention_type'  'Device')  ('intervention_name'  'Conventional incubator')  ('description'  'The embryo culture of consented subjects will be carried outin conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture  all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade will be transferred and will be followed up until the achievement of implantation and confirmation of pregnancy.')  ('arm_group_label'  'Conventional incubator')])]|,,,,,['GERI+'  'TICON'  'EEVA'  'Embryo culture'  'In Vitro Fertilization'  'Intracytoplasmic Sperm Injection']|,May 22  2017|,Industry|,,Link to the current ClinicalTrials.gov record.|,Germany|,,Participant|,,40 Years|,18 Years|,NCT03164551|,2|,,,A Phase IV  Single-blinded  Prospective  Randomized  Controlled  Multi-center Study to Compare the Clinical Outcomes of Genea Embryo Review Instrument Plus (GERI+) Time Lapse System With a Conventional Embryo Culture and Assessment System|,MS200497_0006|,,Merck KGaA|,Not yet recruiting|,No|,,,,,Phase 4|,,,,Clinical Pregnancy is defined as the pregnancy diagnosed by ultrasonographic or clinical documentation of at least one fetus with heart beat in gestational week 6 to 8. It includes ectopic pregnancy.|,Treatment|,,,,,,Sponsor|,,[OrderedDict([('measure'  'Utilizable Embryos Rate')  ('time_frame'  'Day 3 of embryo culture')  ('description'  'Utilizable embryos rate is defined as the number of transferred and cryopreserved embryos divided by the number of 2PN zygotes per subject.')])  OrderedDict([('measure'  'Good Quality Embryos Rate')  ('time_frame'  'Day 3 of embryo culture')  ('description'  'Good Quality Embryos is defined embryos with 7 or more blastomeres  <25% fragmentation  size and symmetry of blastomeres appropriate to the cell number  and no evidence of multinucleation  based on the morphology on Day 3 of embryo culture. Good quality embryos rate is defined as the number of good quality embryos divided by the number of 2Pronuclear stage (PN) zygotes per subject.')])  OrderedDict([('measure'  'Non-viable Embryos Rate')  ('time_frame'  'Days 1 to 3 of embryo culture')  ('description'  'Non-viable Embryos is defined as the embryos in which development has been arrested for at least 24 h or in which all the cells have degenerated or lysed. Non-viable embryos rate is defined as the number of non-viable embryos divided by the number of 2PN zygotes per subject.')])  OrderedDict([('measure'  'Implantation Rate With Positive Fetal Heart Beat')  ('time_frame'  'Gestational Weeks 6 to 8')  ('description'  'A successful implantation is defined as the presence of one gestational sac with fetal heart beat under ultrasonography at gestational weeks 6-8.Implantation rate is calculated per embryo transferred and per subject randomized .')])  OrderedDict([('measure'  'Biochemical Pregnancy Rate')  ('time_frame'  'From Day 12 of Gestational upto Week 8')  ('description'  'Biochemical Pregnancy defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy. Biochemical pregnancy rate is defined as the number of subjects with biochemical pregnancy divided by the number of subjects with embryo transfer.')])  OrderedDict([('measure'  'Ongoing Pregnancy Rate')  ('time_frame'  'Gestational Weeks 10 to 12')  ('description'  'Ongoing pregnancy is defined as the presence of viable fetuses identified by ultrasonography at gestational weeks 10-12. Ongoing pregnancy rate is defined as the number of subjects with ongoing pregnancy divided by the number of subjects with embryo transfer.')])  OrderedDict([('measure'  'Multiple Pregnancy Rate')  ('time_frame'  'Gestational Weeks 10 to 12')  ('description'  'Multiple pregnancy is defined as a pregnancy with more than one fetus. It is identified by ultrasonography at gestational weeks 10-12. Multiple pregnancy rate is defined as the number of subjects with multiple pregnancy divided by the number of subjects with ongoing pregnancy.')])  OrderedDict([('measure'  'Ectopic Pregnancy Rate')  ('time_frame'  'Gestational Weeks 6 to 8')  ('description'  'Ectopic pregnancy is defined as a pregnancy in which implantation takes place outside the uterine cavity. It is identified by ultrasonography at weeks 6-8. Ectopic Pregnancy Rate is defined as the number of subjects with ectopic pregnancy divided by the number of subjects with embryo transfer.')])  OrderedDict([('measure'  'Spontaneous Miscarriage Rate')  ('time_frame'  'Gestational Weeks 10 to 12')  ('description'  'Spontaneous miscarriage is the spontaneous loss of a clinical pregnancy before 20 completed weeks of gestational age (18 weeks after fertilization). In this study  the spontaneous miscarriage is tracked up to 10-12 weeks of gestational age. Spontaneous miscarriage rate is defined as the number of subjects with spontaneous miscarriage divided by the number of subjects with clinical pregnancy.')])]|,Merck KGaA|,,July 2  2017|,,Interventional|,,https://clinicaltrials.gov/show/NCT03164551|,May 2017|,
11,Randomized|,[OrderedDict([('arm_group_label'  'Arm A: CAB + Placebo TDF/FTC + CAB LA')  ('arm_group_type'  'Experimental')  ('description'  'During Step 1  participants will receive daily oral CAB and oral TDF/FTC placebo for 5 weeks. In Step 2  participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily oral TDF/FTC placebo beginning at Week 5. In Step 3  participants will receive daily TDF/FTC for up to 48 weeks  starting no later than 8 weeks after the last injection.')])  OrderedDict([('arm_group_label'  'Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA')  ('arm_group_type'  'Active Comparator')  ('description'  'During Step 1  participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks. In Step 2  participants will receive daily TDF/FTC and placebo for CAB LA injections at two times points 4 weeks apart and every 8 weeks thereafter beginning at Week 5. In Step 3  participants will receive daily TDF/FTC for up to 48 weeks  starting no later than 8 weeks after the last injection.')])]|,,,,This study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.|,Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women|,,,May 2022|,HIV Infections|,,Inclusion Criteria: - Born female - 18-45 years at the time of screening - Willing and able to provide informed consent - Willing and able to undergo all required study procedures - Non-reactive HIV test results at Screening and Enrollment. Note: HIV-uninfected  based on HIV test results obtained at Screening and just prior to randomization at the Enrollment visit. All HIV test results from the Screening visit must be obtained and must all be negative/non-reactive. This includes testing for acute HIV infection  which must be performed within 14 days of Enrollment. In addition  at least one HIV test result using blood drawn at the Enrollment visit must be obtained prior to randomization into the study and must be negative/non-reactive. Individuals who have one or more reactive or positive HIV test result(s) will not be enrolled  even if subsequent confirmatory testing indicates that they are not HIV-infected (see SSP Manual). - Sexually active (i.e.  vaginal intercourse on a minimum of two separate days in the 30 days prior to Screening) - Score of greater than or equal to 2 using a modified VOICE risk score - No plans to re-locate or travel away from the site for greater than or equal to 8 consecutive weeks during study participation - Creatinine clearance of greater than or equal to 60 mL/min (using Cockcroft-Gault equation) - Hepatitis B virus (HBV) surface antigen (HBsAg) negative and accepts vaccination - Alanine aminotransferase (ALT) less than 2 x upper limit of normal (ULN) and total bilirubin (Tbili) less than or equal to 2.5 x ULN - HCV antibody negative - If of reproductive potential (defined as pre-menopausal women who have not had a sterilization procedure per self-report  such as hysterectomy  bilateral oophorectomy  tubal ligation or salpingectomy)  must have a negative beta human chorionic gonadotropin (βHCG) pregnancy test (sensitivity of less than or equal to 25 mIU/mL) performed (and results known) on the same day as and before initiating the protocol-specified study product(s) at Enrollment. - If of reproductive potential  women must agree to use a reliable form of contraception  during the trial and for 52 weeks after stopping the long acting injectable  or 30 days after stopping oral study product  from the list below: - Intrauterine device (IUD) or intrauterine system (IUS) that meets less than 1% failure rate as stated in the product label - Hormone-based contraceptive that meets less than 1% failure rate when used consistently and correctly as stated in the product label - No medical condition that  in the opinion of the study investigator  would interfere with the conduct of the study (e.g.  provided by self-report  or found upon medical history and examination or in available medical records) - No alcohol or substance use that  in the opinion of the study investigator  would interfere with the conduct of the study (e.g.  provided by self-report  or found upon medical history and examination or in available medical records) Exclusion Criteria: - One or more reactive HIV test results at Screening or Enrollment  even if HIV infection is not confirmed - Pregnant or currently breastfeeding  or intends to become pregnant and/or breastfeed during the study - Co-enrollment in any other HIV interventional research study (provided by self-report or other available documentation) - Current or past enrollment in an HIV vaccine trial - Current or chronic history of liver disease (e.g.  non-alcoholic or alcoholic steatohepatitis) or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome  asymptomatic gallstones  or cholecystectomy) - History of seizure disorder  per self-report - Clinically significant cardiovascular disease  as defined by history/evidence of symptomatic arrhythmia  angina/ischemia  coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease - Inflammatory skin conditions that compromise the safety of IM injections  per the discretion of the Investigator of Record (IoR). Mild skin conditions may not be exclusionary at the discretion of the IoR or designee - Has a tattoo or other dermatological condition overlying the buttock region which in the opinion of the IoR or designee may interfere with interpretation of injection site reactions (ISRs) - Coagulopathy (primary or iatrogenic) which would contraindicate IM injection - Active or planned use of prohibited medications as described in the Investigator Brochure (IB) or listed in the Study Specific Procedures Manual (SSP) (provided by self-report  or obtained from medical history or medical records) - Known or suspected allergy to study product components (active or placebo)  including egg or soy products (egg and soy products are contained in Intralipid)|,The purpose of this study is to evaluate the safety and efficacy of the long-acting injectable integrase inhibitor cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in a population of sexually active HIV-uninfected women at risk for HIV. This study will take place in three steps. Participants will be randomly assigned to one of two arms: Arm A: Step 1: Participants will receive daily oral CAB and TDF/FTC placebo for 5 weeks. Step 2: Participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily TDF/FTC placebo beginning at Week 5. Arm B: Step 1: Participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks. Step 2: Participants will receive daily TDF/FTC and intramuscular (IM) placebo injections at two time points 4 weeks apart and every 8 weeks thereafter beginning at Week 5. Step 2 will continue until the last enrolled participant reaches approximately 76 weeks on Step 2 (Week 81 for the last enrolled participant). In Step 3  all participants (Arms A and B) will receive daily TDF/FTC for up to 48 weeks  starting no later than 8 weeks after the last injection. At the end of Step 3  all participants will then transition to locally available HIV prevention services  including services for PrEP  if available. Study visits will occur at Day 0 and at Weeks 2 and 4 during Step 1. During Step 2  participants will attend up to 24 visits  depending on when they enroll in the study. Study visits will occur every 12 weeks during Step 3. Study visits may include physical examinations; blood  urine  and vaginal swab collection; and risk reduction and adherence counseling.|,ClinicalTrials.gov processed this data on May 23  2017|,Inclusion Criteria: - Born female - 18-45 years at the time of screening - Willing and able to provide informed consent - Willing and able to undergo all required study procedures - Non-reactive HIV test results at Screening and Enrollment. Note: HIV-uninfected  based on HIV test results obtained at Screening and just prior to randomization at the Enrollment visit. All HIV test results from the Screening visit must be obtained and must all be negative/non-reactive. This includes testing for acute HIV infection  which must be performed within 14 days of Enrollment. In addition  at least one HIV test result using blood drawn at the Enrollment visit must be obtained prior to randomization into the study and must be negative/non-reactive. Individuals who have one or more reactive or positive HIV test result(s) will not be enrolled  even if subsequent confirmatory testing indicates that they are not HIV-infected (see SSP Manual). - Sexually active (i.e.  vaginal intercourse on a minimum of two separate days in the 30 days prior to Screening) - Score of greater than or equal to 2 using a modified VOICE risk score - No plans to re-locate or travel away from the site for greater than or equal to 8 consecutive weeks during study participation - Creatinine clearance of greater than or equal to 60 mL/min (using Cockcroft-Gault equation) - Hepatitis B virus (HBV) surface antigen (HBsAg) negative and accepts vaccination - Alanine aminotransferase (ALT) less than 2 x upper limit of normal (ULN) and total bilirubin (Tbili) less than or equal to 2.5 x ULN - HCV antibody negative - If of reproductive potential (defined as pre-menopausal women who have not had a sterilization procedure per self-report  such as hysterectomy  bilateral oophorectomy  tubal ligation or salpingectomy)  must have a negative beta human chorionic gonadotropin (βHCG) pregnancy test (sensitivity of less than or equal to 25 mIU/mL) performed (and results known) on the same day as and before initiating the protocol-specified study product(s) at Enrollment. - If of reproductive potential  women must agree to use a reliable form of contraception  during the trial and for 52 weeks after stopping the long acting injectable  or 30 days after stopping oral study product  from the list below: - Intrauterine device (IUD) or intrauterine system (IUS) that meets less than 1% failure rate as stated in the product label - Hormone-based contraceptive that meets less than 1% failure rate when used consistently and correctly as stated in the product label - No medical condition that  in the opinion of the study investigator  would interfere with the conduct of the study (e.g.  provided by self-report  or found upon medical history and examination or in available medical records) - No alcohol or substance use that  in the opinion of the study investigator  would interfere with the conduct of the study (e.g.  provided by self-report  or found upon medical history and examination or in available medical records) Exclusion Criteria: - One or more reactive HIV test results at Screening or Enrollment  even if HIV infection is not confirmed - Pregnant or currently breastfeeding  or intends to become pregnant and/or breastfeed during the study - Co-enrollment in any other HIV interventional research study (provided by self-report or other available documentation) - Current or past enrollment in an HIV vaccine trial - Current or chronic history of liver disease (e.g.  non-alcoholic or alcoholic steatohepatitis) or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome  asymptomatic gallstones  or cholecystectomy) - History of seizure disorder  per self-report - Clinically significant cardiovascular disease  as defined by history/evidence of symptomatic arrhythmia  angina/ischemia  coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease - Inflammatory skin conditions that compromise the safety of IM injections  per the discretion of the Investigator of Record (IoR). Mild skin conditions may not be exclusionary at the discretion of the IoR or designee - Has a tattoo or other dermatological condition overlying the buttock region which in the opinion of the IoR or designee may interfere with interpretation of injection site reactions (ISRs) - Coagulopathy (primary or iatrogenic) which would contraindicate IM injection - Active or planned use of prohibited medications as described in the Investigator Brochure (IB) or listed in the Study Specific Procedures Manual (SSP) (provided by self-report  or obtained from medical history or medical records) - Known or suspected allergy to study product components (active or placebo)  including egg or soy products (egg and soy products are contained in Intralipid)|,Female|,Accepts Healthy Volunteers|,45 Years|,18 Years|,3200|,May 22  2017|,,,Female|,,,No|,,['Tenofovir'  'Emtricitabine']|,,,,,,May 22  2017|,NIH|,,Link to the current ClinicalTrials.gov record.|,,,Participant  Care Provider  Investigator  Outcomes Assessor|,,45 Years|,18 Years|,NCT03164564|,2|,,,A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women|,HPTN 084|,,[OrderedDict([('last_name'  'Sinead Delany-Moretlwe  MBBCh  PhD  DTM&H')  ('role'  'Study Chair')  ('affiliation'  'Wits Reproductive Health and HIV Institute CRS (WRHI CRS)')])  OrderedDict([('last_name'  'Mina Hosseinipour  MD  MPH')  ('role'  'Study Chair')  ('affiliation'  'University of North Carolina (UNC) Project-Malawi  Tidziwe Centre')])]|,Not yet recruiting|,No|,,,,,Phase 3|,,,,"[OrderedDict([('measure'  'Number of documented incident HIV infections in Steps 1 and 2')  ('time_frame'  'Measured through Week 81')  ('description'  'HIV incidence rate will be calculated as the total number of participants with confirmed incident HIV infection during study follow-up of Step 1 and Step 2 divided by the person-years accumulated in each arm.')])  OrderedDict([('measure'  'Number of Grade 3 or higher clinical and laboratory adverse events (AEs)')  ('time_frame'  ""Measured through participant's last study visit  up to 4.6 years after study entry  depending on when they enroll in the study"")  ('description'  'AEs will be summarized using MedDRA System Organ Class and preferred terms.')])]|",Prevention|,,,,,,Sponsor|,,"[OrderedDict([('measure'  'Number of documented incident HIV infections in participants in subgroups broken down by baseline age')  ('time_frame'  ""Measured through participant's last study visit  up to 4.6 years after study entry  depending on when they enroll in the study"")  ('description'  'For each of the specified baseline factors  a Cox proportional hazards model will be fit with treatment arm  baseline factor and their interaction as covariates  stratified by site.')])  OrderedDict([('measure'  'Number of documented incident HIV infections in participants in subgroups broken down by baseline HSV-2 status')  ('time_frame'  ""Measured through participant's last study visit  up to 4.6 years after study entry  depending on when they enroll in the study"")  ('description'  'For each of the specified baseline factors  a Cox proportional hazards model will be fit with treatment arm  baseline factor and their interaction as covariates  stratified by site.')])  OrderedDict([('measure'  'Number of documented incident HIV infections in participants in subgroups broken down by baseline contraceptive use method')  ('time_frame'  ""Measured through participant's last study visit  up to 4.6 years after study entry  depending on when they enroll in the study"")  ('description'  'For each of the specified baseline factors  a Cox proportional hazards model will be fit with treatment arm  baseline factor and their interaction as covariates  stratified by site.')])  OrderedDict([('measure'  'Number of documented incident HIV infections in participants in subgroups broken down by baseline body mass index (BMI) less than/greater than or equal to 25 kg/m^2')  ('time_frame'  ""Measured through participant's last study visit  up to 4.6 years after study entry  depending on when they enroll in the study"")  ('description'  'For each of the specified baseline factors  a Cox proportional hazards model will be fit with treatment arm  baseline factor and their interaction as covariates  stratified by site.')])  OrderedDict([('measure'  'Plasma and dried blood spot (DBS) levels of CAB in participants randomized to CAB/CAB LA')  ('time_frame'  ""Measured through participant's last study visit  up to 4.6 years after study entry  depending on when they enroll in the study"")  ('description'  'Plasma and DBS samples for drug concentrations will be collected throughout the study from all participants  although PK testing may be limited to a subset of the samples.')])  OrderedDict([('measure'  'Plasma levels of tenofovir/tenofovir diphosphate (TFV/TFV-DP) in participants randomized to TDF/FTC')  ('time_frame'  ""Measured through participant's last study visit  up to 4.6 years after study entry  depending on when they enroll in the study"")  ('description'  'Plasma samples for drug concentrations will be collected throughout the study from all participants  although PK testing may be limited to a subset of the samples.')])  OrderedDict([('measure'  'Number of participants willing to use CAB LA and TDF/FTC')  ('time_frame'  ""Measured through participant's last study visit  up to 4.6 years after study entry  depending on when they enroll in the study"")  ('description'  'Assessed through administration of brief behavioral surveys.')])]|",National Institute of Allergy and Infectious Diseases (NIAID)|,,October 2017|,,Interventional|,,https://clinicaltrials.gov/show/NCT03164564|,May 2017|,
12,Randomized|,[OrderedDict([('arm_group_label'  'DARTNA')  ('arm_group_type'  'Active Comparator')  ('description'  'DARTNA is a culturally-adaptable therapeutic drum behavior therapy that incorporates drumming  talking circles  and uses the 12 Steps of Alcoholics Anonymous (AA)/Narcotics Anonymous (NA) program within the conceptual framework of the Northern Plains Medicine Wheel. The Northern Plains Medicine Wheel is widely utilized as a conceptual framework and integrative approach to health and wellness for AI/ANs. This intervention consists of 12 sessions provided 2 times weekly over 6 weeks.')])  OrderedDict([('arm_group_label'  'Usual care plus')  ('arm_group_type'  'Placebo Comparator')  ('description'  'Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use  This typically consists individual counseling  group therapy  and AI/AN traditional activities in their community.')])]|,,,,This study is focused on conducting a stage 1b feasibility pilot trial among 60 AI/AN men and women (for a final sample of 48 at follow-up) in an urban outpatient treatment setting to analyze the potential benefits of Drum-Assisted Recovery Therapy for Native Americans (DARTNA). Dr. Dickerson  Principal Investigator  is collaborating with Dr. Elizabeth D'Amico  co-Investigator  with Sacred Path Indigenous Wellness Center  a community-based organization providing consultative services for American Indians/Alaska Natives (AI/ANs). A feasibility randomized clinical trial will be conducted within an urban setting and will compare urban AI/AN males and females with AOD disorders who receive DARTNA (n=30) to AI/AN males and females with AOD disorders who receive usual care plus (n=30). Compare outcomes at end of treatment and 3-months post-treatment to gather data that can be used to judge the feasibility of a larger trial  and to plan that trial. Obtain information on (a) clinically significant changes in AOD use  (b) clinically significant changes in mental health  physical health  spirituality  cognition  adoption of 12-step principles and practices  and cultural identification  and (c) estimate covariate correlations  reliability of measures and likely effect sizes.|,Utilizing Traditional Practices|,,Other|,October 31  2018|,Substance Use|,,Inclusion Criteria: 1) self-identify as AI/AN male or female  (2) be seeking treatment for their drug or alcohol dependence; (3) be 18-59 years of age or older; (4) meet Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (Text Revision) (DSM-IV-TR) criteria for AOD use disorders; Exclusion Criteria: 1. have a mental health or medical history that  in the judgment of the study physician or PI  show no clinically significant contraindications for study participation.|,Alcohol and other drug (AOD) abuse among American Indians and Alaska Natives (AI/ANs) is a significant health issue in the United States as rates of AOD use among AI/ANs have continually been high since national data were collected among AI/ANs beginning in the 1980's. In 2013  AI/ANs had the highest rate of AOD dependence and abuse compared with other racial groups. However  very few AOD abuse treatments utilizing traditional based healing  such as drumming  have undergone rigorous scientific research. Drum-Assisted Recovery Therapy for Native Americans (DARTNA) is a new AOD use intervention integrating AI/AN drumming  12-step philosophy  and concepts focused on the Medicine Wheel. In a recently completed National Center for Complementary and Alternative Medicine (NCCAM)-funded study (R21AT005360)  the PI completed key components of DARTNA development (stage 1a) including demonstrating feasibility and acceptability  establishing procedures for therapist adherence procedures  developing a treatment manual  and conducting a pretest among ten AI/AN men (n=5) and women (n=5) with promising preliminary findings. This study is focused on conducting a stage 1b feasibility pilot trial among 60 AI/AN men and women (for a final sample of 48 at follow-up) in an urban outpatient treatment setting to analyze the potential benefits of Drum-Assisted Recovery Therapy for Native Americans (DARTNA). Dr. Dickerson  Principal Investigator  is collaborating with Dr. Elizabeth D'Amico  co-Investigator  with Sacred Path Indigenous Wellness Center  a community-based organization providing consultative services for American Indians/Alaska Natives (AI/ANs).|,ClinicalTrials.gov processed this data on May 23  2017|,Inclusion Criteria: 1) self-identify as AI/AN male or female  (2) be seeking treatment for their drug or alcohol dependence; (3) be 18-59 years of age or older; (4) meet Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (Text Revision) (DSM-IV-TR) criteria for AOD use disorders; Exclusion Criteria: 1. have a mental health or medical history that  in the judgment of the study physician or PI  show no clinically significant contraindications for study participation.|,30 males and 30 females|,Accepts Healthy Volunteers|,N/A|,18 Years|,60|,March 27  2017|,,,30 males and 30 females|,,,No|,,[OrderedDict([('intervention_type'  'Behavioral')  ('intervention_name'  'Drum-Assisted Recovery Therapy for Native Americans (DARTNA)')  ('description'  'An intervention that utilizes AI/AN drumming as its core component of treatment.')  ('arm_group_label'  'DARTNA')])  OrderedDict([('intervention_type'  'Other')  ('intervention_name'  'Usual Care Plus')  ('description'  'Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use  This typically consists individual counseling  group therapy  and AI/AN traditional activities in their community.')  ('arm_group_label'  'Usual care plus')])]|,,,,Principal Investigator|,,May 22  2017|,Other|,,Link to the current ClinicalTrials.gov record.|,,,Participant|,,N/A|,18 Years|,NCT03164577|,2|,,,Utilizing Traditional Practices to Decrease Substance Use Among Native Americans|,1R34AA024818-01|,,,Not yet recruiting|,No|,,,,No|,N/A|,,,,recent alcohol and other drug use will be tracked|,Treatment|,,,,,,Principal Investigator|,,"[OrderedDict([('measure'  'Change in physical health status utilizing the Physical health questionnaire (PHQ)')  ('time_frame'  'Change from baseline physical health status at end of treatment (42-72 days) and at 3-month follow-up (132-177 days)')  ('description'  'This assessment is a brief self-report scale of somatic symptoms.')])  OrderedDict([('measure'  'Change in Spirituality utilizing the Functional Assessment of Chronic Illness Therapy (FACIT): Spiritual Questions Only-Expanded')  ('time_frame'  'Change from baseline spirituality at end of treatment (42-72 days) and at 3-month follow-up (132-177 days)')  ('description'  ""This 23-item spirituality scale measures comfort and strength derived from one's spiritual beliefs or connection to God or a Higher Power."")])  OrderedDict([('measure'  'Change in cognitive function utilizing the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog)  Version 3')  ('time_frame'  'Change from baseline cognitive function at end of treatment (42-72 days) and at 3-month follow-up (132-177 days)')  ('description'  'This 37-item cognitive function scale measures areas associated with cognitive function  including perceived cognitive impairments  comments from others (i.e.  observations by others regarding cognition)  perceived cognitive abilities  and impact on quality of life.')])]|",University of California  Los Angeles|,,June 1  2017|,,Interventional|,,https://clinicaltrials.gov/show/NCT03164577|,May 2017|,
13,Randomized|,[OrderedDict([('arm_group_label'  'ketamine')  ('arm_group_type'  'Active Comparator')])  OrderedDict([('arm_group_label'  'dexmedetomidine')  ('arm_group_type'  'Active Comparator')])  OrderedDict([('arm_group_label'  'bupivacaine')  ('arm_group_type'  'Placebo Comparator')])]|,,,,This study aims to compare the effects of local wound infiltration with ketamine versus dexmedetomidine when added to bupivacaine on inflammatory cytokine response after total abdominal hysterectomy.|,Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines|,,,December 2017|,['Adenocarcinoma'  'Uterine Neoplasms']|,,Inclusion Criteria: - ASA I-II patients - age range (18-60) years  - weight (50- 90) kg Exclusion Criteria: - allergy to study drugs - significant cardiac disease - respiratory disease - renal disease - hepatic disease|,,ClinicalTrials.gov processed this data on May 23  2017|,Inclusion Criteria: - ASA I-II patients - age range (18-60) years  - weight (50- 90) kg Exclusion Criteria: - allergy to study drugs - significant cardiac disease - respiratory disease - renal disease - hepatic disease|,Yes|,No|,60 Years|,18 Years|,90|,May 22  2017|,,,Yes|,,,No|,,['Dexmedetomidine'  'Ketamine'  'Bupivacaine']|,,,,lecturer of anesthesia  ICU and pain releif|,,May 22  2017|,Other|,,Link to the current ClinicalTrials.gov record.|,,,Participant  Care Provider  Investigator  Outcomes Assessor|,,60 Years|,18 Years|,NCT03164590|,3|,,,Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy|,388|,,South Egypt Cancer Institute|,Not yet recruiting|,Yes|,,,,Undecided|,Phase 4|,,,,severity of pain at rest and on coughing will be assessed using a 10-cm Visual Analog Scale (0 = no pain and 10 = worst imaginable pain)|,Prevention|,,,,,,Principal Investigator|,,sedation by using sedation score|,Assiut University|,,June 2017|,,Interventional|,,https://clinicaltrials.gov/show/NCT03164590|,May 2017|,
14,,NLG8021 Dose Escalation|,,,,This is an open-label Phase I study to evaluate the safety  tolerability  and pharmacokinetics of escalating oral doses of NLG802  an investigational agent intended to inhibit the indoleamine 2 3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively.|,NLG802 Indoleamine 2 3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors|,,,May 2017|,Solid Tumor|,,Inclusion Criteria: - Histologically or cytologically confirmed solid tumor cancer - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Adequate hematologic and organ function - Negative pregnancy test and willingness to utilize contraception among women of childbearing potential - Life expectancy at least 4 months Exclusion Criteria: - Active or history of medically significant autoimmune disease - Cytotoxic therapy or investigational agent use within 28 days - Human immunodeficiency virus (HIV)  active hepatitis B or C - Untreated brain metastases - Known QT interval prolongation - Use of concomitant medications with high risk of causing Torsades des Pointes. - Use of immune suppressive agents within 30 days - Prior malignancy or therapy for a malignancy within 3 years|,,ClinicalTrials.gov processed this data on May 23  2017|,Inclusion Criteria: - Histologically or cytologically confirmed solid tumor cancer - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Adequate hematologic and organ function - Negative pregnancy test and willingness to utilize contraception among women of childbearing potential - Life expectancy at least 4 months Exclusion Criteria: - Active or history of medically significant autoimmune disease - Cytotoxic therapy or investigational agent use within 28 days - Human immunodeficiency virus (HIV)  active hepatitis B or C - Untreated brain metastases - Known QT interval prolongation - Use of concomitant medications with high risk of causing Torsades des Pointes. - Use of immune suppressive agents within 30 days - Prior malignancy or therapy for a malignancy within 3 years|,All|,No|,N/A|,18 Years|,36|,May 22  2017|,,,All|,,,,,Indoleamine 2 3-Dioxygenase (IDO) Inhibitor|,,,,Principal Investigator|,,May 22  2017|,Industry|,,Link to the current ClinicalTrials.gov record.|,United States|,,No masking|,,N/A|,18 Years|,NCT03164603|,1|,,,A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors|,NLG8021|,,,Not yet recruiting|,No|,,,,No|,Phase 1|,,,,[OrderedDict([('measure'  'Percentage of patients with dose-limiting toxicities')  ('time_frame'  '28 Days')])  OrderedDict([('measure'  'Percentage of patients with adverse events')  ('time_frame'  'From Screening until 30 days after last dose (up to approximately 2 years)')])]|,Treatment|,,,,,,Sponsor|,,[OrderedDict([('measure'  'Pharmacokinetics: Serum concentrations (Cmax/Steady State)')  ('time_frame'  '21 Days')])  OrderedDict([('measure'  'Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as Determined by the Investigator')  ('time_frame'  'From Screening until disease progression  death  new anti-cancer therapy  or premature study withdrawal (up to approximately 3 years)')])  OrderedDict([('measure'  'Percentage of Participants With Progression Free Survival (PFS)')  ('time_frame'  '18 months')  ('description'  'equals date of progression/death - date of study enrollment')])]|,NewLink Genetics Corporation|,,May 2017|,,Interventional|,,https://clinicaltrials.gov/show/NCT03164603|,May 2017|,
15,Randomized|,[OrderedDict([('arm_group_label'  'Treatment Arm 1')  ('arm_group_type'  'Experimental')  ('description'  'durvalumab + tremelimumab comination therapy + SoC chemotherapy')])  OrderedDict([('arm_group_label'  'Treatment Arm 2')  ('arm_group_type'  'Experimental')  ('description'  'durvalumab monotherapy + SoC chemotherapy')])  OrderedDict([('arm_group_label'  'Treatment Arm 3')  ('arm_group_type'  'Active Comparator')  ('description'  'SoC chemotherapy alone')])]|,,,,This is a randomized  open-label  multi-center  global  Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.|,Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).|,,,July 31  2019|,['Lung Neoplasms'  'Carcinoma  Non-Small-Cell Lung']|,,Inclusion Criteria: For inclusion in the study  patients should fulfill the following criteria: 1. Aged at least 18 years. 2. Histologically or cytologically documented Stage IV NSCLC. 3. Confirmed tumor PD-L1 status prior to randomization. 4. Patients must have tumors that lack activating EGFR mutations and ALK fusions. 5. No prior chemotherapy or any other systemic therapy for metastatic NSCLC. 6. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. No prior exposure to immunemediated therapy  excluding therapeutic anticancer vaccines. Exclusion Criteria: Patients should not enter the study if any of the following exclusion criteria are fulfilled: 1. Mixed small-cell lung cancer and NSCLC histology  sarcomatoid variant. 2. Active or prior documented autoimmune or inflammatory disorders. 3. Brain metastases or spinal cord compression unless the patient's condition is stable and off steroids. 4. Active infection including tuberculosis  hepatitis B  hepatitis C  or human immunodeficiency virus.|,Adult patients with a histologically or cytologically documented metastatic NSCLC  with tumors that lack activating EGFR mutations and ALK fusions  are eligible for enrollment. Patients will be randomized in a 1:1:1 ratio to receive treatment with durvalumab + tremelimumab combination therapy + SoC chemotherapy  durvalumab monotherapy + SoC chemotherapy  or SoC chemotherapy alone. Tumor evaluation scans will be performed until objective disease progression as efficacy assessment. All patients will be followed for survival until the end of the study. An independent data monitoring committee (IDMC) composed of independent experts will be convened to confirm the safety and tolerability of the proposed dose and schedule.|,ClinicalTrials.gov processed this data on May 23  2017|,Inclusion Criteria: For inclusion in the study  patients should fulfill the following criteria: 1. Aged at least 18 years. 2. Histologically or cytologically documented Stage IV NSCLC. 3. Confirmed tumor PD-L1 status prior to randomization. 4. Patients must have tumors that lack activating EGFR mutations and ALK fusions. 5. No prior chemotherapy or any other systemic therapy for metastatic NSCLC. 6. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. No prior exposure to immunemediated therapy  excluding therapeutic anticancer vaccines. Exclusion Criteria: Patients should not enter the study if any of the following exclusion criteria are fulfilled: 1. Mixed small-cell lung cancer and NSCLC histology  sarcomatoid variant. 2. Active or prior documented autoimmune or inflammatory disorders. 3. Brain metastases or spinal cord compression unless the patient's condition is stable and off steroids. 4. Active infection including tuberculosis  hepatitis B  hepatitis C  or human immunodeficiency virus.|,All|,No|,130 Years|,18 Years|,801|,May 22  2017|,,,All|,,,No|,,['Gemcitabine'  'Tremelimumab'  'Carboplatin'  'Cisplatin'  'Pemetrexed'  'Albumin-Bound Paclitaxel'  'Antibodies  Monoclonal']|,,,,,['NSCLC'  'PD-L1'  'Durvalumab'  'Tremelimumab'  'PFS']|,May 22  2017|,Industry|,,Link to the current ClinicalTrials.gov record.|,['Hong Kong'  'Korea  Republic of'  'Peru'  'Russian Federation'  'Taiwan'  'Ukraine'  'United Kingdom'  'United States']|,,No masking|,,130 Years|,18 Years|,NCT03164616|,3|,,,A Phase III  Randomized  Multi-Center  Open-Label  Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)|,D419MC00004|,,[OrderedDict([('last_name'  'Phillip Dennis  M.D.  Ph.D.')  ('role'  'Study Director')  ('affiliation'  'One MedImmune Way Gaithersburg  MD 20878 United States of America')])  OrderedDict([('last_name'  'Tony Mok')  ('role'  'Principal Investigator')  ('affiliation'  'The Chinese University of Hong Kong  Prince of Wales Hospital  Shatin  NT  Hong Kong')])  OrderedDict([('last_name'  'Caicun Zhou')  ('role'  'Principal Investigator')  ('affiliation'  'Shanghai Pulmonary Hospital  Affiliated to Tongji University School of Medicine  Shanghai  China')])]|,Not yet recruiting|,No|,,,,,Phase 3|,,,,Up to 3 years after first patient randomized|,Treatment|,,,,,,Sponsor|,,[OrderedDict([('measure'  'Progression-free survival (PFS) using BICR assessments according to RECIST 1.1')  ('time_frame'  'Up to 3 years after first patient randomized')])  OrderedDict([('measure'  'Overall survival (OS)')  ('time_frame'  'Up to 4 years after first patient randomized')])  OrderedDict([('measure'  'Objective response rate (ORR) using BICR assessments according to RECIST 1.1')  ('time_frame'  'Up to 3 years after first patient randomized')])  OrderedDict([('measure'  'Duration of response (DoR) using BICR assessments according to RECIST 1.1')  ('time_frame'  'Up to 3 years after first patient randomized')])  OrderedDict([('measure'  'Time from randomization to second progression (PFS2)')  ('time_frame'  'Up to 3 years after first patient randomized')])  OrderedDict([('measure'  'Proportion of patients alive and progression free at 12 months from randomization (APF12) using BICR assessments according to RECIST 1.1')  ('time_frame'  'Up to 12 months')])  OrderedDict([('measure'  'Best objective response (BoR) using BICR assessments according to RECIST 1.1')  ('time_frame'  'Up to 3 years after first patient randomized')])  OrderedDict([('measure'  'The pharmacokinetics (PK) of durvalumab and tremelimumab as determined by concentration')  ('time_frame'  'Up to 3 years after first patient randomized')])  OrderedDict([('measure'  'The immunogenicity of durvalumab and tremelimumab as assessed by presence of anti-drug antibodies (ADAs)')  ('time_frame'  'Up to 3 years after first patient randomized')])  OrderedDict([('measure'  'Health-related QoL measured by EORTC QLQ-C30 v3')  ('time_frame'  'Up to 3 years after first patient randomized')])  OrderedDict([('measure'  'Disease-related symptoms measured by EORTC QLQ-LC13')  ('time_frame'  'Up to 3 years after first patient randomized')])  OrderedDict([('measure'  'Changes in WHO/ECOG performance status')  ('time_frame'  'Up to 3 years after first patient randomized')])]|,AstraZeneca|,,June 30  2017|,,Interventional|,,https://clinicaltrials.gov/show/NCT03164616|,May 2017|,
16,Non-Randomized|,['Study Group'  'Control Group']|,,,,The purpose of this research study is to learn about how cone-beam Computerized Tomography scans (X-ray images taken from different angles) work together with an embolization guidance software (helps the doctor see the arteries that feed the prostate)to find and see arteries in the prostate.|,3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization|,,Industry|,June 18  2018|,Enlarged Prostate|,,Inclusion Criteria: - Patient is age 50 to 79  inclusive - Patients undergoing Prostate artery embolization for BPH or urinary retention -Patient has signed informed consent. Exclusion Criteria: - Patients with biopsy proven prostate cancer - Patient weight of >300 lbs|,,ClinicalTrials.gov processed this data on May 23  2017|,Inclusion Criteria: - Patient is age 50 to 79  inclusive - Patients undergoing Prostate artery embolization for BPH or urinary retention -Patient has signed informed consent. Exclusion Criteria: - Patients with biopsy proven prostate cancer - Patient weight of >300 lbs|,Male|,No|,79 Years|,50 Years|,50|,May 22  2017|,,,Male|,,,No|,,cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation  by projecting a 3D road map of prostatic arteries on live fluoroscopy  in order to differentiate them from non-target vessels.|,,,,Assistant Professor of Clinical Radiology & Urology|,['BPH'  'Lower Urinary Track Infection'  'Urine Retention']|,May 22  2017|,Other|,,Link to the current ClinicalTrials.gov record.|,United States|,,No masking|,,79 Years|,50 Years|,NCT03164629|,2|,,,3D ROTATIONAL CT ANGIOGRAM WITH EMBOLIZATION GUIDANCE AND CBCT IN PROSTATE ARTERY EMBOLIZATION|,20160589|,,University of Miami|,Recruiting|,No|,,,,No|,N/A|,,,,For the cases using Emboguide this will be measured as the time from which the Emboguide is displayed on the live fluoroscopy to the time of prostatic artery catheterization. Emboguide display is in addition to the angiogram roadmap display.For the control cases this will be measured as the time from which the angiogram is displayed on the live fluoroscopy to the time of prostatic artery catheterization.|,Other|,,,,,,Principal Investigator|,,,University of Miami|,,April 17  2017|,,Interventional|,,https://clinicaltrials.gov/show/NCT03164629|,May 2017|,
17,Randomized|,[OrderedDict([('arm_group_label'  'LENA with Feedback')  ('arm_group_type'  'Experimental')  ('description'  'Mothers who will run the LENA system with their young children  AND who will receive feedback from their service providers on how to enhance the language the home language environment.')])  OrderedDict([('arm_group_label'  'LENA no feedback')  ('arm_group_type'  'Placebo Comparator')  ('description'  'Mothers who will only run the LENA system with their young children. These mothers will NOT receive feedback from their service providers on how to enhance the language the home language environment.')])]|,,,,"This project will determine whether an intervention to enhance communication between infants and toddlers with developmental disabilities and their depressed mothers can be integrated into federally-funded Early Intervention (EI) services. Participants will be mothers with depressive symptoms whose children are receiving EI services  along with their EI service providers. The investigators will conduct a small randomized control trial using the Language ENhancement Assessment/intervention system (LENA)  a technology-supported language monitoring system  with 20 mothers and one of their child's EI service providers. The LENA uses an infant or toddler garment with an integrated audiotape system that records adult speech centered on the child  child vocalizations  and reciprocal parent-child turn-taking conversations. The LENA software produces visual feedback that a mother can use to focus her language interactions with her child. A ""LENA with feedback"" group will follow participants in the intervention over 5 weeks: 5 weeks of LENA data collection (with mothers running the system 1 day/week for 16 consecutive hours)  with feedback during 3 weeks (baseline=LENA  no feedback; 3 week intervention=LENA with feedback; post-intervention=LENA  no feedback). A ""LENA no feedback"" group will complete LENA data collection at baseline on the same schedule but will not receive feedback. The main difference between groups will be provision of LENA feedback and strategies to promote increased mother-child interactions. This design allows the investigators to isolate the effect of LENA with feedback  and minimizes attributing changes in language environments due to exposure to LENA alone. The investigators will analyze data from measures on LENA communication data (adult word count  child vocalizations and conversational turn-taking)  and measures of child language  maternal depressive symptoms  and child disability profiles.|",Using the LENA System in Early Intervention|,,[OrderedDict([('agency'  'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)')  ('agency_class'  'NIH')])  OrderedDict([('agency'  'North Carolina Translational and Clinical Sciences Institute')  ('agency_class'  'Other')])]|,September 30  2017|,Depression|,,Inclusion Criteria: Service Coordinator and Service Provider Inclusion: - Be a CDSA employee in Durham  Wake  Alamance or Guilford Counties  NC - Be a service coordinators or approved Speech-Language Provider(SLP) or Community Based Rehabilitative Service (CBRS) provider (service providers). - Eligibility of the service providers will be determined by the agreement of a mother to participate in the LENA portion of the study and the agreement of the service providers to participate as well. Mothers Inclusion criteria: - Be 18 years or older. Mothers who are 18 years can give consent independently. - Be the biological or adoptive mother of an infant (6 weeks - 18 months old) or toddler (19 -32 months old) enrolled in EI at the time of recruitment; mothers must be the primary caretaker of the child. - EI services are offered only to infants and toddlers up to the age of 36 months; this study caps the age of enrollment at 32 months to ensure that toddlers are continuously enrolled in EI during the data collection period. - Able to independently give consent. Mothers must have adequate capacity to participate in the LENA intervention as well as understand what they will be asked to do as participants. - Score 8 or higher on the PHQ-9. This score is indicative of depressive symptoms. Exclusion Criteria: Service Coordinator and Service Provider Inclusion: none Mothers Exclusion criteria: - Currently pregnant by self-report. - Child is completely deaf|,Early Intervention (EI) services are provided to infants and toddlers with documented developmental delays in all 50 states and US territories. EI improves long-term infant-toddler adaptation and lowers the cost of care if parents use the services. However  depressive symptoms can reduce mothers' ability to provide the daily child development-promoting activities recommended by EI  increasing the child's risk for communication and behavioral problems. Indeed  repeated studies have shown that depressive symptoms reduce mothers' consistent use of developmentally sensitive  child-centered speech which  in turn  lead to negative child cognitive and behavioral outcomes. Previous research showed that over one-third of mothers of children with disabilities have significant levels of depressive symptoms  a rate higher than the population at large. Infants and toddlers of depressed mothers have been shown to receive fewer intensive services and have been shown to interfere with uptake of EI services through impaired mother-child interactions. A preliminary study by the investigators found that over a third of mothers of infants and toddlers enrolled in EI in a large North Carolina county had severe depressive symptoms and depression histories. Fortunately  the investigators also found that when depressed mothers were provided with concrete  attainable skills for improving interactions with their child  the impact of depression on both mother and child was substantially reduced. Focusing on a depressed mother's child-centered speech and reciprocal communication also improves child outcomes  even when the child is cognitively compromised. However  none of these specialized services are part of EI best practices. Thus  EI is an ideal setting in which to integrate screening  referral and targeted skills for depressed mothers in order to improve parent-child interactions and ultimately  child outcomes. This project will develop an intervention focused on communication between infants and toddlers with diagnosed or suspected developmental disabilities and their mothers who have depressive symptoms. The primary aim of the study is to test the initial efficacy of embedding a language pedometer  the Language ENhancement Assessment/intervention system (LENA)  into EI to teach mothers to increase child-centered speech and reciprocal communication  which have been linked to positive child outcomes  and to increase parenting efficacy in depressed mothers of children in EI. While maternal depressive symptoms can disrupt developmentally stimulating  child-centered speech  simple tools to assess and provide feedback to mothers can improve the child-centered speech and reciprocal language interactions that positively impact child outcomes. Although the LENA has been used in other studies and shown improvements in mothers' child-centered speech  the system has not been used with mothers showing depressive symptoms or in the EI context. Using a randomized wait-list controlled design  the investigators will examine whether use of the LENA with feedback from a supportive EI provider has an impact on the child's language environment  parenting efficacy and maternal depressive symptoms. The investigators will stratify mothers by group based on depressive symptoms (mild  moderate  moderately severe) and randomly assign them to intervention (LENA with feedback) or wait-list control (LENA no feedback). The investigators will examine the use of the LENA system and the impact on short term child outcomes including receptive/expressive language  functional and social communication  and social-emotional behavior  and on maternal depressive symptoms. Positive intervention outcomes may ultimately lead to a sustainable addition to EI programs in all 50 US states and territories.|,ClinicalTrials.gov processed this data on May 23  2017|,Inclusion Criteria: Service Coordinator and Service Provider Inclusion: - Be a CDSA employee in Durham  Wake  Alamance or Guilford Counties  NC - Be a service coordinators or approved Speech-Language Provider(SLP) or Community Based Rehabilitative Service (CBRS) provider (service providers). - Eligibility of the service providers will be determined by the agreement of a mother to participate in the LENA portion of the study and the agreement of the service providers to participate as well. Mothers Inclusion criteria: - Be 18 years or older. Mothers who are 18 years can give consent independently. - Be the biological or adoptive mother of an infant (6 weeks - 18 months old) or toddler (19 -32 months old) enrolled in EI at the time of recruitment; mothers must be the primary caretaker of the child. - EI services are offered only to infants and toddlers up to the age of 36 months; this study caps the age of enrollment at 32 months to ensure that toddlers are continuously enrolled in EI during the data collection period. - Able to independently give consent. Mothers must have adequate capacity to participate in the LENA intervention as well as understand what they will be asked to do as participants. - Score 8 or higher on the PHQ-9. This score is indicative of depressive symptoms. Exclusion Criteria: Service Coordinator and Service Provider Inclusion: none Mothers Exclusion criteria: - Currently pregnant by self-report. - Child is completely deaf|,Yes|,No|,99 Years|,18 Years|,20|,May 22  2017|,,,Yes|,,,No|,,"[OrderedDict([('intervention_type'  'Behavioral')  ('intervention_name'  'LENA with Feedback')  ('description'  ""The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system  an audiorecorder language pedometer that records adult speech centered on the child  child vocalizations  and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths  reviewing the LENA visual output from the previous recording  and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges  encouragement  and practical ways to individually tailor the strategies to the family."")  ('arm_group_label'  'LENA with Feedback')])  OrderedDict([('intervention_type'  'Behavioral')  ('intervention_name'  'LENA no feedback')  ('description'  'The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system  an audiorecorder language pedometer that records adult speech centered on the child  child vocalizations  and parent-child reciprocal turn-taking conversations')  ('arm_group_label'  'LENA no feedback')])]|",,,,,['Depressive Symptoms'  'Developmental Disabilities'  'Early Intervention'  'Language Development'  'Communication'  'Maternal Empowerment']|,May 22  2017|,Other|,,Link to the current ClinicalTrials.gov record.|,United States|,,Outcomes Assessor|,,99 Years|,18 Years|,NCT03164642|,2|,,,Enhancing Communication Between Children in EI and Their Depressed Mothers|,15-2105|,,[OrderedDict([('last_name'  'Linda Beeber  PhD')  ('role'  'Principal Investigator')  ('affiliation'  'University of North Carolina  Chapel Hill')])  OrderedDict([('last_name'  'Anne Wheeler  PhD')  ('role'  'Principal Investigator')  ('affiliation'  'RTI International')])  OrderedDict([('last_name'  'Doré LaForett  PhD')  ('role'  'Principal Investigator')  ('affiliation'  'University of North Carolina  Chapel Hill')])]|,Not yet recruiting|,No|,,,,No|,N/A|,,,,The LENA system  which records adult-child vocalizations  measures the number of the target adult's (e.g.  parent) child-directed words (child-directed speech). The total possible range is 0-n  where higher scores indicate an increased number of child-directed words spoken by the target adult and higher degrees of a language-rich environment. Lower scores indicate fewer words spoken by the target adult and represent an environment that is not language-rich.|,Treatment|,,,,,,Sponsor|,,"[OrderedDict([('measure'  'Change in Parenting Sense of Competence Scale Efficacy subscale score after 5 weeks')  ('time_frame'  'pre/post for a 5-week intervention window')  ('description'  'The Parenting Sense of Competence Scale is a 17-item measure assessing parental competence. Each item is rated on a 6 point Likert scale anchored by 1 = ""Strongly Disagree"" and 6 = ""Strongly Agree"". The Efficacy subscale measures feelings of efficacy as a parent. It has 7 questions (1 6 7 10 11 13 15)  producing a range of 6-42. Higher scores indicate greater self-efficacy. Lower scores mean more impairment.')])  OrderedDict([('measure'  'Change in Patient Health Questionnaire-9 (PHQ-9) score after 5 weeks')  ('time_frame'  'pre/post for a 5-week intervention window')  ('description'  'The PHQ-9 is a depression scale used to assess brief depression severity by rating symptoms and functional impairment experienced in the last two weeks. The questionnaire contains a total of 9 questions  and each question is scored on a range from 0-3. The minimum value ""0"" represents not at all  ""1"" several days  ""2"" indicates more than half the days  and the maximum value ""3"" stands for nearly every day. The total possible range is 0-27  with higher scores indicating more depressive symptoms. The total number of each 0  1  2  3 is added and multiplied by its value (0=0  1=1  etc.) to produce a total score generated from the subtotal sum. The PHQ-9 total score is interpreted as follows: 0-4 represents minimal depression  5-9 as mild depression  10-14 as moderate depression  15-19 moderately severe depression  and 20-27 severe depression.')])  OrderedDict([('measure'  'Change in LENA Mother/Child Turn-Taking score after 5 weeks')  ('time_frame'  'pre/post for a 5-week intervention window')  ('description'  'The LENA system  which records adult-child vocalizations  measures the number of conversational turns between the target adult (e.g.  parent) and child. The total possible range is 0-n  where higher scores indicate an increased number of turns (back-and-forth  or ""reciprocal"" language exchanges) between the adult and child  reflecting higher degrees of a language-rich environment. Lower scores indicate fewer conversational turns between the adult and child  and represent an environment that is not language-rich.')])  OrderedDict([('measure'  'Change in LENA Child Vocalization score after 5 weeks')  ('time_frame'  'pre/post for a 5-week intervention window')  ('description'  'The LENA system  which records adult-child vocalizations  measures the number of vocalizations of the target child. The total possible range is 0-n  where higher scores indicate an increased number of vocalizations from the child  reflecting higher levels of language development. Lower scores indicate fewer vocalizations from child  and represent lower levels of language development.')])]|",University of North Carolina  Chapel Hill|,,July 1  2017|,,Interventional|,,https://clinicaltrials.gov/show/NCT03164642|,May 2017|,
18,Randomized|,['HAI oxaliplatin combined with I.V. FOLFIRI + target therapy'  'conventional systemic CT alone']|,,,,National trial  multicenter  randomized  phase II comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy (CT) to systemic chemotherapy alone in patients with liver-only colorectal metastases (CRLM) considered still non resectable after at least two months of systemic induction chemotherapy.|,SULTAN (Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network)|,,,June 2021|,Colorectal Neoplasms|,,Inclusion Criteria: 1. Histologically confirmed colorectal cancer (CRC)  and radiologic or histologic proof of CRLM 2. CRLM not amenable to a curative intent-treatment after at least two months and no more than 6 months of first-line induction CT 3. First-line CT with oxaliplatin and/or irinotecan combined with a fluoropyrimidine and a targeted therapy (e.g.  anti-EGFR or antiangiogenic antibody) for metastatic disease (patients ending their adjuvant chemotherapy after primary tumor resection since less than 6 months should also have received first-line chemotherapy for metastatic desease) 4. Unresectability of the CRLM will be confirmed by a centralized multidisciplinary expert panel (composed of surgeons  radiologists  interventional radiologists and medical oncologists). The panel will review the CT-Scan and MRI of the patients (weekly web conference) 5. Non-resectability criteria (one of the following criteria): - Upfront R0/R1 resection of all CRLM (that leaves at least two adequately perfused and drained segments) is not possible - and/or metastases in contact with major vessels of the remnant liver which would require resection of the vessel for an R0 resection (i.e.  tumor involvement of main portal right and left portal veins  of the three main hepatic veins  or of the retrohepatic vena cava) - and/or documented progressive disease on imaging (according to the RECIST v1.1 criteria) or doubling of serum levels of carcinoembryonic antigen (CEA) or CA 19.9 following ≥ 2 months of induction CT 6. At least one measurable liver metastasis according to the RECIST v1.1 7. Age ≥ 18 years 8. ECOG performance status 0-1 9. Normal liver function  i.e. bilirubin < 1.5 times the upper limit of normal values (ULN)  aminotransferases < 5ULN  alkaline phosphatase < 5ULN 10. International normalized ratio (INR) < 1.5ULN 11. Neutrophils > 1500/mm3  platelets > 100 000/mm3  haemoglobin > 9 g/dL (transfusion allowed) 12. Calculated creatinine clearance > 50 mL/min (Cockcroft and Gault formula) 13. Informed consent signed by the patient or his/her legal representative 14. Patient affiliated to a social security regimen 15. Adequate contraception if applicable Exclusion Criteria: 1. Patient eligible for curative-intent treatment of CRLM (i.e. resection and/or thermoablation)  according to the local multidisciplinary team and/or the central review. 2. Extrahepatic tumour disease (except ≤ 3 lung nodules < 10 mm deemed amenable to curative-intent resection/thermoablation and non-resected primary tumour with no or mild symptoms) 3. Patient with contraindication for trial drugs (investigators have to refer to SmPC drugs  see appendix 1) 4. Sensory neuropathy ≥ grade 2 (NCIC CTAE v.4.0) 5. Significant chronic liver disease (resulting in portal hypertension and/or liver insufficiency) 6. Allergy to contrast media that cannot be managed with standard care 7. Previous organ transplantation  HIV or other immunodeficiency syndromes 8. Concomitant or past history of cancer within 5 years prior to entry into the trial other than adequately treated basal-cell skin cancer or in situ carcinoma of the cervix 9. Concomitant medications/comorbidities that may prevent the patient from receiving study treatments as uncontrolled intercurrent illness (for instance: active infection  active inflammatory disorders  inflammatory bowel disease  intestinal obstruction  symptomatic congestive heart failure  uncontrolled hypertension…) 10. Ionic disorders as: - Kalemia ≤ 1 x ULN - Magnesemia < 0.5 mmol/L - Calcemia < 2 mmol/L 11. Patient with known dihydropyrimidine dehydrogenase deficiency 12. QT/QTc > 450 msec for men and > 470 msec for women 13. Concomitant intake of St. John's wort 14. Patient already included in another clinical trial with an experimental molecule 15. Pregnancy or lactation 16. Patients deprived of liberty or under guardianship 17. Patients unable to undergo medical monitoring test for geographical  social or psychological reasons|,,ClinicalTrials.gov processed this data on May 23  2017|,Inclusion Criteria: 1. Histologically confirmed colorectal cancer (CRC)  and radiologic or histologic proof of CRLM 2. CRLM not amenable to a curative intent-treatment after at least two months and no more than 6 months of first-line induction CT 3. First-line CT with oxaliplatin and/or irinotecan combined with a fluoropyrimidine and a targeted therapy (e.g.  anti-EGFR or antiangiogenic antibody) for metastatic disease (patients ending their adjuvant chemotherapy after primary tumor resection since less than 6 months should also have received first-line chemotherapy for metastatic desease) 4. Unresectability of the CRLM will be confirmed by a centralized multidisciplinary expert panel (composed of surgeons  radiologists  interventional radiologists and medical oncologists). The panel will review the CT-Scan and MRI of the patients (weekly web conference) 5. Non-resectability criteria (one of the following criteria): - Upfront R0/R1 resection of all CRLM (that leaves at least two adequately perfused and drained segments) is not possible - and/or metastases in contact with major vessels of the remnant liver which would require resection of the vessel for an R0 resection (i.e.  tumor involvement of main portal right and left portal veins  of the three main hepatic veins  or of the retrohepatic vena cava) - and/or documented progressive disease on imaging (according to the RECIST v1.1 criteria) or doubling of serum levels of carcinoembryonic antigen (CEA) or CA 19.9 following ≥ 2 months of induction CT 6. At least one measurable liver metastasis according to the RECIST v1.1 7. Age ≥ 18 years 8. ECOG performance status 0-1 9. Normal liver function  i.e. bilirubin < 1.5 times the upper limit of normal values (ULN)  aminotransferases < 5ULN  alkaline phosphatase < 5ULN 10. International normalized ratio (INR) < 1.5ULN 11. Neutrophils > 1500/mm3  platelets > 100 000/mm3  haemoglobin > 9 g/dL (transfusion allowed) 12. Calculated creatinine clearance > 50 mL/min (Cockcroft and Gault formula) 13. Informed consent signed by the patient or his/her legal representative 14. Patient affiliated to a social security regimen 15. Adequate contraception if applicable Exclusion Criteria: 1. Patient eligible for curative-intent treatment of CRLM (i.e. resection and/or thermoablation)  according to the local multidisciplinary team and/or the central review. 2. Extrahepatic tumour disease (except ≤ 3 lung nodules < 10 mm deemed amenable to curative-intent resection/thermoablation and non-resected primary tumour with no or mild symptoms) 3. Patient with contraindication for trial drugs (investigators have to refer to SmPC drugs  see appendix 1) 4. Sensory neuropathy ≥ grade 2 (NCIC CTAE v.4.0) 5. Significant chronic liver disease (resulting in portal hypertension and/or liver insufficiency) 6. Allergy to contrast media that cannot be managed with standard care 7. Previous organ transplantation  HIV or other immunodeficiency syndromes 8. Concomitant or past history of cancer within 5 years prior to entry into the trial other than adequately treated basal-cell skin cancer or in situ carcinoma of the cervix 9. Concomitant medications/comorbidities that may prevent the patient from receiving study treatments as uncontrolled intercurrent illness (for instance: active infection  active inflammatory disorders  inflammatory bowel disease  intestinal obstruction  symptomatic congestive heart failure  uncontrolled hypertension…) 10. Ionic disorders as: - Kalemia ≤ 1 x ULN - Magnesemia < 0.5 mmol/L - Calcemia < 2 mmol/L 11. Patient with known dihydropyrimidine dehydrogenase deficiency 12. QT/QTc > 450 msec for men and > 470 msec for women 13. Concomitant intake of St. John's wort 14. Patient already included in another clinical trial with an experimental molecule 15. Pregnancy or lactation 16. Patients deprived of liberty or under guardianship 17. Patients unable to undergo medical monitoring test for geographical  social or psychological reasons|,All|,No|,N/A|,18 Years|,140|,May 22  2017|,,,All|,,,No|,,['Bevacizumab'  'Oxaliplatin'  'Irinotecan'  'Cetuximab'  'Fluorouracil']|,,,,,,May 22  2017|,Other|,,Link to the current ClinicalTrials.gov record.|,,,Participant  Investigator|,,N/A|,18 Years|,NCT03164655|,2|,,,A Randomized Phase II Study Comparing Treatment Intensification With Hepatic Arterial Infusion Chemotherapy Plus Systemic Chemotherapy to Systemic Chemotherapy Alone in Patients With Liver-only Colorectal Metastases Considered Still Non Resectable After at Least Two Months of Systemic Induction Chemotherapy: SULTAN (Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network)|,UCGI 30 - PRODIGE 53 SULTAN|,,,Not yet recruiting|,No|,,,,,Phase 2|,,,,Curative-intent (R0-R1) resection (and/or ablation) rate (CRR) of CRLM confirmed by a systematic review of the surgical and pathological report by an independent committee blind to the treatment received|,Treatment|,,,,,,Sponsor|,,,UNICANCER|,,November 2017|,,Interventional|,,https://clinicaltrials.gov/show/NCT03164655|,May 2017|,
19,Randomized|,[OrderedDict([('arm_group_label'  'Usual cigs; menthol e-cig then tobacco e-cigs')  ('arm_group_type'  'Other')  ('description'  'Participants can continue to smoke their usual cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes')])  OrderedDict([('arm_group_label'  'Usual cigs; tobacco e-cig then menthol e-cigs')  ('arm_group_type'  'Other')  ('description'  'Participants can continue to smoke their usual cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes')])  OrderedDict([('arm_group_label'  'avoid menthol cigs; menthol e-cig then tobacco e-cigs')  ('arm_group_type'  'Other')  ('description'  'Participants avoid smoking menthol cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes')])  OrderedDict([('arm_group_label'  'avoid menthol cigs; tobacco e-cig then menthol e-cigs')  ('arm_group_type'  'Other')  ('description'  'Participants avoid smoking menthol cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes')])]|,,,,The purpose of this formative study is to provide preliminary data regarding how the availability of menthol flavored e-cigarettes affects tobacco use behavior in the context of a ban on menthol flavored cigarettes|,Menthol Flavored E-cigarette Use During a Simulated Ban of Menthol Cigarettes|,,,June 2018|,Tobacco Use Disorder|,,Inclusion Criteria: - Self identify as African American - smoke primarily menthol cigarettes - be between the ages of 18 and 64 - smoke a minimum number of cigarettes per day - agree to abstain from menthol cigarettes for an 8 week period Exclusion Criteria: - current unstable medical / psychiatric condition - regular use any form of nicotine or tobacco other than cigarettes - are pregnant or breast feeding The investigators will evaluate if there are other reasons why someone may not be eligible to participate|,,ClinicalTrials.gov processed this data on May 23  2017|,Inclusion Criteria: - Self identify as African American - smoke primarily menthol cigarettes - be between the ages of 18 and 64 - smoke a minimum number of cigarettes per day - agree to abstain from menthol cigarettes for an 8 week period Exclusion Criteria: - current unstable medical / psychiatric condition - regular use any form of nicotine or tobacco other than cigarettes - are pregnant or breast feeding The investigators will evaluate if there are other reasons why someone may not be eligible to participate|,All|,Accepts Healthy Volunteers|,64 Years|,18 Years|,40|,May 22  2017|,,,All|,,,No|,,Menthol|,,,,Principal Investigator|,,May 22  2017|,Other|,,Link to the current ClinicalTrials.gov record.|,United States|,,No masking|,,64 Years|,18 Years|,NCT03164668|,4|,,,Menthol Flavored E-cigarette Use During a Simulated Ban of Menthol Cigarettes|,RC-2016-0004|,,,Recruiting|,No|,,,,,N/A|,,,,[OrderedDict([('measure'  'number of cigarettes smoked')  ('time_frame'  '1 month')])  OrderedDict([('measure'  'number of e-cigarettes used')  ('time_frame'  '1 month')])]|,Other|,,,,,,Sponsor|,,,University of Minnesota - Clinical and Translational Science Institute|,,May 3  2017|,,Interventional|,,https://clinicaltrials.gov/show/NCT03164668|,May 2017|,
